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Background: There is currently no disease-modifying treatment available to halt or delay the progression
of the disease pathology in dementia. An agreed core set of the best-available and most appropriate
outcomes for disease modification would facilitate the design of trials and ensure consistency across
disease modification trials, as well as making results comparable and meta-analysable in future trials.
Objectives: To agree a set of core outcomes for disease modification trials for mild to moderate dementia
with the UK dementia research community and patient and public involvement (PPI).
Data sources: We included disease modification trials with quantitative outcomes of efficacy from
(1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia
and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials,
Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health
Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard
Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and
(3) hand-searches of reference lists of relevant systematic reviews from database searches.
Review methods: The project consisted of four workstreams. (1) We obtained related core outcome sets
and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification
trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording
how many used each outcome and with how many participants. We divided outcomes into the domains
measured and searched for validation data. (3) We consulted with PPI participants about recommended
outcomes. (4) We presented all the synthesised information at a conference attended by the wider body
of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set
of outcomes.
Results: We included 149 papers from the 22,918 papers screened, referring to 125 individual trials.
Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily
living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques.
We consulted with 18 people for PPI. The conference decided that only cognition and biological markers
are core measures of disease modification. Cognition should be measured by the Mini Mental State
Examination (MMSE) or the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog),
and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All
other domains are important but not core. We recommend using the Neuropsychiatric Inventory for
neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life
Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally.
ABSTRACT
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Limitations: Most of the trials included participants with Alzheimer’s disease, so recommendations may
not apply to other types of dementia. We did not conduct economic analyses. The PPI consultation was
limited to members of the Alzheimer’s Society Research Network.
Conclusions: Cognitive outcomes and biological markers form the core outcome set for future disease
modification trials, measured by the MMSE or ADAS-Cog, and structural MRI in a subset of participants.
Future work: We envisage that the core set may be superseded in the future, particularly for other types
of dementia. There is a need to develop an algorithm to compare scores on the MMSE and ADAS-Cog.
Study registration: The project was registered with Core Outcome Measures in Effectiveness Trials
[www.comet-initiative.org/studies/details/819?result=true (accessed 7 April 2016)]. The systematic review
protocol is registered as PROSPERO CRD42015027346.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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CINAHL Cumulative Index to Nursing and
Allied Health Literature
COMET Core Outcome Measures in
Effectiveness Trials
CSF cerebrospinal fluid
DAD Disability Assessment For Dementia
DEMQOL Dementia Quality of Life measure
DSRS Dementia Severity Rating Scale
EEG electroencephalography
EQ-5D EuroQol-5 Dimensions
HRQoL health-related quality of life
IADL instrumental activities of daily living
ICHOM International Consortium for Health
Outcomes Measurement Working
Group
ISRCTN International Standard Randomised
Controlled Trial Number
JPND European Union Joint Programme –
Neurodegenerative Disease
Research
LILACS Latin American and Caribbean
Health Sciences Literature
MCI mild cognitive impairment
MMSE Mini Mental State Examination
MRI magnetic resonance imaging
NIHR National Institute for Health
Research
NPI Neuropsychiatric Inventory
NTB Neuropsychological Test Battery
P-tau phosphorylated tau
P-tau181 phosphorylated tau 181
PET positron emission tomography
PiB Pittsburgh compound B
PPI patient and public involvement
PRISMA Preferred Reporting Items for
Systematic Reviews and
Meta-Analyses
PSMS Personal Self-Maintenance Scale
PWD person with dementia
QALY quality-adjusted life-year
QOL-AD Quality of Life in Alzheimer’s
Disease
RCT randomised controlled trial
T-tau total tau
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Plain English summary
In the UK, around 850,000 people have dementia. If a treatment can change the underlying pathology ofdementia this is called disease modification, although no trials have yet found effective disease-modifying
treatments. Trials have used differing outcome measures to evaluate if a treatment works, making it
difficult to compare and contrast results. To address this issue we aimed, in collaboration with the UK
dementia research community and the Alzheimer’s Society’s Research Network, to develop a core set of
outcome measures for use in future disease-modifying trials for mild to moderate dementia.
We looked at the outcomes used across completed and ongoing disease modification trials and found
measures in six test areas: cognition, biological, behaviour, quality of life, activities of daily living and global.
We used these findings to conduct a small consultation with people living with dementia and family carers.
We presented all results at our consensus conference and discussed them to reach our conclusions.
We recommend that the core set of outcome measures should include a cognitive measure, namely the
Mini Mental State Examination or the Alzheimer’s Disease Assessment Scale – Cognitive subscale, and an
optional magnetic resonance imaging scan looking at brain structure as a biological measure. We have
specified measures for the other areas that are important but not core. The recommendations may change
as new measures are developed, and, as most of the trials included participants with Alzheimer’s disease
only, recommendations need to be developed for different dementias. They apply only to mild to moderate
stages of dementia.
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Scientific summary
Introduction
In the UK, as in the rest of the developed and developing world, the prevalence of dementia is increasing,
primarily driven by the ageing population. People living with dementia can currently only be offered
management to improve their symptoms as no disease-modifying treatments that would halt or delay the
progression of the underlying disease pathology are available. The G8 Dementia Summit in 2013 committed to
find a disease-modifying treatment by 2025. If a treatment were found to slow disease progression of mild to
moderate dementia, then this would reduce the number of people living with severe dementia in the future.
However, across both published and ongoing disease modification trials there is large variation in the outcomes
used as end points, making it difficult to compare and contrast results. To improve future disease modification
trials there is a need for harmonisation among the outcomes measured, as well as for outcomes to be
appropriate, sensitive to change and clinically meaningful. An agreed core set of the best-available outcomes
would enhance interpretation of data across trials, including the combination of results in meta-analyses.
There is, therefore, an urgent need for consensus from National Institute for Health Research (NIHR)
dementia researchers in the UK on a core outcome set of measures to be used across future disease
modification trials in mild to moderate dementia. This will ensure that new trials can be combined in
systematic reviews and contrasted as to their effectiveness.
Review question
What are the core clinical health outcomes that should be used in all NIHR-funded trials of disease
modification in mild to moderate dementia, and how should they be measured?
Methods
The project consisted of four workstreams.
1. First, we used overlapping core outcome sets and work from co-applicants.
2. At the same time we performed a systematic review to identify which outcomes are used in published
and ongoing disease modification trials.
3. We then consulted with people living with dementia and carers about the outcomes found in the
systematic review.
4. Finally, we held a conference where the synthesis of information from the previous workstreams was
debated by a wider body of NIHR dementia researchers to reach consensus on a core set of outcomes.
Workstream 1: co-applicants core outcome sets and work
First, we considered overlapping core outcome sets that had been, or were currently being, developed by
co-applicants of the project, as well as reference lists from co-applicants. This included:
1. an outcome set of what is most important to people living with dementia
2. an outcome set for psychosocial interventions in dementia
3. reference lists from a systematic review of non-pharmacological interventions previously conducted by a
co-applicant
4. the Cochrane Dementia and Cognitive Improvement Group study register (ALOIS), a database of
dementia studies run by the Cochrane Dementia and Cognitive Improvement Group, which was
represented by a co-applicant.
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Workstream 2: systematic review
Protocol
We registered the protocol with PROSPERO [CRD42015027346; www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42015027346 (accessed 7 April 2016)].
Searches
We conducted database searches (ALOIS, Cochrane Central Register of Controlled Trials, Cumulative Index
to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature
and PsycINFO) on 11 December 2015. Additionally, we decided to search ongoing trials on clinical trials
registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov) on
22 and 29 January 2016, respectively, to ensure that we had complete data about what measures are
currently being used. We also hand-searched the reference lists of relevant systematic reviews found within
the database searches.
Inclusion and exclusion criteria
We included trials that met all of the inclusion criteria:
1. The full text is written in English.
2. The trial is published in a peer-reviewed journal article or is an ongoing trial.
3. At least some of the participants have clinically diagnosed mild or moderate dementia.
4. The intervention aimed to modify the dementia disease.
5. It is a randomised controlled trial (RCT) or clinical controlled trial with:
i. the intervention directed at the person with dementia
ii. the control or comparator arm comprising treatment as usual, no intervention, sham therapy, other
therapy or placebo.
6. At least one quantitative outcome measure related to disease modification in mild or moderate dementia.
We excluded studies in which all participants had severe dementia or mild cognitive impairment, and if the
whole study was set in care homes, as very few people with mild to moderate dementia would be resident
in care homes. We also excluded trials if the outcomes were only qualitative, economic or related only to
carers or drug levels.
Data extraction
We extracted characteristics from each of the trials, including trial type, location, intervention, control
group, participants and which outcomes were measured at what time points. Across the trials we
calculated how many used each outcome and with how many participants. We also divided the outcomes
into the domains that they measured, namely cognition, biological markers, activities of daily living (ADLs),
global assessment, neuropsychiatric symptoms and quality of life.
Validation data
We searched separately for validation data for each outcome measure. This included information about
any relevant populations that the outcome is validated for use with, minimal clinically important difference,
reliability (inter-rater and test–retest), ceiling-and-floor effects, sensitivity to change and any risks associated
with using the measure.
Workstream 3: patient and public involvement
We conducted three focus groups, one in each of Cambridge, London and Sheffield, in partnership with
the Alzheimer’s Society (AS) volunteer research network; consulting with people living with dementia
and family carers about the acceptability of outcomes, which they felt were core and any difficulties in
completing outcomes.
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We conducted an e-mail consultation with focus group participants afterwards on a report of the main
recommendations from across the three groups, to allow participants to comment on domains they had
not discussed and to make sure the recommendations to be presented at the conference represented what
had been said across the groups.
We also conducted a second e-mail consultation after the consensus conference with the wider AS
research network who had not attended the focus groups, to gain further feedback on a report of the
main recommendations made at the conference.
Workstream 4: consensus conference
We invited all co-applicants and collaborators of the project to the conference, thus including the wider
body of NIHR dementia researchers and additional people who had been involved during the project.
Twenty-seven people attended the conference from a wide range of specialties within dementia research.
The conference began with an overview of the project, the systematic review results and recommendations
from the focus group consultations. We had previously selected champions with expertise within each of the
domains and asked them to synthesise the results of the systematic review and validation data to present
recommendations for that domain at the conference. The conference attendees discussed their opinions
after each presentation. After this was finished the whole group agreed on overall recommendations.
Results
Systematic review results
Included studies
We found 22,918 original references from database searches and additional references from workstream 1,
and included 149 references referring to 125 trials.
Of the 125 included trials, 95 were published completed studies, three were published protocols and
27 were ongoing trials listed on trial registries. Most were RCTs (n = 124), and all tested the efficacy of
pharmacological interventions.
Outcomes
There were 81 different outcomes used across the trials; 72 questionnaire-/interview-based measures and
nine biological techniques used to measure biomarkers. We categorised outcomes by the domain they
measured. The domains were:
l cognition (31 outcome measures)
l quality of life (three outcome measures)
l ADLs (12 outcome measures)
l neuropsychiatric symptoms (16 outcome measures)
l global assessment (10 outcome measures)
l biological markers (nine biological techniques).
Patient and public involvement results
Participants
Overall, 18 people participated in patient and public involvement (PPI). The focus groups comprised 12 people:
three people living with dementia, two current family carers, six former family carers and one PPI group member.
Five of the focus group participants replied to the first e-mail consultation. Six people replied to the second
e-mail consultation: one person with dementia, three current family carers and two former family carers.
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Main recommendations
The participants made general recommendations around completing outcomes, as well as recommendations
specific to the domains.
Questionnaires’ content and delivery
Questioning should be clear, as participants may give different answers depending on the wording of the
questions, and too many questions and fast delivery can cause anxiety.
Time and travel
The maximum time for a meeting without a break is 1.5 hours, although researchers should aim for
shorter periods. Being able to participate in research locally, rather than having to travel far to a specific
centre, would encourage and help with participation.
Carers’ participation
Volunteers highlighted the probable disparity between the answers given by people with dementia and
carers, although they also thought that this could provide additional data. Volunteers also highlighted that
not all people with dementia will have a defined carer and, in the case of those who do, carers should be
involved in decisions around participating in research if their time and availability is needed.
Engagement
Many participants thought that clear restatement during the study of the reasons why they were completing
particular measures would aid continued engagement in the trial.
Activities of daily living
Volunteers had differing opinions about the use of ADL measures, but generally judged that instrumental
ADLs, rather than basic ADLs, were more relevant in mild to moderate dementia. Volunteers suggested
that questions should ask about the reasons for impairment, as this is not included in ADL measures.
Biological markers
Volunteers generally thought that biomarkers should be core, viewing them as being the most reliable,
objective measures, although carers questioned the value of the data collected, particularly from
blood tests.
Some volunteers particularly liked cerebrospinal fluid (CSF) measures, even though they were aware of
possible side effects, but they thought that misconceptions about what the procedure involves might
discourage participation. Those who had experienced CSF tests did not like the need to have it done in a
specific location.
Most volunteers thought that imaging could be core, as it can provide objective data, and that many
would consent to scans as giving biological data can make a person with dementia feel that they are
contributing useful information. Practical issues around travel were raised, and volunteers agreed that
scanning may be difficult for some people with dementia.
Cognition
Overall, volunteers agreed that cognition should be core. People with dementia described the distress of
seeing their score worsen, and a tendency to try to prepare for tests to prevent this from happening. Some
people preferred the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog) to the Mini
Mental State Examination (MMSE) as it is more detailed.
Neuropsychiatric symptoms
Some participants said that behaviour is core because it is a significant aspect of dementia and seems more
sensitive to illness than ADLs; others thought that behaviour should not be considered in isolation, as it may
be less applicable in mild to moderate stages and does not measure the reasons behind behaviour changes.
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Quality of life
Volunteers had different opinions over the inclusion of quality-of-life measures as core. One volunteer
thought that quality of life is core, as it can give a summary of an individual’s experience of dementia.
Others were unsure about the sensitivity of quality-of-life measures. It was suggested that comparing carer
and patient responses would give the most accurate account of quality of life.
Global
Volunteers had differing opinions about global rating scales. Some approved of the breadth of the
measures. However, others suggested that global measures are superficial, depending too much on
the individual’s experience on the day, and not meaningful.
Consensus conference results
Core domains
Cognition
Cognitive impairment is the core symptom of dementia, and it was therefore judged to be a core domain.
The conference recommended the use of either the ADAS-Cog or MMSE, as both are the best available of
the included tests based on psychometric properties and are the most commonly used. It would be helpful
for a future study to formulate an algorithm to be able to compare scores on both the ADAS-Cog and MMSE.
Biological markers
The conference concluded that structural magnetic resonance imaging (MRI) currently offers the best
biological marker of disease progression, although it is not a perfect biomarker. The conference recommends
MRI as a core outcome, but only as an optional part of the study, as it would not require as many participants
as a cognitive outcome for satisfactory power. This would enable people who are unable or unwilling to
undergo MRI to participate.
Non-core domains
The conference judged that the other four domains are important but not core. It was thought that they
will frequently be measured in studies and, therefore, we have made recommendations as to which to use
on the basis of their frequency of use and psychometric properties.
Activities of daily living
We recommend using an informant-rated measure as people with dementia can underestimate their
functional impairment. We recommend the use of the Disability Assessment for Dementia (DAD),
a dementia-specific ADL measure that has acceptable psychometric properties in this domain.
Neuropsychiatric
Within this category we recommend the Neuropsychiatric Inventory (NPI), the only measure being used in
ongoing disease modification trials and with satisfactory psychometric measures in this population.
Quality of life
We recommend the Dementia Quality of Life Measure (DEMQOL), as it is a dementia-specific measure with
acceptable psychometric properties and because it is possible to collect data for it from both the person
with dementia and an informant.
Global
For global outcomes we recommend the Clinical Dementia Rating (CDR) scale, a staging instrument
specific to dementia with adequate psychometric properties. We recommend using the global CDR score,
as using the sum of boxes score makes the scale a multidomain instrument rather than a staging one.
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Conclusions
Recommendations
The main recommendations are that cognition and biological markers are the only core outcome domains,
and should be measured by the ADAS-Cog or MMSE, respectively, and structural MRI. MRI can be
conducted on a subset of trial participants and so MRI findings are an optional outcome. We have also made
recommendations for the important, but non-core, domains of ADLs, global, neuropsychiatric and quality of
life, recommending the DAD, CDR, NPI and DEMQOL, respectively. As the recommended measures are
currently the best available, we expect that additional or alternative outcome measures may supersede the
current core set, particularly biological markers, which are the subject of considerable ongoing research.
Future research
As we recommend using either the ADAS-Cog or MMSE for cognition, it would be useful to develop an
algorithm to directly compare the scale scores. It would also be useful to conduct further detailed
qualitative research with PPI and trial staff, such as clinical research nurses.
Study registration
The project was registered with Core Outcome Measures in Effectiveness Trials [www.comet-initiative.org/
studies/details/819?result=true (accessed 7 April)]. The systematic review protocol is registered as
PROSPERO CRD42015027346.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the NIHR.
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Chapter 1 Introduction
I t is estimated that 850,000 people in the UK are currently living with dementia (> 1% of the entireUK population),1 and one-third of people born in the UK in 2015 will develop dementia during their
lifetime.2 Dementia care currently costs in excess of £23B per annum,1 with costs expected to triple in the
next 30 years as the number of older people increases. Dementia affects not only the person with the
illness, but also their family and wider society, and with the current absence of a preventative treatment,
the number of people with dementia is projected to reach > 1 million by 2020 and double again in the
subsequent 20 years.1 However, some recent population studies3,4 have suggested that the prevalence
of dementia among those now reaching 65–75 years of age may be slightly lower and, therefore, the rate
of increase, primarily driven by the ageing of the population, may not be as great as once thought. These
new data increase the optimism about potential primary prevention of dementia and of finding a disease-
modifying treatment5 that would either halt or delay underlying pathology.
There have been huge strides forward across dementia research, in particular with early diagnosis, information,
advanced decision-making, psychological therapies, management of neuropsychiatric symptoms, strategies
for family carers and cholinesterase inhibitors in Alzheimer’s disease (AD). There have also been positive
changes in attitudes, including highlighting personhood and living well with dementia. There is, however,
currently no cure or disease-modifying treatment for the common dementias. This may be partly because
our research knowledge and funding of dementia lags behind that of other major diseases, such as cancer
or heart disease.6
Following the successful expansion of NHS Memory Services, the number of people diagnosed with dementia
has increased dramatically in England.7 Currently, dementia sufferers can be offered only symptomatic
treatments, as well as access to social and psychological treatment, education, support and advice.1,8 The NHS
thus has a huge potential to use effective disease course-modifying treatments (which may be pharmacological
or non-pharmacological, and aimed at dementia in general or individual subtypes) and provides a large and
highly motivated group of affected patients and their families who would want to support research and
developments in this area.
The National Institute for Health Research (NIHR) has identified this as an important area of research and,
through the Efficacy and Mechanism Evaluation programme, is supporting two large drug-repurposing
disease modification trials of AD. The first of these, the RADAR trial (Reducing pathology in Alzheimer’s
Disease through Angiotensin TaRgeting),9 is a Phase II randomised controlled trial (RCT) evaluating the effect
of losartan on brain tissue changes in AD, with magnetic resonance imaging (MRI) brain volume change over
12 months as a primary outcome measure. Second, the MADE study (Minocycline for Alzheimer’s Disease
Trial),10 looking at the efficacy of minocycline in AD, measures change in cognition at 24 months with the
Mini Mental State Examination (MMSE) and function with the Bristol Activities of Daily Living (BADL) scale.
These trials were developed, funded and set up without any liaison between the trial teams. Indeed, both
had been funded for almost 2 years before the chief investigators found out about each other’s trials and
began to communicate about progress and difficulties. The completely different nature of the designs and
choice of outcome measures for these trials, together with the lack of co-ordinated activity of the trial teams,
illustrate starkly just how much more the UK dementia research community could do at this early stage to
strategically develop a co-ordinated approach to developing research in an effective and cost-efficient way,
particularly with the outcomes used across trials. Demonstrating efficacy in AD modification has so far
defeated the resources and efforts of the global pharmaceutical industry, and it is unlikely that individual
academic and NHS organisations will do any better if we cannot agree a unified approach that will allow us
to co-ordinate resources and integrate findings.
Delivering high-quality research in dementia is fundamentally important to the NHS and, since May 2013,
the NIHR has made good progress towards the target of recruiting 10% of dementia patients into clinical
trials. Working in partnership with the Alzheimer’s Society (AS) and Alzheimer’s Research UK, the NIHR
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launched ‘Join Dementia Research’ to provide ‘ready’ cohorts of patients consenting to be approached about
research. In addition, it has established ENRICH (Enabling Research in Care Homes), a network to support an
increase of dementia research in care homes. In February 2015, the UK prime minister announced plans for
a further £300M investment in dementia research. The UK has an experienced cadre of dementia triallists
with a track record of designing and delivering studies of pharmacological, psychological, educational and
other complex interventions, the results of which have often had an international impact on practice. The
NIHR has intimated that prospective investigators’ testing of putative disease modifiers should very seriously
consider the use of adaptive trial designs to improve the efficiency of trials.
Between 1998 and 2012, 101 new potential pharmacological treatments for AD entered trials internationally,
but only four drugs have received regulatory approval, all of which were symptomatic treatments rather than
disease modifying;11 these included cholinesterase inhibitors (donepezil, rivastigmine and galantamine).
Memantine, the last new drug to receive regulatory approval, was approved more than 10 years ago.12 Since
then, many promising disease-modifying drugs have been proposed, but all have failed at the point of Phase III
trials or at earlier stages of development.13 As a consequence, the number of pharmaceutical companies
with drug development programmes in neurodegeneration is shrinking. One suggested explanation for the
failure of so many new drugs for AD has been that by the point of clinical presentation the burden of
neurodegeneration may already be too great for disease-modifying interventions to have efficacy. Another is
that the majority of new drugs target just one of the numerous pathological mechanisms (e.g. inflammation,
hypoxia and oxidative stress, reduced energy metabolism) that are active and probably contribute to disease
severity and progression. It is predicted that if a treatment that could slow the progression of mild to moderate
dementia by 50% became available in 2020, this could reduce the numbers of people living with severe
dementia from 14% to 2% by 2050.14 At the G8 Dementia Summit held in London in December 2013, a
commitment was made to find a disease-modifying treatment by 2025.15
To improve the possibility of identifying a disease-modifying treatment, it is important that the outcomes
measured in trials are appropriate, sensitive and clinically meaningful.16–18 It is also essential that there is a
harmonisation of the outcome measures being used across trials to combat the large variance of measures
currently used.19 In 2015, the NIHR commissioned a call for the development of a core set of outcomes to be
used in future disease modification trials, particularly in mild to moderate dementia. Developing standardised
outcome sets is now being recognised as important across medical research, so that there should be a
commitment to measuring minimum sufficient sets of outcomes for every major medical condition.20
An agreed core set of outcomes would improve the efficiency and effectiveness of trials, and enhance
interpretation of data across disease-modifying trials. This applies to both drugs and non-pharmacological
interventions so that the efficacy of, for example, exercise, diet changes and new drugs can be compared.
It is also important to consider the acceptability of measurement packages and the burden that they put on
patients and their families. The priorities of patients in disease-modifying trials may not be the same as those
of researchers, and patients in focus groups appear to be less concerned about stigma and other negative
effects of diagnoses but wish to unambiguously know their disease status and accept biological and possibly
invasive tests.21 These may include quality-of-life and related outcomes that people with dementia and their
families report as being important to them, and can inform cost-effectiveness analysis, as well as more
symptom-related scales, such as cognition. Finally, a standardised core outcome set would aid meta-analysis
and thus enable the combination of small data sets to better inform practice. Therefore, there is an urgent
need for a consensus from dementia researchers in the UK about the core outcomes that should be used in
future disease modification trials in mild to moderate dementia.
This has led to the current project, which intends to produce a consensus within the dementia community
about the core outcomes for disease modification trials. It is funded by the NIHR Health Technology
Assessment programme, and brings together as co-applicants and collaborators, a large multidisciplinary
team of experts who are co-authors of the report and the AS, which has led the public involvement of
experts by experience arm of the study. The aims of the project are detailed in Chapter 2.
INTRODUCTION
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In workstream 1 we gathered possible relevant references that had been identified by other related systematic
reviews. These came from co-applicant Louise Lafortune, who led a systematic review on non-pharmacological
interventions for people living with dementia. We also searched the Cochrane Dementia and Cognitive
Improvement Group study register (ALOIS), which is maintained by the Cochrane Dementia and Cognitive
Improvement Group, represented by co-applicant Jenny McCleery. The use of additional references from
workstream 1 is detailed in Chapter 3. In addition, we looked at other core sets being developed by members
of the group, including an AS and European Union Joint Programme – Neurodegenerative Disease Research
(JPND)-funded study about outcomes used in psychosocial interventions in dementia, led by co-applicant
Gail Mountain, and a review of measures which are important to patients with dementia funded by the
International Consortium for Health Outcomes Measurement Working Group (ICHOM) led by co-applicant
Charlotte Roberts.
In workstream 2, we conducted a systematic review of the outcome measures that have been, and are
currently, used in disease-modifying trials of dementia; to our knowledge this is the first systematic
review of outcomes used in disease modification trials, the methods and results of which are detailed in
Chapters 3 and 4.
We considered the frequency of outcome use and validation, and discussed these outcomes with people
living with dementia and their carers. This patient and public involvement (PPI) consultation method and
results are detailed in Chapters 5 and 6.
We then brought all of the systematic review information together, with each potential domain being
presented by a champion, as well as presentation of the PPI focus groups results. This expert body debated
the questions and came to conclusions. Summaries of these presentations and the conference discussion
are detailed in Chapter 7. The discussions and conclusions are in Chapters 8 and 9.
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Chapter 2 Research question and objectives
The research question we set out to answer was ‘what are the core clinical and patient-relevant healthoutcomes that should be used in all NIHR-funded trials of disease modification in mild to moderate
dementia, and how should they be measured?’.
Objectives
1. To appraise existing research into outcome sets being developed for use in psychosocial interventions
(funded by the AS and JPND) and around what is most important to patients (measured by the
ICHOM), in the light of the goals of this study.
2. To update and add to the existing body of work by a systematic search of the outcomes used in
pharmacological and non-pharmacological studies of disease modification.
3. To appraise the outcomes identified through this systematic search, either using the existing research as
above or through the literature.
4. To synthesise the evidence to identify important, valid, reliable and acceptable outcome measures in
mild to moderate dementia.
5. To ensure by consultation that these outcome measures are acceptable and relevant to patients, carers,
clinicians and the research community, and that they would be practical to include in NIHR trials and
other studies.
6. To produce updated, evidence-based recommendations on the best outcome measures for disease
modification in mild to moderate dementia research and practice.
7. To validate these recommendations through a consensus conference.
8. To set out these results in a research paper and report for the Health Technology Assessment journal.
9. To enable the NIHR to specify an agreed set of core outcomes to be used for all funded trials of disease
modification in mild to moderate dementia.
Core Outcome Measures in Effectiveness Trials
We registered the project with Core Outcome Measures in Effectiveness Trials (COMET), a database
of planned, ongoing and completed core outcome sets. The project’s COMET record is accessible at
www.comet-initiative.org/studies/details/819?result=true (accessed 7 April 2016).
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Chapter 3 Systematic review methods
Protocol
We created the protocol for the systematic review according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) criteria22 and registered it with PROSPERO [no. CRD42015027346;
accessible at www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015027346 (accessed
7 April 2016)].
Search strategy
Database searches
As specified in the protocol, we searched Cochrane Central Register of Controlled Trials (CENTRAL),
Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, MEDLINE, Latin American
and Caribbean Health Sciences Literature (LILACS) and PsycINFO.
The search terms within the protocol were originally adapted from another systematic review being carried
out by a member of the group.23 These search terms, however, resulted in an unacceptably high number
of irrelevant results, with > 85,000 references identified in a search of MEDLINE alone. Therefore, in
consultation with the project steering group, we adapted the search terms to reduce irrelevant references
being picked up. The full search strategy for MEDLINE (via OvidSP) is shown in Appendix 1, with the same
strategy used for EMBASE and PsycINFO (via OvidSP), and modified for searches in CENTRAL (via The
Cochrane Library), CINAHL (via EBSCOhost), and LILACS [via the Virtual Health Library (VHL) Regional
Portal]. As we are interested in outcome measures available in English, we limited database searches to
English language where possible (CINAHL, EMBASE, LILACS, MEDLINE and PsycINFO).
As part of workstream 1 we also searched ALOIS and added these references to the ones found in the
other database searches. We used the advanced search for intervention studies, with a combination of
search terms: (‘outcome’ OR outcome OR outcomes OR ‘instrument’ OR instrument OR instruments OR
‘measure’ OR measure OR measures) AND (intervention OR therapy OR therapeutic OR trial OR trials) AND
(control OR controlled), selecting ‘Treatment dementia’ as the study aim, all study designs, <any>
interventions, and <any> if included in Cochrane.
Additional databases
In order to ensure that we picked up all outcomes that are currently being used, we adapted the protocol
to include searches of the International Standard Randomised Controlled Trial Number (ISRCTN) and
ClinicalTrials.gov trial registries for ongoing disease modification trials in dementia. To search the ISRCTN
database we selected the trial status as ‘ongoing’ and the condition as ‘dementia’. To search ClinicalTrials.gov
we combined ‘dementia’ AND ‘(control OR controlled)’, and limited the search to ‘open studies’.
Hand-searches
We hand-searched the bibliographies of relevant systematic reviews that were found within the database
searches. We then also searched additional references collected in workstream 1, from a systematic review
of non-pharmacological interventions for dementia.
Search dates
Searches were conducted on 11 December 2015 (for ALOIS, CENTRAL, CINAHL, EMBASE, LILACS and
PsycINFO), 22 January 2016 (for ISRCTN) and 29 January 2016 (for ClinicalTrials.gov). All of the searches
were conducted from database inception, with no limit on the end date.
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Study inclusion
Inclusion criteria
We defined a disease modification trial as one where the intervention aims to change the underlying
pathology of the dementia disease. This is as opposed to trials that aim solely to treat the symptoms of
dementia, but not affect the underlying illness.
We included trials if they met all of the following criteria:
1. The full text is written in English.
2. The trial is published in a peer-reviewed journal or is an ongoing trial.
3. At least some of the participants have clinically diagnosed mild or moderate dementia.
4. It is a trial that aimed to modify the dementia disease.
5. It is a RCT or clinical controlled trial (CCT) with:
i. the intervention directed at the person with dementia
ii. the control or comparator arm comprising treatment as usual, no intervention, sham therapy,
other therapy or placebo.
6. At least one quantitative outcome measure related to disease modification in mild or moderate dementia.
Exclusion criteria
We excluded studies where:
1. all participants had severe dementia (according to the study inclusion criteria, including a MMSE score
of < 12 or equivalent)
2. the whole study was set in care homes, as the commission call specified a review of outcome measures
that modify the disease of mild to moderate dementia and very few of whom would be resident in
care homes
3. all participants had mild cognitive impairment (MCI)
4. the outcomes were only:
i. qualitative
ii. related to carers
iii. economic
iv. related to drug levels.
Screening titles and abstracts, and full texts
We screened titles and abstracts found across the searches for relevance. Two reviewers (DG and LW)
piloted this procedure by independently screening the first 20 titles and abstracts and then compared their
decisions. There were no disagreements, confirming the reliability of the first screening.
Three raters (AGS, DG and LW) also piloted the screening of full texts for inclusion criteria. They screened
the first 10 papers independently, comparing answers and discussing, and then repeating the process with
the next 10 papers. The three raters agreed on 80% of the first 20 papers, with no decision to exclude a
paper that was eventually included. The raters disagreed regarding whether or not four papers should be
excluded (see Appendix 2). The disagreements were whether or not the intervention was aiming to modify
the underlying pathology of the disease of dementia. We agreed to solve this by examining in detail how
the intervention is described in the background section, as well as the aim of the intervention within the
trial. We also agreed to discuss any trials where we were unsure if the aim was to modify the disease
between the raters and Gill Livingston if necessary. If a trial seemed to fulfil the inclusion criteria but we
needed extra information about it, we contacted the authors to ask for this.
SYSTEMATIC REVIEW METHODS
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Data extraction
We extracted data about trial location, trial type, dementia type and severity, how the dementia diagnosis
was made, participants’ sex and age, description of the intervention (number of participants; n), description
of the comparator group (n), outcomes related to disease modification (primary or secondary if reported)
and when outcomes were measured. To assess the accuracy of extracted data, Derek Groskreutz and
Lucy Webster independently extracted data from the same subsample of five trials and compared their
answers. There were no differences between the raters’ extracted data. We used this exercise, and an
additional five papers, to pilot the data extraction tool and ensure that all relevant data from trials were
captured. After piloting the tool, we created a second data extraction tool, which included the time period
from baseline when each outcome was measured for each study, as within trials different outcomes were
measured at different time points.
Data synthesis
For each outcome measure we listed how frequently it was used (i.e. number of trials) with how many
participants there were across the trials. We searched Google Scholar (Google Inc., Mountain View, CA,
USA) to find a copy of each outcome measure in English, either the manual or a key paper relating to its
development. We divided all outcomes into domains [specifically cognition, activities of daily living (ADLs),
biological markers, neuropsychiatric symptoms, quality of life and global]. Initially we had not planned to
consider global outcomes, but we added it as a separate outcome category as we found relevant measures.
Quality assessment
As our aim was to synthesise the outcomes used across trials, rather than to report results, we did not
consider it necessary to assess the quality of studies.
Outcome validation
We conducted separate iterative searches on Google Scholar using the name of the measure and
psychometric terms, and consulted within our expert group for each outcome measure to find information
on the measures’ psychometric properties relevant to people living with dementia. Specifically, we sought
information about:
l if the measure is validated in people with mild to moderate dementia for the outcome in which it is
used as a measure
l if there are any relevant populations in which the measure is validated (e.g. mild to moderate
dementia, ethnic groups, languages)
l unit of measurement
l sensitivity to change
l minimal clinically important difference
l reliability (inter-rater and test–retest)
l acceptability
l ceiling-and-floor effects
l average time taken to complete
l who fills in the questionnaire (i.e. researcher through patient, family carer, paid carer or observation, or
self-complete)
l any risks identified of use of the measure.
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Chapter 4 Results of the systematic review
Details of included and excluded studies
Figure 1 shows a PRISMA flow diagram with the results of the searches. Altogether we found 22,918
original references from searches of databases and workstream 1 (ALOIS and another systematic review of
non-pharmacological interventions for dementia). From the screening of all titles and abstracts, we excluded
22,021 references and sought the full texts of 897 abstracts. From the full texts, we excluded 748 papers;
a list of excluded studies and reasons for exclusion is in Appendix 3. We included 149 reports of 125 trials.
The 125 trials included 95 published trials, three published protocols and 27 ongoing trials, the characteristics
of which are available, respectively, in Tables 1–3 in this chapter. One trial was a CCT, with the other
Records 
identified 
through 
hand-searching
 (n = 39)
Records identified 
through sources in 
workstream 1
ALOIS 
(n = 167)
Sytematic review of 
non-pharmacological
interventions
(n = 167)
Records identified 
through sources in 
workstream 2
CENTRAL (n = 5689)
MEDLINE (n = 8509)
PsycINFO (n = 2973)
EMBASE (n = 16,426)
LILACS (n = 203)
CINAHL (n = 3085)
ISRCTN (n = 36)
ClinicalTrials.gov (n = 493)
Records after 
duplicates removed 
(n = 22,918)
Full-text articles 
asessed for eligibility
(n = 897)
Studies included
(n = 149 reports, 
including 125 trials)
Records screened
(n = 22,918)
Records excluded
(n = 22,021)
Full-text articles excluded, with reasons
(n = 748)
• Unable to find a copy of the full text, n = 4
• Full text unavailable in English, n = 30
• Not published in a peer-reviewed journal
   or an ongoing trial, n = 150
• No participants with mild or moderate 
   dementia, n = 5
• Not a disease-modification trial, n = 550
• Not a RCT or CCT, n = 5
• No quantitative outcome relating to
   disease modification, n = 4
FIGURE 1 The PRISMA flow diagram.
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124 trials being RCTs. Trials were carried out in Australia (n = 2), Austria (n = 1), Canada (n = 1), China (n = 2),
Denmark (n = 1), France (n = 2), Germany (n= 5), Iran (n= 2), Italy (n = 4), Japan (n = 1), Korea (n= 1), the
Netherlands (n = 2), New Zealand (n= 1), Poland (n= 2), Russia (n = 1), Spain (n= 3), Sweden (n= 4), Taiwan
(n= 1), the UK (n = 6) and the USA (n = 46); 37 were multicountry studies.
Across the trials, most participants had only AD; 16 studies included only patients with mild AD (seven of
which specified early AD), six included patients with moderate AD, 84 involved patients with mild to moderate
AD, two included patients with mild to severe AD, two studies included patients with moderate to severe AD
and in one study all participants had AD of unspecified severity but were living at home. Eight trials also
included participants with MCI, alongside mild (n = 5) or mild to moderate AD (n = 3). Three trials combined
participants with AD and vascular dementia, two included patients with mild to moderate AD or vascular
dementia, and one comprised patients with mild to moderate AD, with or without vascular dementia. Two
trials included participants with vascular dementia only, one included patients with mild to moderately severe
vascular dementia and one included patients with mild to moderate subcortical ischaemic vascular dementia.
One trial included participants with mild to moderate primary degenerative dementia or vascular dementia.
Outcomes found in the review
An overview of the findings of the systematic review is available in Box 1.
BOX 1 Overview of findings of the systematic review
Findings (number of trials)
Cognitive outcomes (117 trials measured at least one cognitive outcome; 31 different outcomes)
Global: Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog) (n = 92); Mattis Dementia
Rating Scale (n = 1); MMSE (n = 83); Modified Telephone Interview for Cognitive Status (n = 1); and Vascular
Dementia Assessment Scale Cognitive subscale (n = 1).
Batteries: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)’s Neuropsychological Test
Battery (n = 2); Cogstate Alzheimer’s Battery (n= 6); Computerised Neuropsychological Test Battery (n= 1); Frontal
Assessment Battery (n= 1); Mental Deterioration Battery (n= 1); Neuropsychological Test Battery (n= 7); Severe
Impairment Battery (n = 1); Syndrome Short Test (n = 2); Wechsler Adult Intelligence Scale – Revised (n = 1);
Wechsler Memory Scale (n = 5); and Western Aphasia Battery (n = 1).
Individual tests (either used in combination or to supplement the ADAS-Cog or MMSE): Buschke Selective
Reminding Test (n= 3); Benton Visual Retention Test (n= 1); clock drawing test (n= 2); controlled oral word
association test (n= 2); digit span test (n= 2); digit symbol (n= 3); dot counting n-back task (n= 1); fluency tests
(n= 7); Mohs number cancellation test (n= 1); recall tasks (n= 3); Rey 15-Item Memory Test (n= 1); Stroop Colour
Word Interference Test (n= 4); token test (n= 1); trail making test (n= 10); and word recognition (n= 1).
Techniques for biological markers (71 trials measured at least one biological marker;
nine different techniques)
Imaging: electroencephalography (n= 3); Doppler ultrasound (n= 1); MRI (n= 30); magnetic resonance spectroscopy
(n= 1); positron emission tomography (n= 20); and single-photon emission computerised tomography (n= 1).
Fluid: blood tests (n = 35); cerebrospinal fluid analysis (n = 48); and urine analysis (n = 1).
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We contacted three authors to request extra information regarding outcomes; two of whom provided
this.9,24 There were 81 different outcomes used across the trials; 72 questionnaire- or interview-based
measures and nine biological techniques used to measure biomarkers. We categorised outcomes by the
domain they measured. The domains were:
l cognition
l quality of life
l ADLs
l neuropsychiatric symptoms
Neuropsychiatric outcomes (58 trials measured at least one neuropsychiatric outcome;
16 different outcomes)
Global: Alzheimer’s Disease Assessment Scale – Non-Cognitive subscale (n = 7); Behavioural Pathology in
Alzheimer’s Disease Rating Scale (n = 1); Brief Psychiatric Rating Scale (n = 3); CERAD’s Behavioural Scale (n = 1);
Dysfunctional Behavior Rating Instrument (n = 1); Neuropsychiatric Inventory (n = 38); Nurses’ Observation Scale
for Geriatric Patients (n = 2); Plutchik Geriatric Rating Scale (n = 1); and Revised Memory and Behaviour Problems
Checklist (n = 1).
Specific symptoms: Cohen-Mansfield Agitation Inventory (n = 1); Columbia Suicide Severity Rating Scale (n = 3);
Cornell Scale for Depression in Dementia (n = 3); Geriatric Depression Scale (n = 10); Hamilton Depression
Rating Scale (n = 5); Montgomery Depression Rating Scale (n = 2); and Zerssen Adjective Mood Scale (n = 2).
Quality-of-life outcomes (16 trials measured at least one quality-of-life outcome;
three different measures)
Dementia quality-of-life measure (n = 4); EuroQol-5 Dimensions Scale (n = 5); and Quality of Life in Alzheimer’s
Disease Scale (n = 8).
Activities of daily living outcomes (68 trials measured at least one activities of daily living outcome;
12 different measures)
Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory (n = 35); Alzheimer’s Disease
Functional Assessment and Change Scale (n = 2); BADL (n = 5); Dependence scale (n = 2); Disability Assessment
For Dementia (n = 13); Functional Activities Questionnaire (n = 3); Interview for Deterioration in Daily Living
Activities in Dementia (n = 2); Katz Index of Activities of Daily Living Scale (n = 4); Lawton Instrumental Activities
of Daily Living Scale (n = 8); Nuremberg Gerontopsychological Rating Scale for Activities of Daily Living (n = 3);
Physical Self-Maintenance Scale (n = 3); and Video Recorder Home Behavioural Assessment (n = 1).
Global outcomes (80 trials measured at least one global outcome; 10 different measures)
Impression of change: Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (n = 8);
Clinical Global Impression’s Scale (n = 15); and Clinician’s Interview-Based Impression of Change plus Caregiver
Input (n = 12).
Multiple domains: Blessed Dementia Rating Scale (n = 3); Dementia Severity Rating Scale (n = 3);
Gottfries–Bråne–Steen Rating Scale for Dementia (n = 4); Sandoz Clinical Assessment-Geriatric Scale (n = 2);
and Short Cambridge Mental Disorders of the Elderly Examination (n = 1).
Staging of dementia: Clinical Dementia Rating Scale (n = 48); and Global Deterioration Scale (n = 6).
BOX 1 Overview of findings of the systematic review (continued)
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l global assessment
l biological markers.
To help understand the findings of the review, we first provide an overview of the outcome measures used
and their frequency of use in individual studies before describing the characteristics of these studies.
We have divided the studies into published studies, ongoing trials and protocols.
Box 1 shows the outcome measures found. When outcome measures were categorised by domains,
cognition was the largest domain in terms of the variety of instruments used, with 31 outcome measures
used across the trials. Furthermore, cognition was the most widely used domain, being measured through
at least one outcome measure in 117 of the 125 included trials. The domain included measures that look
at cognition globally (n = 5), individual neuropsychological tests focusing on specific elements of cognition
(n = 15) and then batteries of individual cognitive tests (n = 11). Of the included batteries, two are solely
computerised (Cogstate Alzheimer’s Battery and Computerised Neuropsychological Test Battery).
The second most widely used outcomes were global measures, with 80 trials using at least one global
outcome from a variety of 10 measures. The 10 measures included scales that look at clinical impressions
of change (n = 3) that consider multiple domains (n = 5) and that stage dementia (n = 2). Seventy trials
measured at least one biological marker, using one of nine biological techniques. The techniques can be
further divided into imaging techniques [e.g. MRI (n = 6)] and fluid [e.g. blood tests (n = 3)]. Some of
the biological markers measured via these techniques included the levels of amyloid-β peptide and
microtubule-associated protein tau in blood and cerebrospinal fluid (CSF), changes in brain volume on MRI
and changes in glucose metabolism and the density of amyloid-β peptide plaques on positron emission
tomography (PET).
Activities of daily living were measured across 68 trials, with 12 different measures used. Neuropsychiatric
symptoms were measured across 58 trials using 16 different measures. The neuropsychiatric outcomes
included scales measuring symptoms globally (n = 9) and scales that focus on specific symptoms [e.g.
depression or agitation (n = 7)]. Finally, quality-of-life outcomes were the least used across the trials; only
16 of the 124 trials measured this domain and they employed one of three measures.
Published trials
Characteristics of the included published trials are given in Table 1.
We included 95 trials published between 1990 and 2015. Most studies included all or some participants
with AD (n = 94), and one study included only participants with vascular dementia. All were RCTs, except
for one CCT. The trials included a total of 22,362 participants.
A total of 79 different outcomes were used. The majority of trials (n = 94) used at least one cognitive
outcome,25,27–29,31,33,37–41,43,45–47,49,51–55,57–59,61–64,66,68–71,73,75,77,78,81,85–90,92,93,96–99,101–116,118,119,121–146 of which there
were 30 different measurement tools. The second most commonly measured domain was a global
outcome, with nine different measures used across 64 trials.25,27–29,31,33,37–39,41,45–47,49,52,54,55,57–59,62–64,66,68,73,75,78,81,
86–90,92,97,104,106–108,110,112–114,118,119,121–128,131,133,134,137,139,142–146 Fifty trials included a neuropsychiatric outcome,25,27,
28,33,37,41,43,45–47,51,52,55,57,64,66,68,75,78,86–93,97,104,106,107,110,112,115,118,119,121,123,125,126,130,131,133,134,137–140,143,145,146 with a variety
of 16 measures used. ADLs were measured in 55 trials, using 12 measures.27,28,33,37,41,45,46,49,51,52,54,55,57,59,61,63,64,
66,68,77,78,81,85–90,92,97,104,106–108,110–112,114,115,118,119,121–125,128,134,135,137,138,142–145 Biological markers were measured in
51 trials using a variety of nine biological techniques.29,31,33,37,40,43,47,53–55,59,63,66,68–71,73,77,78,81,85,86,89,93,95,96,98,101,
103–105,109–113,115,116,121,122,129–132,137,139–141,144,145 Eleven of the published trials measured quality of life, using one
of three outcomes.28,33,66,68,78,86,89,90,104,112,124
Published protocols
The characteristics of the published protocols are described in Table 2.
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We included three protocols, published between 2011 and 2015. None of the results of the three trials
have, as yet, been published. All three are randomised placebo-controlled trials, with participants with AD.
All three are being conducted in Europe: one in Denmark,148 one in France147 and one multicountry study
in France, Germany, Greece, the Netherlands, Hungary, Ireland, Italy, Sweden and the UK.149
All three trials used at least one cognitive outcome; there were five different cognitive outcomes. ADLs
were measured across two trials using a variety of three measures. One trial measured biological markers,
via two biological techniques. Only one trial used a global outcome. None of the published protocols
measured neuropsychiatric or quality-of-life outcomes.
Ongoing trials
The characteristics of the ongoing trials are available in Table 3.
We included 27 ongoing trials registered on clinical trial databases as ongoing at the time of the search.9,10,24,
150–173 All are RCTs, including participants with vascular dementia (n = 1),150 only AD (n = 21),9,10,24,151,152,154–158,
161,162,164–168,170–173 and AD or MCI (n = 5).153,159,160,163,169 There was a total of 32 outcome measures used across
the trials. Twenty of the trials measured cognition, using 1 of 12 outcome measures.9,10,24,150,152–155,157–160,163,165,
167–169,171–173 Similarly, 19 of the trials measured biological markers, using a variety of five biological
techniques.9,150–159,161–164,166,169,172,173 Thirteen trials measured the domain of neuropsychiatric symptoms, using
four measures.9,150,152,155–159,161,163,169,171,173 Quality of life was measured in five trials using three measures.9,150,152,
158,173 ADLs were measured across 11 trials, using four measures.9,10,150,152,155,157–159,169,171,173 Fifteen trials
measured a global outcome, using a variety of four measures.24,150–154,157–160,167–172
Validation data
The validation data for the outcomes in each domain are available in Tables 4–9.
We searched separately for validation information for each outcome measure, and also recorded how long
each measure takes on average to complete and who completes it. Both the results of the review and the
validation data were used at the consensus conference, which is discussed in Chapter 6.
Cognitive outcomes
As a result of the large number of cognitive outcomes, we shortlisted five cognitive outcomes for which
we would search for validation data. These were the Alzheimer’s Disease Assessment Scale – Cognitive
subscale (ADAS-Cog), MMSE, the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)’s
Neuropsychological Battery, the Neuropsychological Battery and the Cogstate Alzheimer’s Battery.
We excluded the other cognitive outcomes for a number of reasons. They had only been used in one trial:
l Mattis Dementia Rating Scale416 (one published trial; 149 participants)
l Modified Telephone Interview for Cognitive Status417 (one ongoing trial)
l Vascular Dementia Assessment Scale Cognitive Subscale418 (one ongoing trial)
l Computerised Neuropsychological Test Battery419 (one published trial; 20 participants)
l Frontal Assessment Battery420 (one protocol)
l Mental Deterioration Battery421 (one published trial; 142 participants)
l Wechsler Adult Intelligence Scale422 (one published trial; 48 participants).
They measure cognition in severe dementia:
l Severe Impairment Battery423 (one published trial; 26 participants).
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They are not available in the English language:
l Syndrome Short Test424 (two published trials; 410 participants).
They refer to only one domain:
l Wechsler Memory Scale425 (five trials; three published, one protocol and one ongoing; 238 participants)
l Western Aphasia Battery426 (one published trial; 48 participants).
We also did not search for validation of the individual cognitive tests, as they are neuropsychological tests
rather than cognitive scales, with the validation process of these tasks different as they are designed to
do different things.427 Furthermore, the individual tests focus on specific domains of cognition, and as
dementia is an impairment of more than one cognitive domain a global scale is more appropriate. Most of
the individual tests have only been used in a small number of trials and often in combination. These include:
l Buschke Selective Reminding Test428 (three published trials; 108 participants)
l Benton Visual Retention Test429 (one published trial; 60 participants)
l clock drawing task430 (two published trials; 30 participants)
l controlled oral word association test431 (two trials; one published and one ongoing; 399 participants)
l digit span test432 (two trials; one published and one ongoing; 399 participants)
l digit symbol substitution test422 (three published trials; 680 participants)
l dot counting n-back task58 (one published trial; 60 participants)
l fluency tests (seven trials; four published and three ongoing; 385 participants)
l Mohs Number Cancellation Test433 (one ongoing trial)
l recall tasks (three published trials; 116 participants)
l Rey Memory Test434 (one published trial; 213 participants)
l Stroop Colour Word Interference Test435 (four published trials; 507 participants)
l token test436 (one published trial; 12 participants)
l trail making test437 (10 trials; six published, one protocol and three ongoing; 866 participants)
l word recognition (one published trial; 20 participants).
Neuropsychiatric outcomes
Similarly, for the neuropsychiatric outcomes we decided that we would not recommend measures of
specific neuropsychiatric symptoms, such as agitation or depression; therefore, we did not search for
validation data for the seven specific symptom measures included. These were:
1. Cohen-Mansfield Agitation Inventory438 (one trial, 89 participants)
2. Columbia Suicide Severity Rating Scale439 (three trials, all ongoing)
3. Cornell Scale for Depression in Dementia440 (three trials, 464 participants)
4. Geriatric Depression Scale441 (10 trials, 803 participants)
5. Hamilton Depression Rating Scale442 (five trials, 677 participants)
6. Montgomery Depression Rating Scale443 (two trials, 269 participants)
7. Zerssen Adjective Mood Scale444 (two trials, 381 participants).
Biological outcomes
For the validation of the biological outcomes, the two champions first used their expertise and own
searches for validation information to make their recommendations. Afterwards we added to this with
regard to serial structural MRI, as this is the only biological outcome we are recommending; therefore,
MRI is the only biological outcome we have recorded validation information for in Table 9.
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Chapter 5 Methods of patient and public
involvement consultation
Purpose
The purpose of PPI within this project was to present people both directly and indirectly affected by
dementia, including those with experience of research participation, with some of the findings from our
systematic review to seek their views on which of the domains they considered core and their assessment
of the acceptability of individual and packages of measures. We also wanted to know their thoughts about
general matters around completing outcome measures, including the length of testing that was acceptable,
who they thought should complete outcomes, opinions about invasive tests and travel distances to a
research site.
Procedure
We planned to consult through face-to-face focus groups followed by e-mail consultation, with people
recruited from AS’s Research Network volunteers. After meeting with the groups we sent a summary by
e-mail to those who attended to check that the recommendations we intended to present at the consensus
conference reflected what they thought had been said across the groups. We also asked participants if they
had anything else to add.
After the consensus conference we conducted a second e-mail consultation with people from the AS
Research Network, excluding those who had already attended the focus groups, to gain further feedback
about the conclusions of the consensus conference.
Focus groups
We held three consultations, one in each of Cambridge, London and Sheffield, in February and March
2016. All were led by Lucy Webster and Anna Grinbergs-Saull from the AS. Champions within the group
agreed to co-facilitate the focus groups. The AS had found that in previous focus groups including a
clinician who uses these measures, and is therefore able to explain them, aids discussion, allowing
participants to ask specific questions. The clinicians in each group were Gail Mountain in Sheffield, Gill
Livingston in London and John O’Brien in Cambridge. Participants were e-mailed an information sheet and
asked at the groups if they all consented to the session being recorded, with only Lucy Webster or the AS
able to listen to the recording before it was destroyed (see Appendix 4). Participants who lived within
travelling distance of each focus group were invited from the research network. For the Cambridge focus
group, following recommendations made by a co-applicant, we also invited additional people from a local
dementia and ageing research PPI group. Focus groups lasted 1–2 hours.
We focused on a different set of domains in each group, although there was an overlap between domains
discussed at focus groups (Table 10). Discussions were audio-recorded and, to allow the participants to
generate conclusions as easily as possible throughout the discussion, we summarised the conversations on
TABLE 10 Consultation topics
Sheffield London Cambridge
ADLs, cognition Quality of life, global, outcome sets Biomarkers, neuropsychiatric, outcome sets
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flipchart paper. This allowed volunteers to see the notes that we were recording and refer to them when
they felt it was necessary.
First e-mail consultation
To gain a wider range of views, we ran an e-mail consultation with focus group participants on a summary
report of the focus group discussions. This was to allow the volunteers to comment on measures that they
had not discussed in their focus group and respond to the conclusions we drew (see Appendix 5).
Second e-mail consultation
We then ran a second e-mail consultation on a report including recommendations made at the consensus
conference (see Appendix 6). This was sent to research network volunteers who had not participated in a
focus group. This consultation included volunteers who had expressed an interest in focus groups but were
unable to attend, and those living in different areas, including Wales, Northern Ireland and the Midlands.
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Chapter 6 Results of patient and public
involvement consultation
Demographic details of participants
Table 11 includes an overview of the experiences and geographical locations of all 18 participants who
were involved in the PPI consultations.
Focus groups
The face-to-face focus groups involved 12 people overall: three people living with dementia, two current
family carers, six former family carers and one PPI group member. Some had participated in research or
supported a family member through participation; others had no trial experience. There was an even split
between men and women. Participants gave their ages in bands as 45–54 years (n = 1), 55–64 years
(n = 2), 65–74 years (n = 5) or ≥ 75 years (n = 4). Ten of the participants were white British and two were
TABLE 11 Volunteer background information
Background information Number of participants
Care experience
Person living with dementia 4
Current carer 6
Former carer 7
Ageing and research PPI 1
Dementia experience
AD 14
Vascular 2
FTD 1
PCA 1
Research experience
Participant 6
Carer of participant 1
Steering group 7
None 7
Geographical region
London 1
East Anglia 7
North England 8
Northern Ireland 1
Wales 1
FTD, frontotemporal dementia; PCA, posterior cortical atrophy.
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white other (one white South American and one not specified). Most participants were married or living
with their partner (n = 7), four were widowed and one divorced. Participants had a range of occupational
backgrounds with current or last employment given as architect, care assistant, civil servant, footwear
manufacturer, ecotoxicologist, civil servant, information technology manager, marketing communications
director, NHS team leader, NHS therapy manager, senior staff nurse and retiree.
First e-mail consultation
The first e-mail consultation was sent to the 12 people who participated in the focus groups, of which
five responded.
Second e-mail consultation
The second consultation was sent to the wider AS research network, excluding focus group participants.
We received six responses from people with experience of AD, including one person with dementia and
five carers (three current carers and two former carers).
This report gives a summary of the views of those consulted on different outcome measures, their use and
the design of a core outcome package. Where possible we have included direct quotes from volunteers,
identifying only whether they were a person with dementia (PWD) or a carer. We have separated the
recommendations by the most common themes that were suggested by participants during the focus groups.
What should be measured?
At the start of each focus group session people were asked ‘what should be measured?’. Responses were
varied but gave broad support to each of the six domains covered. Suggestions not directly covered by the
domains were:
l side effects of pharmacological interventions
l frequency of falls
l sleep disturbance – thought to be a significant indicator of progression
l carer outcomes – described by carers as a potential indicator of progression and likely to affect
patient outcomes.
General recommendations
Throughout our discussions participants suggested potential improvements to the way in which outcome
measures are delivered or packaged. Volunteers suggested several factors affecting the acceptability of
outcome measures. We also received feedback on these suggestions during the e-mail consultation.
Questioning and terms used
Too many questions and fast delivery can cause anxiety in people with dementia, and intensive questioning
can be perceived as ‘getting at you’ (carer).
The way in which questions were asked and the types of questions asked were also discussed. People with
dementia stated that the questioning should be clear, as they may give completely different answers
dependent on certain words. For example, the questions ‘On a good day? or ‘On a bad day?’ (PWD)
would elicit different responses.
Across the questionnaires shown to people living with dementia, two people had a preference for positive
questions that did not ‘focus on the negative stuff as much’ and rather the ‘things we can do’. However,
another person living with dementia also noted ‘it’s more relevant what they cannot do than they can do,
because there’s an awful lot more we can’t do than we can do’.
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Several volunteers also strongly disagreed with the word ‘carer’, suggesting that this discounted those
who did not identify as caring/cared for by a family member and those who lived alone. To conform to
conventions within the literature, the word ‘carer’ is used here. However, we felt it was important to note
the dislike for the term.
Time and travel requirements
The groups all thought that both time and travel could be a barrier to participation. Measures were
deemed less appropriate if they required participants to travel to a specific centre each time. Long, single
meetings were described as too tiring for people with dementia (most preferred a full day with several
breaks). One and a half hours was described as the absolute maximum time for a single meeting or test
without a break; however, volunteers suggested that researchers should be encouraged to aim for shorter
periods. People with dementia particularly discussed reaching a stage where they cannot concentrate
during longer sessions, but suggested that they may not be immediately aware that they had reached this
point. Shorter testing would prevent this from happening:
Where it’s got to the stage that you’re not aware that you’re not giving the right answer, or what you
would have given at the beginning.
PWD
Volunteers also stressed the importance of clearly explaining the time required, including any breaks and
waiting periods. Carers suggested that waiting for a meeting can seem aimless and can therefore be
particularly difficult to explain to the person they support.
Having to travel far is a barrier, as people with dementia are ‘going to have comorbidities . . . They’re
going to have all the other things going on . . . so it makes it much more difficult’ (carer). Carers noted
that being able to participate in research locally, rather than having to travel far, would encourage and
help with participation.
Role of the ‘carer’ in completing outcomes
Discussing carer-assessed measures, volunteers highlighted the likely disparity between the answers given
by people with dementia and carers. Although some thought that this was a problem, two volunteers also
pointed out that a difference in responses might provide an additional source of data. The participants said
that many people with dementia live alone. Although measures do not require co-residence, volunteers
also pointed out that not all people with dementia will have a defined carer, family member or friend
who could give an accurate assessment. However, all agreed the ‘importance of the carer in the
decision-making’ around participating in research, as their time and availability play a part in the trial:
You can’t expect them to take days off work to come with you to an assessment . . . it’s difficult
because then you’re relying on what I’m saying.
PWD
Engagement: communication and relevance
Many participants thought that clear communication about the reasons why particular measures were
chosen would aid continued engagement in the trial. Participation requires commitment and time, and
they felt that participants need to know what they are contributing and why. Although volunteers
understood the need for standardisation to improve the usefulness of data, some people with dementia
and carers did not like standardised questionnaires. It was suggested that standard sets of questions might
not be relevant to different types of dementia. For example, a carer with frontotemporal dementia
experience suggested that receiving questions about memory made the research seem ‘a waste of time’.
Furthermore, some volunteers felt that standardised questions lack contextual detail about an individual’s
background, and that results would be relative to each person’s experience of dementia and its symptoms.
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Standardised interviews
Cognition
Overall, volunteers agreed that cognition should be core. However, volunteers felt that it should not be
used in isolation as the only core measure and suggested that cognitive scores needed contextual,
qualitative information. Carers, in particular, suggested that more weight should be placed on the
interaction between cognition and ability rather than cognition alone:
It is more important to understand how a person’s cognitive impairments affect their activities of daily
living and quality of life . . . than it is to rate their underlying cognitive skills.
Carer
Although they acknowledged its use as a standard cognitive measure, performed in a range of research
and clinical contexts, several people did not like the MMSE. People with dementia suggested that it
seemed irrelevant, as it gives a restricted account of dementia and carers described how they thought it
would be difficult to have a cognitive measure that seemed relevant to all people with dementia:
It doesn’t seem useful.
PWD
It doesn’t have anything to do with what we have.
PWD
Cognitive testing, because we are so different and the way it progresses in the different forms of
dementia makes it so complicated to try and produce some kind of standardised measure.
Carer
Volunteers, including both people with dementia and carers, felt that memory tests can be demoralising;
carers particularly felt that it is distressing ‘watching someone fail a test’. People with dementia described
the distress of seeing their score and performance worsen, and a tendency to try to prepare for tests to
prevent this from happening. Some people preferred the ADAS-Cog to the MMSE, as it is more detailed in
terms of the answers you can give.
Activities of daily living
Volunteers disagreed over the use of ADLs. Some focus group discussions concluded that it was not core;
however, other people with dementia considered ADLs an accurate, practical measure of dementia.
Volunteers consulted electronically also expressed some support for ADLs as a useful measure. Overall,
volunteers preferred instrumental ADLs, rather than basic ADLs, as the activities seemed more relevant to
daily life in mild to moderate dementia:
A lot of what’s down there now doesn’t apply to me.
PWD on the items of the Katz ADL scale that refers to basic ADLs
Some people with dementia also suggested that discussing reduced ability to perform tasks was less
distressing than cognition:
Your body thinks it can do it, but your brain doesn’t allow it.
PWD
Some days you can do them and you are brilliant . . . other days you cannot do them.
PWD
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The Katz instrument was not liked by some people with dementia because yes/no questions did not allow
for gradations in ability. Volunteers suggested that questions should ask why someone cannot perform a
task or what they do differently to complete it. For example, volunteers pointed out that they may still be
able to do activities but in a different way to how they may have performed them before dementia, such
as by wearing clothes that are easier to put on or cooking simpler meals:
Some task you can still do, just differently, just adapted.
PWD
People with dementia felt that this should be considered when questioning them about ADLs:
Say can you do them but differently than what you used to?
PWD
Additionally, people living with dementia suggested that they might avoid tasks because of a lack of
confidence rather than an inability to complete them:
I can use the telephone, but I don’t have the confidence, I don’t like using the telephone.
PWD
Therefore, several volunteers felt that ADL measures lacked the nuance necessary to understand how, and
if, an individual’s ability to perform daily tasks had been impaired.
Carers also raised the interesting point that some ADL questionnaires that they have had to complete were
very similar to disability benefits assessments. The similarity was strong enough that they felt it could cause
alarm and suspicion as to the use of trial data, and may affect the answers that participants give:
The link across into disability benefits . . . it’s suspicious.
Carer
Neuropsychiatric symptoms
Some participants said that behaviour is core because it is a significant aspect of dementia and seems
more sensitive to illness than ADLs. However, some volunteers felt that behaviour should not be used in
isolation, as it may be less applicable in mild to moderate stages and does not consider the reasons behind
behaviour changes. Volunteers suggested that behavioural measures should be analysed alongside
contextual information about the individual and their personality to give a more accurate insight into the
behavioural changes caused by dementia:
It’s teasing out the brain damage from actual personality traits.
Carer
It’s about behavioural change over time.
Carer
In particular, some felt that behaviour should be measured alongside cognition and understanding, which
could affect agitation and aggression. Volunteers suggested that, if behaviour were measured, it should, as
it usually does, include sleep, agitation, walking (‘wandering’), violence/temperament, compulsive/repetitive
behaviours and changes in diet and taste (i.e. preferences for certain foods). Some participants thought
that measures should include an ability to hold a conversation or follow a television programme, which are
usually not considered as behavioural.
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Quality of life
Volunteers disagreed over the inclusion of quality-of-life measures as core. One volunteer considered these
to be core, as they can give a summary of an individual’s experience of dementia. However, throughout
the discussions and consultation there was some debate as to the sensitivity of quality-of-life measures.
Some carers suggested that it would be difficult to assess another person’s quality of life and that these
measures rely on accurate interpretation of an individual’s responses. Others thought that carer assessment
would be necessary, as they may have a clearer insight into changes. It was suggested that comparing
carer and patient responses would give the most accurate account of quality of life.
When one volunteer was shown all three of the measures, they described both the EuroQol-5 Dimensions
(EQ-5D) and Quality of Life in Alzheimer’s Disease (QOL-AD) as lacking in detail. In particular, in reference
to the EQ-5D, they said, ‘I don’t know how much you’d get out of it’ (carer). However, the Dementia
Quality of Life measure (DEMQOL) was decided to be ‘reasonably easy to do and it’s going to give a lot of
information’ (carer).
In particular, some felt that quality-of-life measures lack detail regarding the individual’s personality; for
example, they may always have disliked social events. Therefore, in general, quality of life was considered
important but not a core measure for all trials.
Global measures
Volunteers had differing opinions about global rating scales. Some approved of the breadth of
the measure:
I like the global one . . . it’s all encompassing.
Carer
However, others suggested that global measures were superficial, depending too much on the individual’s
experience on the day, and not meaningful:
You might be feeling particularly bad that day.
Carer
Is that really valuable . . . . Am I giving my time for something that’s meaningful? I’m not really
convinced.
Carer
Those who did not like global scores suggested that a larger package of specific measures would give the
holistic view of an individual with more detail.
Biological measures
Volunteers generally agreed that biomarkers should be core, viewing them as being the most reliable,
objective measure and, therefore, least affected by environmental factors and day-to-day symptom
variation. However, although these were thought to be more tangible and objective measures, there was
also some uncertainty about their value and what type of data they actually provide.
For example, biomarkers were described as the more tangible measures:
Biological measures you’ve got something that everyone can agree on . . . you can compare like
with like.
Carer
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That said, there was some disagreement as to the use of certain measures, and volunteers also suggested
that, although reliable, biomarkers should not be used in isolation and should be combined with measures
such as cognition and behaviour.
Carers had a number of general questions about the type and quality of data biological measures could
actually provide, including:
Do you get more information from a lumbar puncture than a scan?
Carer
Would you be looking for a reduction in amyloid or tau, or would you be looking for an arrest in the
size of brain shrinkage?
Carer
How many people would you need for it to be significant?
Carer
Cerebrospinal fluid measures
Some volunteers particularly liked CSF measures, even though they were aware of possible side effects and
general misconceptions about what the procedure involves (e.g. very large needles) that might discourage
some from taking part. However, the volunteers felt that having to give CSF would not discourage most
people from participating and that, although uncomfortable, it would be bearable. One volunteer
described the person they care for as happy to undergo annual CSF as part of an ongoing trial:
A couple of hours and its done . . . it doesn’t put him off going the following year . . . he knows
exactly what he’s let himself in for and he does it.
Indeed, for most, the main criticism was the need to take CSF measurements in a specific location. Those
with experience of the measure suggested that travelling to and from the specified site was the greatest
drawback. Some suggested that, if it were possible to take CSF in convenient locations, they would
consent to two or three samples a year:
I think the practicalities of it would be the bit that concerns me . . . practicalities should be made easier
for the patient.
Carer
That being said, the support was not unanimous, and one volunteer suggested that the two people she
had cared for would not be able to cope with the procedure, and that ‘it might put people off taking
part’ (carer).
Blood tests
The usefulness of blood tests in terms of showing disease modification was questioned by carers:
Do they produce something meaningful?
Carer
One volunteer who spoke against CSF measurements suggested that taking blood had been difficult for
her family members (this was the reason that she doubted their tolerance for CSF procedures). However,
overall, volunteers agreed that blood tests were unproblematic and that it would not be difficult to commit
to frequent tests. The main barrier discussed was travel, with one group suggesting that, subject to
location, ‘weekly blood tests would be very happily tolerated’ (carer).
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Imaging
Most volunteers agreed that imaging could be core. However, their discussion focused on hopes and
expectations that this would provide ‘sophisticated’, ‘sensitive’, ‘objective’ and ‘useful’ data:
Making sure the scans themselves are sophisticated enough to be able to give you what you’re
looking for . . . are they sensitive enough to give the objective results you’re looking for?
Carer
Volunteers also suggested that many would consent to scans, as giving biological data can make the
person with dementia feel that they are contributing useful information:
In going through that he is doing absolutely everything he can to further the research.
Carer
It’s a positive action.
Carer
It’s something physical happening . . . now logically you know it isn’t going to alter your dementia or
do anything to it, but somehow it would make me feel better, that somebody somehow was actually
doing something . . . although it has drawbacks obviously.
Carer
Practical issues around travel and the need for concentration were raised but, in general, 3- to 6-monthly
scans were considered bearable. However, volunteers agreed that, although MRI is straightforward, it
could be difficult for some people with dementia. Four people caring for someone with either vascular
dementia or AD felt strongly that the person they cared for would be unable to lie still for 10 minutes and
that doing so for 45–60 minutes would be impossible:
Vascular and Alzheimer’s when it gets to the middle . . . you can’t keep people still . . . they don’t
understand what’s happening.
Carer
It bothers me about the scan . . . incredible noise being lashed down. I knew what was going on . . .
but for people with dementia it could ruin them.
Carer
I’ve been in one and I can imagine her staying in there still . . . not for an hour.
Carer
I can’t imagine they’d tolerate an hour.
Carer
Participants did also note that ‘different people react in different ways’ (carer). Some had more positive
experiences: one carer said that the person they care for ‘quite enjoys these’. Having music or a screen to
watch was said to improve the experience, giving the individual something to focus on, and that could be
done for most participants ‘If there is some flexibility’ (carer) around the MRI environment.
Carers agreed that PET scanners were less restrictive than MRI scanners, although the issue of having to
keep still remains.
Overall, volunteers agreed with the suggestion made at the consensus conference regarding the use of
MRI in a select number of participants who had consented to the procedure, rather than including MRI as
a core component for every individual in the study design. Volunteers agreed that this could improve
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recruitment and retention, as the prospect of MRI can discourage participation. Allowing those who are
anxious about MRI to opt out of that part of the study would enable them to join trials they would
otherwise not consider.
Summary
During the focus groups, some volunteers thought that an outcome set should include biological tests,
cognition and possibly behaviour. One volunteer suggested that a package could potentially include global
measures. Most participants favoured biological measures as they perceived these to provide a more
objective outcome. The volunteers who reviewed our report of the focus group discussions broadly
supported this recommendation and the recommendations made in the consensus conference. Volunteers
also suggested additional considerations for the design of a core package:
l Burden of time: 1–1.5 hours maximum without a break.
l Include both people with dementia and carers: carer assessments rely on positive relationships and an
accurate understanding of an individual’s dementia. Consider how to involve those without a
defined carer.
l Prioritise explaining the reason for the test; clear idea of purpose may improve retention.
l Efficiency: several tests within 1 day cuts further visits, weekend visits would remove the need for
working carers to take time off.
l Different types of dementia may need different core measures: some of those consulted felt that this
was illustrated by the variation in volunteer opinions.
Volunteers suggested that the current research would present the opportunity to encourage dementia-friendly
trial designs, with fewer individual measures and a lower burden on the person with dementia and their carer.
This was despite consistently advocating for individualised and longer measures. One carer, when discussing
a trial protocol involving a large number of exploratory measures, said:
There is a need to ensure that does not happen in dementia trials as the extra burden on patients
cannot be justified.
The practicalities of research and carer and patient burden were in many ways a greater concern for those
consulted here than the individual measures:
When you’re trying to recruit people, take as many of the barriers out of the way as possible.
Carer
The recommendations made by people with dementia and carers focus on the importance of reducing the
personal impact of research participation, ensuring that the research methods chosen are relevant and
acceptable to people affected by dementia, and the importance of trials enhancing a sense of achievement
from participation:
That’s where I think research can come into its own on enhancing our situation by making us feel
good that we’re taking part in something.
PWD
The experience of dementia is extremely isolating . . . being part of a dementia study certainly made
me feel as though someone was remotely interested in what was going on, which was actually
terribly important.
Carer
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Chapter 7 Consensus conference
Purpose
The purpose of the consensus conference was to bring together the NIHR dementia research community
to discuss which outcome domains should be core, any specific recommendations of outcomes within each
domain and other issues that should be considered for potential participants completing the core set.
Preparations
We chose a central London venue for the conference; this was felt to be the easiest location for group
members to travel to from around the UK and many of the participants were based in London.
We chose champions for each domain from within the group based on expertise. We split the biological
marker domain into imaging markers and fluid-based markers with a champion for each, meaning that
there were seven champions overall. The champions were:
1. ADLs: Gail Mountain
2. biological markers: fluid – Robert Perneczky
3. biological markers: imaging – John O’Brien
4. cognition: Rob Howard
5. global: Bob Woods
6. neuropsychiatric symptoms: Gill Livingston
7. quality of life: Sube Banerjee.
Each champion was sent the data from the systematic review about their domain, along with some
validation information, and was asked to use both of these alongside their professional expertise and
knowledge to evaluate if the domain was core and which measures they would recommend. Each
champion was asked to prepare a short presentation (10–15 minutes) for the consensus conference
around their recommendations and to write up their presentation in up to 1000 words.
Participants
The list of people who attended the conference is in Appendix 7.
We invited all participants who agreed to collaborate on the project within the protocol, and also
additional people who had become involved during the project: a Master of Science student who had
volunteered to work on the project (DG), the AS Research Engagement Officer who had led the day-to-day
work on the PPI (AGS) and a representative from Alzheimer’s Research UK. A member of the original
collaboration left academia (Mary Bond) and so put forward a colleague in her place (JTC).
Participants who attended had a range of academic and clinical expertise within dementia research,
including:
l AS research lead – James Pickett
l applied psychosocial dementia research/occupational therapy – Gail Mountain (co-applicant)
l dementia care – Frances Bunn and Claire Goodman
l health service research – Sasha Shepperd
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l health outcome measurement – Sallie Lamb and Charlotte Roberts (co-applicant)
l old age medicine – Roy Jones
l old age psychiatry – Sube Banerjee, Chris Fox, Rob Howard (co-applicant), Gill Livingston (principal
investigator), John T O’Brien and Robert Perneczky
l psychology and dementia – Georgina Charlesworth, Esme Moniz-Cook and Bob Woods
l public health and ageing – Louise Lafortune (co-applicant)
l social care and social policy – David Challis, Katie Featherstone, Justine Schneider and Claire Surr
l systematic reviews – Jo Thompson-Coon.
Conference proceedings
The conference began with a summary of the project, including the background, aims and workstreams
of the project. Gill Livingston, who was chief investigator of the project, gave an overview of the purpose
and workstreams of the project. Lucy Webster presented an overview of the systematic review, including
the methods, numbers screened and searched, and the main findings from this in terms of outcomes.
The main feedback from the focus groups was also presented by Anna Grinbergs-Saull. Gill Livingston
and Rob Howard chaired the meeting and Gill Livingston and Lucy Webster took notes of the discussion.
Cognition
Champion: Rob Howard, Professor of Old Age Psychiatry, University College London
With the central feature of dementia being cognitive impairment, it is essential that a cognitive outcome
would be a core measure in disease-modifying trials. By definition, at least two cognitive domains are
disrupted in dementia and different dementias are characterised by disruption to different cognitive
domains. Therefore, no single neuropsychological test will be sufficient as an outcome tool, hence the
need to recommend a global cognitive scale or battery of tests that can be used across all dementia trials.
We therefore did not consider cognitive scales that focused on only one cognitive domain. We shortlisted
the five most commonly used scales and searched for validation data for these scales: ADAS-Cog, MMSE,
CERAD’s Neuropsychological Battery, the Neuropsychological Battery and the Cogstate Alzheimer’s Battery.
For cognition, there are really only two serious contenders. The ADAS-Cog and the MMSE have overwhelmingly
been the most widely used cognitive measures in disease-modifying trials. The ADAS-Cog has been used in
92 trials involving 20,419 participants, the MMSE in 83 trials involving 17,736 participants and both scales
have been used in combination in 68 trials involving 15,949 participants. The MMSE has mostly been used
with the ADAS-Cog or other cognitive tests; it has been the sole cognitive measure in only six of the
included trials. ADAS-Cog, on the other hand, has solely been used in 20 of the trials.
Both scales are validated and demonstrated good sensitivity to change in the earlier cholinesterase inhibitor
trials. The ADAS-Cog is scored out of 70 points, whereas the MMSE is scored out of 30 points. Minimum
clinically important difference figures of 3.0 points for the ADAS-Cog and 1.4 points for the MMSE have
been used. If trials can be designed to anticipate differences of this magnitude, either scale could be used.
Both scales are pencil and paper tests. The ADAS-Cog can only be administered by a trained tester and
takes 45 minutes to complete. The MMSE can be administered by clinical staff with minimal extra training
and takes 10 minutes to complete.
The MMSE has been criticised for being affected by age and education, for lacking sensitivity in
differentiating between very early AD or MCI and normal ageing, for not including items sensitive to
executive functioning and for being insensitive to disease progression in severe AD. However, in mild to
moderate AD it has reasonable psychometric properties and performed well in the detection of small
treatment effects in trials of cholinesterase inhibitors and memantine.
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The ADAS-Cog was developed to detect incremental improvement or decline in cognitive functioning in
clinical trials. It has been the gold standard cognitive assessment for use within AD trials conducted by the
pharmaceutical industry. The larger number of items included certainly gives the impression of potential
greater sensitivity to change than the MMSE, but superiority was not seen in the trials of symptomatic
treatments. That is to say, in trials in which the ADAS-Cog showed a significant drug–placebo difference,
the MMSE (if it was also used) would also detect this. Furthermore, because the ADAS-Cog is not used
in clinical practice, clinicians do not have a ‘feel’ for what difference in score would constitute a
meaningful change.
The ADAS-Cog has been criticised for not sufficiently assessing attention, planning, working memory and
executive functioning, all of which are impaired at the earliest stages of AD. This has led to the addition of
extra tests to the original ADAS-Cog, including delayed word recall, a maze and digit cancellation task,
and a subjective assessment of concentration and distractibility.
Batteries of neuropsychological tests
In response to concerns that the ADAS-Cog and MMSE show low sensitivity to change in mild AD, with
placebo-allocated patients typically showing a mean decline of as little as 1 ADAS-Cog point over 6 months
in some trials, the Neuropsychological Test Battery (NTB) was developed to include measures of memory and
executive function considered to be most affected at this stage of the disease. Through a combination of
six validated neuropsychological tests, the NTB has been shown to have excellent psychometric properties
across mild to moderate AD. The NTB has been used in seven trials involving 3429 participants. As a test of
high sensitivity, but uncertain clinical significance, the NTB would seem most useful in early-phase trials in
which detection of preliminary, proof of concept signal is sought. The battery can only be administered by
trained raters.
Biological markers: imaging
Champion: John O’Brien, Professor of Old Age Psychiatry, University of Cambridge
Imaging biomarkers are used in clinical trials of disease-modifying therapies in AD for a number of reasons.
First, they are used to clarify the clinical diagnosis through the application of research diagnostic criteria
for AD. Second, they are used to stratify subjects for entry; for example, a trial using a therapy based on
decreasing amyloid might stratify subjects by including only those who showed increased amyloid burden.
This may be important, as previous failed studies of immunotherapy in AD have found that around
one-third of subjects with supposed AD did not have any evidence of increased brain amyloid.122 Third,
imaging is used to ensure that inclusion criteria are met, for example the absence of multiple microbleeds
on MRI for an immunotherapy trial. Fourth, MRI, in particular, is used as a safety outcome measure
(examining for an increase in microbleeds and/or oedema). Fifth, imaging is used to demonstrate target
engagement (e.g. showing that anti-amyloid therapy actually lowers brain amyloid). Finally, imaging
markers are used as outcome measures in their own right, either because imaging changes are more
directly related to pathology (e.g. amyloid or tau imaging) or because they have much greater reliability
and sensitivity to change than clinical measures (e.g. serial structural MRI), therefore allowing studies to be
done more quickly and with fewer subjects.
Imaging outcome measures used in 49 (30.4%) of the studies identified in the literature review included
magnetic resonance spectroscopy (one study, 353 subjects), serial structural MRI (30 studies, 4788 subjects),
PET (19 studies, 761 subjects), electroencephalography (EEG) (three studies, 96 subjects), perfusion
single-photon emission computerised tomography (one study, 135 subjects) and Doppler ultrasound
(one study, 45 subjects). PET can be divided into studies that used metabolic PET (13 studies) or amyloid
PET (10 studies). Some studies have used multiple markers. Metabolic PET has been exclusively undertaken
with fludeoxyglucose PET, while amyloid imaging most frequently uses Pittsburgh compound B (PiB) or
florbetapir, although that may reflect the order in which amyloid imaging ligands became available, with PiB
the best established, followed by florbetapir. There are two other amyloid imaging compounds that have
been licensed for clinical use, flutemetamol and florbetaben. Tau imaging ligands are now available, with at
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least three (AV1451, PBB3 and THK) being the subject of ongoing validation studies. One ongoing trial was
identified using AV1451 PET, but several more are planned. Magnetic resonance spectroscopy and Doppler
blood flow measurement were each included in only one clinical trial. There is a strong suggestion that the
inclusion of imaging biomarkers is increasing over time, as they were present in 25% of published studies
but are included in 53% of currently ongoing studies.
Serial structural MRI has, therefore, been the most widely used imaging outcome measure, with scans
repeated over a period ranging from 24 weeks to 2 years. Most studies have used 1.5-T magnetic
resonance, although some a mixture of 1.5 T and 3 T. The outcome measures analysed most commonly
are whole-brain volume change and/or change in hippocampal volume. Structural MRI has proved sensitive
to change over time, but changes between placebo and treatment have not always been as expected.
For example, in some of the early immunotherapy studies serial brain volume loss was actually higher in
the treated (amyloid-lowering) groups,79 a finding explicable in terms of greater amyloid removal but not
paralleling the accepted relationship between greater volumetric loss and worse disease progression.
Fludeoxyglucose PET has shown itself to be a sensitive marker of disease progression in studies over
6–18 months. In some studies, decreased glucose metabolism has been greater in placebo groups.59,64,140
Amyloid imaging is becoming an almost essential requirement, both for target engagement and as an
outcome measure, in clinical trials aimed at lowering brain amyloid. Its use was particularly important in
the bapineuzumab studies,122 as clear differences in brain PiB retention could be demonstrated between
placebo and actively treated groups, demonstrating to some extent target engagement, despite no effect
on clinical outcome measures. This study was particularly interesting because whole-brain volume change
was similar between groups, so not sensitive to the effect of amyloid lowering (although paralleling the
lack of change in clinical measures). Perfusion single-photon emission computerised tomography, although
a well-validated marker, has been used in only one Phase II study and is unlikely to be a useful biomarker
for the future given the much greater sensitivity, wider availability and similar cost of fludeoxyglucose PET.
Electrophysiological and functional imaging markers have not been well studied in AD trials, despite the
fact that they have potential for greater sensitivity to change over shorter temporal periods than structural,
metabolic or amyloid imaging. Only three studies (of which two have completed) have used EEG, although,
interestingly, both showed a change in EEG in the treated group.40,109 There are too few data to draw any
conclusions, but both EEG (and magnetoencephalography) and functional MRI merit further investigation
and validation in future studies, especially those undertaken over short treatment periods (4–26 weeks).
Cerebrospinal fluid biomarkers can also capture information on tau and amyloid, and show a relationship
to changes on imaging. Advantages of CSF include the ability to capture both amyloid and tau in a single
measure, and the fact that it is relatively cheap to collect compared with imaging. Disadvantages include
still considerable and largely unexplained variability between sites in results, the loss of any spatial (regional
brain) information about pathology, a relatively indirect relationship to brain changes, the need for an
invasive lumbar puncture and the inability to capture information provided by some imaging modalities
(e.g. structural MRI).
In conclusion, around one-third of disease modification studies have used imaging biomarkers as outcome
measures, with an increasing proportion over time. Serial structural MRI remains the most widely used
and best-validated biomarker, and robustly demonstrates disease progression in untreated AD subjects.
For example, it can be measured in a study to show that improvement in cognition is related to disease
modification via a reduction in atrophy, rather than just a symptomatic change, and it does not require all
participants to undergo MRI.
Metabolic PET has also been widely used and demonstrates sensitivity to change in untreated patients, and
may be of particular interest for compounds that are purported to influence glucose or energy metabolism.
More specific ligands, including those for amyloid and tau, are now available and are becoming increasingly
validated as outcome markers. Longitudinal changes in amyloid PET, and most likely in tau PET (although
CONSENSUS CONFERENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
this remains to be demonstrated), will be expected to be less sensitive to change over shorter periods than,
for example, serial MRI. However, they will be essential to include in some studies of disease modification in
AD, depending on the mechanism of action of the compound under study, to show target engagement.
Biological markers: cerebrospinal fluid
Cerebrospinal fluid and blood biomarkers
Champion: Robert Perneczky, Reader in Cognitive Impairment and Dementia,
Imperial College London
Recently revised diagnostic guidelines for AD emphasise the use of biomarkers, heralding a paradigm shift
towards a more biological definition of the disorder. Currently available biomarkers offer added diagnostic
accuracy in certain situations, but their performance in terms of early diagnostic sensitivity and specificity
does not fully live up to the desired standards. The hope for disease modification as well as technological
advances in biomarker discovery fuel the search for biological indicators of the AD pathophysiological
process, which can be used to identify neurodegeneration independently of its clinical manifestations.
Ideally, such a biomarker, alone or in combination with other markers, would distinguish between
individuals with and without AD pathology independently of the clinical symptomatology. Individuals with
asymptomatic early AD would probably benefit most from interventions aiming to prevent further neural
damage to maintain their independence, ability to work and fulfilment of social roles. Furthermore,
pathophysiological markers may also offer the added benefit of directly assessing response to treatment
options that target core processes of AD pathogenesis. The application of novel therapeutics with
potentially significant side effects could thereby be restricted to patients with biological evidence of
treatment response in line with the notion of personalised medicine. However, biomarker evidence of
treatment efficacy should not replace clinical evidence of patient benefit.
Currently available AD biomarkers can generally be grouped into two categories. The first category comprises
markers that indicate the type of pathology present, including CSF levels of amyloid-β (Aβ) 42, total tau (T-tau)
and phosphorylated tau (P-tau)181 and PET tracers of fibrillar amyloid such as flutemetamol, florbetapir,
florbetaben and PiB. The second category consists of markers that provide information on the topography of
pathological changes, such as MRI and fludeoxyglucose PET. The diagnostic accuracy of the aforementioned
biomarkers to distinguish between AD dementia and physiological ageing is high in selected patient cohorts,
recruited at specialised centres and, therefore, enriched with relatively pure AD cases. However, the clinical
usefulness of available biomarkers is limited when it comes to the identification of early or atypical AD cases,
especially in unselected populations.
The sensitivity and specificity requirements set out in the consensus report of the Working Group on
Molecular and Biochemical Markers of AD445 are rarely met when fluid biomarkers are compared with
autopsy results. Little is known about the ability of biomarkers to identify AD pathophysiology in
asymptomatic individuals. Studies in carriers of pathogenic mutations have shown that biomarkers can
become abnormal many years before the onset of clinical symptoms. In addition, longitudinal observations
in cognitively healthy older people have demonstrated that an AD-typical CSF biomarker profile is
associated with greater cognitive decline. However, it is unclear how accurately current biomarkers can
predict future dementia and the time of onset in individuals who have no symptoms. Furthermore, Aβ
immunisation trials show that markers of AD pathophysiology show changes even if no clinical benefit is
present, which limits their usefulness as study end points or surrogate measures (even though they may be
useful to show target engagement).
Our systematic review confirms that the three established markers Aβ42, T-tau and P-tau181 are also the
most widely used markers in AD dementia clinical trials. CSF levels were measured in 51 out of 125 (41%)
studies, whereas 35 out of 125 (28%) studies reported blood levels. Even though AD fluid markers are
useful for diagnosis to ensure that studies have AD cases with true AD pathology, and to measure target
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engagement, their usefulness as outcome measures is limited based on the available evidence. They are
therefore not recommended as core outcomes for dementia clinical trials.
Neuropsychiatric symptoms
Champion: Gill Livingston, Professor of Psychiatry of Older People, University
College London
Neuropsychiatric symptoms or behavioural and psychological symptoms of dementia are the symptoms of
abnormal mood, disturbed behaviour, thinking or perception, which become more common as dementia
progresses from mild to moderate so that each individual with dementia will almost inevitably develop
neuropsychiatric symptoms at some point during the illness.446
Although neuropsychiatric symptoms are almost universal if individuals are considered throughout the
course of the disease, individuals with mild to moderate dementia occasionally have no neuropsychiatric
symptoms and frequently have no clinically significant symptoms. For example, 94% of participants with
dementia in a study designed to be representative of people with AD had one or more neuropsychiatric
symptoms, but only 74% had clinically significant symptoms.447 Similarly, a study of newly diagnosed
patients with AD found that 78% had neuropsychiatric symptoms and 59% had clinically significant
symptoms.448 As people with mild to moderate dementia may not have any or clinically significant
neuropsychiatric symptoms and, therefore, have no potential for these to improve, if the underlying
disease is modified, this floor effect means that effective treatments for disease modification would require
hugely increased samples size to show a significant effect on neuropsychiatric symptoms.
Neuropsychiatric symptoms are common and contribute significantly to decreased quality of life for
patients with dementia, caregiver burden and care home admission.449 These are therefore very important
symptoms and we would like to encourage their measurements to understand what a disease-modifying
treatment is doing in important domains. It is also important to recognise that neuropsychiatric symptoms
can sometimes be influenced by social factors (e.g. care and relationships around a person). Therefore,
if neuropsychiatric symptoms are being measured, studies would need to account for whether social or
relational factors external to the intervention might be influencing this, possibly through measurement in
control and intervention groups.
We will use the opportunity afforded by our systematic review of the literature in this field, PPI and
consensus conference to make recommendations for which instrument to use.
Desirable characteristics of measures
1. We prespecified that potential measures must have some form of validation and reliability in the
population to be tested. This particularly includes content validity for neuropsychiatric symptoms
(i.e. not only reliability and concurrent validity but that the measure covers neuropsychiatric and only
neuropsychiatric items rather than include, for example, ADLs or memory). In addition, these items
should be neuropsychiatric symptoms found in dementia rather than, for example, symptoms
of schizophrenia.
2. We measured how often they had been (or are being) used. Ideally, they would have been used often,
as this is a measure of how an instrument is valued, how practical it is and how much it is likely to be
used in practice. The frequency of use in disease-modifying trials to date is summarised in Table 12.
3. Neuropsychiatric symptoms can be considered in terms of severity or frequency. Some scales cover only
one of these. Knowing the frequency without the severity or vice versa means that the scale is less
useful in measuring change. This is because the symptoms may improve either by being of reduced
frequency or severity, or one of these dimensions may improve while the other deteriorates. Both
dimensions are important characteristics and are often used in a summary score in an instrument, and
this is desirable.
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4. The time taken should not be too long as the instrument would be part of a package ideally, but not
essentially. In addition, the minimal clinically important difference should have been calculated and it
should be translated into different languages.
Our systematic review has identified nine measures that have been used to detail the range of
neuropsychiatric symptoms in disease-modifying trials in dementia, detailed in Table 12. These are the
Neuropsychiatric Inventory (NPI),236 Brief Psychiatric Rating Scale (BPRS),229 Alzheimer’s Disease Assessment
Scale-Non Cognitive scale (ADAS-Noncog),174 CERAD’s Behavioural Rating Scale for Dementia,231 the
Revised Memory and Behaviour Problems Checklist,247 Dysfunctional Behaviour Rating Instrument,234
Behavioural Pathology in Alzheimer’s Disease (BEHAVE-AD),450 Nurses’ Observation Scale for Geriatric
Patients243 and Plutchik Geriatric Rating Scale.246
Measure of individual neuropsychiatric symptoms
There are also some measures that have been used to consider individual neuropsychiatric symptoms
(e.g. agitation451 and depression) but these are too specialist to recommend for all trials of disease modification
as no specific symptom is common enough to measure individually, unless the object of the study is to change
it. The NPI was the most commonly used measure and is being used most often currently. It is valid and reliable,
and measures both frequency and severity. It has good reliability statistics and sensitivity to change. It takes
slightly less time than CERAD and, possibly, BEHAVE-AD (10–20 minutes). The minimal clinically important
difference has been calculated as 8 points.452 It has also been translated into Italian, Greek, Japanese, Korean,
Mexican, Polish, Spanish and Dutch.176,237
The measures included that only assess the severity of symptoms are:
l BEHAVE-AD – sensitivity to change in moderate and severe dementia, but unclear in mild dementia.
It takes 20 minutes to complete, and there are 26 items on a four-point scale. There was no floor or
ceiling effects. The questions ask about severity not frequency. It has been translated into French,
Swedish, German, Dutch, Spanish, Chinese and Korean.176
TABLE 12 Neuropsychiatric outcomes found
Name of measure
Number of
Time taken to
complete measure
(minutes)Studies
Studies
published
Studies
ongoing Participants
NPI 38 30 8 11,756 10–20
ADAS-Noncog 7 7 0 792 20–25
BPRS 3 3 0 190 20
Nurses’ Observation Scale for Geriatric
Patients
2 2 0 454 3–5
CERAD’s Behavioural Rating Scale for
Dementia
1 1 0 486 20–30
BEHAVE-AD 1 1 0 425 20
Dysfunctional Behaviour Rating Instrument 1 1 0 406 20
Plutchik Geriatric Rating Scale 1 1 0 178 5–10
Revised Memory and Behaviour Problems
Checklist
1 1 0 168 10
ADAS-Noncog, Alzheimer’s Disease Assessment Scale – Non-Cognitive scale; BEHAVE-AD, Behavioural Pathology in
Alzheimer’s Disease; BPRS, Brief Psychiatric Rating Scale; NPI, Neuropsychiatric Inventory.
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l ADAS-Noncog – is commonly used (in terms of number of studies), but measures only the severity
of symptoms. It is long, taking around 20–25 minutes to complete. It is sensitive to change in
mild to moderate AD.
The measures included that only assess the frequency of symptoms are:
l Nurses’ Observation Scale for Geriatric Patients – it only covers 3 days, which may be too short a
period. It is commonly used (in terms of patient numbers), but measures only the frequency of
symptoms. It is rapid to complete and has test–retest validity.
l CERAD’s Behavioural Rating Scale for Dementia – is reliable and valid, and sensitive to change in
mild to severe dementia. Takes 20–30 minutes to complete and is designed for mild to moderate
dementia. It measures frequency but not severity, and has been translated into French and Spanish.176
l Dysfunctional Behaviour Rating Instrument – only measures frequency.
Content includes other domains:
l BPRS – only measures severity and is designed for general psychiatric patients (e.g. includes blunted
effect and concerns about physical illness).
l Revised Memory and Behaviour Problems Checklist – incorporates memory problems in its total and,
therefore, is not a pure test of behaviour. This may be why it is the least used.
l Plutchik Geriatric Rating Scale – is validated in geriatric inpatients who are not necessarily those with
mild to moderate dementia. It incorporates sensory impairment, social isolation and activities, and is
therefore not a good measure of behaviour.
In summary, neuropsychiatric symptoms should not be core measures in dementia modification studies
but, as they are very important, many studies may wish to measure them. We recommend the NPI for the
reasons outlined above.
Activities of daily living
Champion: Gail Mountain, Professor of Health Services Research, University
of Sheffield
The main rationale for applying ADL measures in disease-modifying studies is to assess changes in
participant abilities to undertake functional activities following an intervention, with scores providing an
estimation of deterioration or improvement. Such measures can include basic ADLs such as washing,
dressing and toileting and complex or instrumental ADLs (IADL) such as cooking, shopping and money
management. Newer measures are also taking into account other daily activities such as engagement with
social and leisure activities.
The systematic review identified 12 measures that have been applied in disease-modifying studies:
1. Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) (34 studies:
28 studies published, six ongoing; 11,500 participants)
2. Alzheimer’s Disease Functional Activity and Change Scale (ADFACS) (two studies: two published;
350 participants)
3. BADL (five studies: three published, two ongoing; 1117 participants)
4. Dependence Scale (three studies: three published; 3343 participants)
5. Disability Assessment for Dementia (DAD) (12 studies: 10 published, one protocol and one ongoing;
2914 participants)
6. Functional Activities Questionnaire (two studies: two ongoing)
7. Interview for Deterioration in Daily Living Activities in Dementia (two studies: two published;
219 participants)
8. Katz ADL (four studies: three published and one protocol; 185 participants)
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9. Lawton IADL (eight studies: seven published and one protocol; 1125 participants
10. Nuremberg ADL (three studies: three published; 530 participants)
11. Personal Self-Maintenance Scale (PSMS) (three studies: three published; 429 participants)
12. Video Recorder Home Behavioural Assessment (one published; 48 participants).
Initial considerations
1. The ADCS-ADL and ADFACS are both derived from the work of the Alzheimer’s Disease Cooperative
Group and have the same primary reference.286 The author has now confirmed that the ADFACS is a
version of the ADCS-ADL developed by one of the team (Rachelle Doody, Baylor College of Medicine
Medical Center), who has since participated in studies led by Douglas Galasko (University of California
San Diego Medical School) using the ADCS-ADL.
2. Lawton IADLs and the PSMS are derived from the same authors and are frequently used in
combination, thereby spanning both ADLs and IADLs.
3. The Video Recorder Home Behavioural Assessment has only been applied in a single study and,
therefore, has been discounted.
This leaves nine measures for consideration. The following four measures have been used most frequently:
1. ADCS-ADL
2. DAD
3. Lawton/PSMS
4. BADL.
The Dependence Scale has been used in only three studies, but with a large number of participants.
Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale
There is a 19-item scale for basic ADLs and a 23-item IADL scale, which includes reading, leisure activities
and basic chores. The measure has good test–retest reliability (assessed in four studies),286,289,292,293 is
sensitive for use with people with mild to moderate dementia and sensitive to change in three out of four
studies.288–291 It has been translated and validated in several European languages.
Disability Assessment for Dementia
The 40-item measure was developed for use with people with different severities of AD living in the
community. It can be applied in 15 minutes by a clinician interviewing the carer or by a trained observer
rating performance. It determines whether or not the person with dementia needs help to initiate,
organise, plan and perform in 10 ADL and IADL areas (including leisure activities). Content validity and
reliability has been demonstrated independently331 and by the measure developers,301 and there are
reportedly no floor or ceiling effects.301,309
Lawton Instrumental Activities for Daily Living/Personal Self-Maintenance Scale
These two measures were originally developed for use with non-cognitively impaired older people and can
be used separately or in combination. The PSMS contains six domains of basic ADL functions (toileting,
bathing, feeding, dressing, mobility and physical ambulation), rated from 0 to 1. The Lawton ADL has
eight IADL domains (ability to use the telephone, shopping, food preparation, housekeeping, laundry,
transport, managing medications and finance) rated on a scale from 1 to 5. Both can be completed in a
short (5- to 10-minute) interview with the person with dementia, as well as through a proxy.331 There are
questions regarding the extent of sensitivity with dementia.331,453 It has also been noted that this ADL
measure has a ceiling effect.331
Bristol Activities of Daily Living scale
This 20-item questionnaire is used to measure abilities in both ADLs and IADLs by people in the early stages of
dementia, using proxy report.295 Face validity is determined by carer agreement regarding important items.
BADL has good content and construct validity, but there are different views regarding test–retest reliability.331,454
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Dependence Scale
The Dependence Scale comprises 13 items, completed with an informant. It was designed to identify
the level of required care. Items range from need for reminders or advice to undertake IADL/recreational
activities to needs for assistance with basic ADLs and need for supervision. The final four items in the
measure are concerned with needs for interventions to maintain basic function (catheterisation/tube
feeding). The developer of the measure was able to demonstrate good psychometric properties and
sensitivity to dementia progression, but this has not been replicated.298 In addition, given the wide range of
items within the measure, dependency at different stages of dementia is estimated by very few items.
The following measures are less frequently applied.
Interview for Deterioration in Daily Living Activities in Dementia
This is designed to assess both basic ADLs and IADLs in community living people with dementia, with both
initiative to perform tasks and performance being assessed. The 33 items are assessed on a seven-point
scale.319 It was initially designed for use in a 15-minute carer interview, but there is now a self-complete
version for the carer.
Functional Activities Questionnaire
This 10-item measure solely comprises IADL items, including travel and recreation, each being assessed on
a six-point scale by an informant. It is valid for use only with people with mild dementia and has been used
to distinguish between MCI and dementia.
Katz Activities of Daily Living
This measures independence in basic activities of older adults and is not dementia specific. Included items
are bathing, feeding, dressing, toileting, transferring, continence and bathing, with rating being
independence or dependence. The results from application of the Katz are highly correlated with MMSE
scores,455 and it is sensitive to dementia progression.
Nuremberg Activities of Daily Living
The Nuremberg Activities of Daily Living is for use with people with severe dementia in a residential setting
and, therefore, should not be considered for mild to moderate dementia.
Conclusions and recommendations
Only five of the most frequently applied instruments measure ADLs; the Dependence Scale includes items
to measure dependency. All are for use with people with mild to moderate dementia apart from the PSMS
and the Dependence Scale. All are dementia specific apart from the Lawton/PSMS measures.
The shortlist is:
1. DAD
2. Bristol ADL
3. Lawton ADL/PSMS
4. ADCS-ADL.
Although the ADL outcome is very important and is necessary for regulatory purposes and definitive trials,
in some countries it is not core as it may change for other reasons than a change in dementia. However,
we would encourage its inclusion and based on use and psychometrics the following measures
are recommended:
1. DAD is the most often used for community living people and has an observation option
2. Lawton ADL/PSMS is the only measure that includes self-completion; however, this may not be reliable
in terms of the answers given.
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Quality of life
Champion: Sube Banerjee, Professor of Dementia, Brighton and Sussex Medical School
Health-related quality of life (HRQoL) is a multidimensional concept that reflects the individual’s subjective
perception of the impact of a health condition on everyday life.456 The science of developing instruments
that can measure HRQoL has grown during the past 30 years. Such measures are increasingly seen as a
useful complementary source of evidence of the value of impact throughout health care. They provide one
approach to the measurement of overall impact and, importantly, they generate an appraisal of the
subjective view of the individual affected. It has become clear that people with dementia have things that
positively and negatively influence the quality of their lives, and that they can report these.457–459
However, measuring HRQoL in people with dementia is difficult. In any type of dementia there are
disorders of memory, attention, communication, insight, judgement and behaviour, all of which might
impair the ability to complete measures of HRQoL. In addition, because of its progressive nature, what
works at one stage of dementia may not work later on as the disease becomes more severe. All this means
that instruments not developed for those with cognitive impairment will generally not work well in those
with dementia. Thus, the generic instruments available to measure HRQoL across different disease states
(e.g. the EQ-5D or Short Form Health Survey) do not work well in dementia.252 For example, one study
found that 48% of people with dementia self-reported being in full health using the EQ-5D questionnaire,
with no problems on any dimension.266 Disease-specific measures of HRQoL in dementia have therefore
been developed.267,460–462 The field is one that has developed rapidly, and there has been progressive
improvement in methodology and measurement during the past 15 years.
There has been an underlying assumption in much of the literature until quite recently that HRQoL must
necessarily decrease as dementia becomes more severe. From the outside, it might seem counterintuitive
that HRQoL could do anything other than drop with increasing cognitive impairment and activity limitation.
In this case there would be limited value in measuring multiple variables that all vary predictably together,
rather than just measuring one (such as cognition). However, it now seems clear that activity limitation and
cognition do not have a simple or linear relationship with HRQoL in dementia.463–465 The data suggest that
there is the possibility of good quality of life at all stages of dementia and that there are individuals with
poor quality of life at all stages of the illness who may therefore benefit from interventions to improve
quality of life in dementia. This does not mean that improving cognition would not cause an improvement
in HRQoL. Woods et al.272 looked in detail at data from a trial in which a psychological therapy had both a
positive impact on HRQoL and a positive effect on cognition. In that study there were no cross-sectional
associations between severity of dementia and HRQoL. This makes clear the limitations of using a profile
approach, with HRQoL being more than the sum of the discrete measures used.
Depending on the specific questions being investigated, HRQoL can be a primary or secondary outcome in
itself. The focus here is the evaluation of disease-modifying medication in mild to moderately severe AD,
and it is unlikely that HRQoL would be used as a primary outcome measure in any Phase II or pivotal
Phase III study. However, the measurement of HRQoL is an obligatory part of the economic evaluation of
emerging health technologies or interventions. In cost–utility analyses, quality-adjusted life-years (QALYs)
are used to measure the impact of an intervention on both quality and quantity of life. Quality of life is
measured by using health-state values that are scored using preference information typically gained from
a representative sample of the general population. Generic preference-based measures of health, such as
the EQ-5D, discussed previously in this section, are widely used as a means of generating health-state
values for use in the calculation of QALYs. Given the debate around the extent to which generic
preference-based measures fully capture aspects of quality of life associated with some medical conditions,
and that the validity of using generic preference-based measures in dementia is uncertain, there has been
interest in developing preference-based measures from condition-specific measures to target medical
conditions more effectively in terms of HRQoL. Recent developments of the DEMQOL system allow the use of
a dementia-specific instrument to be used in cost-effectiveness analyses of interventions in dementia.466–468
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The systematic review identifies one generic measure of HRQoL, the EQ-5D, and two measures of
disease-specific HRQoL that have been and are being used in evaluations of potentially disease-modifying
compounds in AD. The information on their use is summarised in Table 13.
An assessment of the relative merits of the two disease-specific systems in terms of their psychometrics is
presented in Table 14. This enables a comparison of the two instruments with earlier instruments and
shows that the current instruments are a significant advance on the earlier methodologies.
The main points from this analysis are as follows:
l the QOL-AD is older and has been used more widely, particularly in the USA
l the DEMQOL system development process was stronger in psychometric terms
l the quality of development and subsequent data on DEMQOL-Proxy is symmetrical with that of the
self-report versions, unlike the QOL-AD
l there are questions about the validity of the framing of the questions in the proxy-rated QOL-AD,
which are not present for DEMQOL-Proxy
l the QOL-AD is less time-consuming for patients by 5–10 minutes
l there are relatively few data on responsiveness published for either, although because of the
DEMQOL’s longer form, development process and framing, it confers theoretical advantages in
sensitivity to change
l in economic evaluations DEMQOL has advantages because of the unique programme of work
developing it as a preference-based measure with no additional burden to respondents or researchers.
In summary, there is a need for broad measures of overall impact of interventions in dementia but
nonetheless, although important, it is not a core measure in disease modification. We are now at a stage
in which HRQoL in dementia can be measured with instruments specifically designed to do so. It appears
that cognition (or activity limitation) is not the same as HRQoL and is in fact a rather poor proxy for it.
HRQoL should be measured as and for itself. It is complementary to the measurement of discrete specific
outcomes, and a rational approach to measurement would ensure that both sorts of instrument were
completed in evaluation of interventions in dementia. It is therefore not core but health decision-makers,
such as the National Institute for Health and Care Excellence, place high value on such data when
reimbursement decisions are being made. This is likely to include a generic quality-of-life measure, but a
dementia-specific quality-of-life measure will be more likely to be valid. If one is used the current evidence
suggests that it should be the DEMQOL.
Global
Champion: BobWoods, Professor of Clinical Psychology of Older People, Bangor University
The development of global assessments of outcome in relation to disease-modifying treatments in the
field of dementia may be seen as a rational response to the wide-ranging effects of the dementias.
TABLE 13 Use of measures of HRQoL in published and ongoing studies
Studies measure is used across
Instrument
EQ-5D QOL-AD scale DEMQOL
Number of studies 5 9 4
Studies published 4 7 1
Studies ongoing 1 2 3
Number of participants 4084 3341 399
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Diagnostic criteria have highlighted the presence of difficulties in multiple domains, including memory
and other cognitive impairments, changes in day-to-day function and changes in behaviour. An outcome
measure that is able to encompass the range of domains affected and, accordingly the range of potential
targets for change, may have advantages over multiple measures, each evaluating a single domain.
Specifically, if a treatment is an effective disease-modifying agent, but different aspects of the condition
are improved in different individuals, for example through differences in disease progression or symptom
expression, a global measure may reflect this through its combination of multiple domains. Global
measures also have the potential to combine multiple perspectives, with input from caregivers and the
person with dementia informing a global rating, again reflecting the reality of a condition that has effects
beyond those reported by the person with the diagnosed condition.
TABLE 14 Summary of psychometric properties of HRQoL instruments by gold standard criteria
Psychometric
properties
Instrument
Progressive
Deterioration Scale
Pleasant Events
Schedule – Alzheimer’s
Disease
QOL-AD DEMQOL
Patient Proxy Patient Proxy
Conceptual model 0 + ++ 0 +++ +++
Acceptability 0 0 ++ ++ ++ ++
Reliability
Internal consistency 0 0 +++ +++ +++ +++
Test–retest +++ 0 +++ ++ +++ +++
Inter-rater reliability 0 0 NA 0 + +
Validity
Content + 0 +++ +++ +++ +++
Criterion related 0 0 0 0 ++ ++
Construct
Convergent validity 0 + +++ +++ +++ +++
Discriminant validity 0 0 0 0 ++ ++
Known groups
differences
+ 0 +++ 0 +++ +++
Experimental intervention 0 0 0 0 ++ ++
Factor analysis 0 0 + + + +
Responsiveness 0 0 + + + +
Respondent burden 0 ++ +++ +++ ++ +++
Cultural and language
adaptations
0 0 ++ ++ ++ ++
Economic evaluations 0 0 0 0 +++ +++
Health state classification 0 0 0 0 +++ +++
Preference-based
measures
0 0 0 0 +++ +++
Population values 0 0 0 0 +++ +++
0, no evidence or not tested; +, some limited evidence; ++, some good evidence, but some aspects do not meet criteria or
some aspects not tested/reported; +++, good evidence; NA, not applicable.
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Our literature search identified 10 global outcome measures in the included studies. These could be
grouped into three distinct types: global rating scales, dementia staging instruments and clinician impression
of change interviews. One of the staging instruments, the Clinical Dementia Rating scale (CDR) had been
used in 48 studies. The Clinician Impression of Change interviews had been used in 35 studies altogether,
with each of the five global rating scales being used in four or fewer studies.
The five global rating scales identified each included a number of domains, typically without a clear
rationale for how each domain might contribute to any total global outcome score. Among the earliest of
these scales was the Blessed Dementia Rating Scale, comprising a total of 22 items. These cover three
domains, rated in an interview with an informant: everyday activities (eight items), ADLs – eating, dressing,
toilet (three items) and personality changes (11 items). The scale does not specifically include cognitive
items, but is often used with the Blessed Dementia Information, Memory and Concentration Test, a brief
cognitive test. Completion of the Sandoz Clinical Assessment Geriatric Scale is based on an interview with
the person with dementia and on observation. The 19 domains (which fall into five factors) include aspects
of cognition (‘confusion’ and mental alertness), self-care ability, mood (e.g. anxiety, fatigue) and behaviour
(e.g. hostility, ‘bothersome’, irritability, unsociability). The Gottfries–Bråne–Steen Rating Scale for Dementia
is similarly completed from a semistructured interview with the person with dementia and observation,
and comprises subscales measuring intellectual (12 items), emotional (three items), ADLs (primarily items of
self-care) (six items), and behavioural and psychological symptoms of dementia (six items). The most recent
of these global rating scales, the Dementia Severity Rating Scale (DSRS),354 is designed for completion by a
carer, with 12 domains ranging from cognitive aspects such as memory, orientation, speech and language,
and the ability to make decisions, through higher-level functional abilities such as social and community
activity, home activities and responsibilities to basic functions (e.g. personal care and cleanliness, and
control of urination and bowels). Rikkert et al.469 comment from their systematic review of dementia
staging scales that the reliability (inter-rater, intra-rater and internal consistency) of the DSRS and the
Gottfries–Bråne–Steen scales are well established, but that evidence for their validity in staging severity of
dementia has not been studied, although our review identified a report of sensitivity of change for each
scale. The focus of the DSRS on ratings by a family carer, without external moderation, may introduce bias
related to factors such as carer stress and depression.
Our review identified two staging scales for dementia severity that have been used as outcome measures:
the CDR and the Global Deterioration Scale. The CDR is based on an interview with the person with
dementia and caregivers, covering six domains: memory, orientation, judgement and problem-solving,
community affairs, home and hobbies and personal care. An algorithm is used to combine the ratings of
each domain into an overall stage categorisation, ranging from ‘no dementia’ to ‘severe dementia’, usually
on a five-point scale (although extended versions are available). The algorithm does not weight different
domains equally, although interestingly in many of the trials using the CDR, an unweighted ‘sum-of-boxes’
score is used, presumably to increase the range of scores. The Global Deterioration Scale has seven stages
(three being ‘pre-dementia’) and is intended to be used with measures of cognition and functional ability.
Rikkert et al.469 comment on the strong support for the reliability of the CDR and for its discriminant
validity (including with the sum-of-boxes scoring). Our review suggested that the CDR shows sensitivity to
change, whereas the evidence for both reliability and sensitivity to change of the Global Deterioration
Scale is more limited.
The third group of outcome measures has two additional features. First, they bring to bear the judgement
of an experienced clinician in combining the different domains, balancing the significance and relevance of
specific areas of strength and impairment in each case. There is no predetermined algorithm or a simple
summation of scores across domain; the clinician simply rates their ‘impression’ of the person’s situation,
taking into account all available sources of information. Second, at follow-up assessments, the clinician’s
task is to rate how much change there has been since the baseline assessment, using detailed notes taken
at that time to assist this judgement. The final outcome is then a score on a seven-point scale ranging
from ‘marked worsening’ to ‘very much improved’. This overcomes the potential weakness of the staging
instruments in that they would not be sensitive to change within what may in practice be quite a broad
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severity category, such as ‘mild dementia’, missing clinically significant change. The emphasis on change
and being able to focus on changes of most importance to the individual are commendable features of
these scales. It should be noted that they would only be suitable for studies that are double blind; in a trial
of a non-pharmacological intervention where the participant is aware of the treatment being received,
maintaining the blindness of the assessor would be impossible to guarantee.
Our review initially identified three scales of this type: the Clinical Global Impressions Scale, the Alzheimer’s
Disease Cooperative Study – Clinical Global Impression of Change and the Clinician’s Interview-Based
Impression of Change plus Caregiver Input (CIBIC+). However, for this purpose they may be viewed as a
single entity. They are completed following a semistructured interview, with both the person with dementia
and a caregiver. Four major categories are covered in the interview: (1) ‘general’ including relevant history
(and at follow-up assessments changes since baseline), (2) cognitive function, (3) behaviour and (4) ADLs.
Each category is divided into domains, with probe questions suggested for each domain. After completing
the interview, the clinician is able to consult all available information, including cognitive tests such as the
MMSE or ADAS-Cog carried out on that visit. Inter-rater reliability would be a key issue for these measures,
which are so dependent on the clinician’s judgement, but there appears to be little evidence to support
this,469 although there is better evidence of retest reliability. Sensitivity to change has been demonstrated in
at least one study in our review.
Of the three types of approach to global assessment, both staging and impression of change outcome
measures have merits, in combining different aspects through algorithms or clinical judgement, whereas
the multiple domain rating scales do not offer advantages over carrying out a specific assessment of each
of the included domains. The potential for the CIBIC+ to be sensitive to individual trajectories of change is
attractive, in view of the diversity of profiles of function of people even with the same type of dementia.
The CDR, which has been the most widely used staging scale, shows good reliability and has demonstrated
sensitivity to change. Disease-modifying treatments should have a demonstrable influence on the rate of
progress through the stages of dementia reflected by the CDR. However, it should be noted that, if the
sum-of-boxes score is used, this places it in the same category as the multiple domain rating scales.
Discussion
Cognition
It was agreed that cognition is a core domain. Any recommended cognitive outcomes should show reliable
detection of decline in cognition, which the ADAS-Cog and MMSE have both been shown to do. They are
also the most commonly used and validated outcomes. The PPI consultation emphasised that patients dislike
failing in tests of cognition and it was recommended that to improve the experience of cognitive tests in the
future timed measures which estimate cognitive processing speed should be considered, although they
would need validating, including looking for clinical significance and calculating the minimal clinically
important difference. The ADAS-Cog is longer, but if more sensitive to change then it may need fewer
participants than a trial powered on the MMSE. However, the ADAS-Cog has a problem when there are lots
of missing data.
Recommendation
Overall, for cognition we recommend the MMSE or ADAS-Cog, as they are the best-available measures.
Imaging
Imaging is important; however, changes in imaging and cognition are not always highly correlated;
between-group differences may show mechanism of change as well as disease modification.
Magnetic resonance imaging is the most sensitive imaging technique to change, and because of this may
need fewer participants to still be fully powered, as well as to be able to see changes over 1 year.
MRI changes, therefore, can be conducted in a subgroup of participants in disease modification trials.
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This means that, for example, it would be unnecessary to exclude from a study all patients who do not
tolerate MRI, are unable to travel or who have a pacemaker. However, volumetric MRI does not always
show expected changes in terms of atrophy (e.g. if amyloid is removed, then the volume may go down in
treated patients), but does show changes, which is important.
Recommendation
The recommendation of the consensus conference was that serial structural MRI was the core biological
marker that has utility to monitor disease progression. There is rapid innovation of biomarkers and this
recommendation may change in the future.
Fluid makers
The four types of biological markers were discussed, as was how fluid biomarkers for AD are more advanced
than other illnesses. However, CSF examination is expensive as people may need to go to hospital as a day
case. Importantly, they are not helpful biomarkers for disease modification – a meta-analysis showed that
changes in putative biomarkers of Aβ42 are not related to change in the MMSE470 – but they can be useful in
aiding diagnosis.
Recommendation
It was agreed that currently CSF level does not have a role as an outcome measure for disease
modification studies in dementia and, therefore, we do not recommend a fluid biomarker as part of the
core set.
Neuropsychiatric symptoms
There was debate around whether or not neuropsychiatric symptoms should be a core domain. Not every
individual with dementia, particularly in the early stages, will have neuropsychiatric symptoms, and if they
do they may not be clinically significant, meaning that, if they are measured, no difference may be found.
Problematic behavioural symptoms may also be measured in measures of global functioning or quality
of life.
However, neuropsychiatric symptoms were considered to be core by many members of the group as
symptoms increase with the progression of dementia severity. If a disease-modifying treatment was found,
they would want behaviour to improve, or at least not decline. If cognition improved, but neuropsychiatric
symptoms increased, potentially as a side effect of a pharmacological intervention, then this would be an
important outcome to identify. The group judged this to be important but not core to every future study
of disease modification as many people with mild dementia do not have any neuropsychiatric symptoms;
if this was a core or primary measure it might lead to a false-negative finding.
Recommendation
We recommend that the NPI should be used to measure neuropsychiatric symptoms, as it includes
frequency and severity of symptoms and has appropriate psychometric properties, but this is not a
core outcome.
Activities of daily living
Function, in terms of ability to complete everyday activities, is often a driver of presentation. In the USA,
ADLs is a possible measure in disease modification, whereas in Europe it has been mandatory. It should
be measured by proxy, ideally as some people with dementia may underestimate any impairments,
although not all will. Some scales try to differentiate between the performance and initiation of ADLs,
and also may include that people with dementia may need prompting to complete ADLs.
Activity of daily living is being used less often in new disease modification trials as physical health
confounds it and it may not demonstrate change over 1 year. Most of the included ADL scales have good
psychometric properties, but sensitivity to change may be a problem and it may not measure what is
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relevant to mild to moderate dementia, and people from a range of backgrounds. Overall, it was therefore
decided that it is not core.
Recommendation
Overall, we recommend the DAD as it is the best-available dementia-specific measure of ADLs.
Quality of life
Quality of life is different from other domains, as people with severe dementia can have good life quality
and, thus, it is not a sensible primary outcome to measure disease progression. Nonetheless, it is a useful
measure, as it could record any negative or positive impact of pharmacological interventions.
As the EQ-5D is not dementia specific, it may not necessarily give an accurate reflection. In addition, as the
self-reporting of quality of life becomes worse over time, it is sensible to get a proxy report too so that
measures can be compared over the whole population in a trial.
It was also discussed how quality of life is important in Phase III trials where economics need to be
measured for cost by a dementia QALY. The conference did not have the required expertise to discuss or
make recommendations about QALYs.
Recommendation
We recommend the DEMQOL, which measures quality of life from both the person with dementia and
proxy perspectives, and from which QALYs can be calculated.
Global functioning
The group considered that global functioning could be an important measure as it encompasses several
domains and could replace ADLs. Either a staging or impression-of-change outcome measure should be
used, rather than a multidomain scale, with a staging instrument most favourably regarded.
Recommendation
We therefore recommend the CDR, as it has good psychometric properties. However, as the sum-of-boxes
score of the CDR is similar to a multidomain scale, we recommend the global functioning score, which
may be more appropriate.
Main findings
Although all domains are potentially relevant and important, cognition and biological outcomes are the
only two domains that were decided to be core by consensus within the group (i.e. they should be
measured in every trial of disease-modifying treatment in dementia). Overall, the group consensus was to
recommend either the MMSE or ADAS-Cog for cognition. For biomarkers, serial structural MRI currently
should be included as a core, but optional, outcome for individuals and used in a subset of participants.
If and when future biological markers become available, it would be necessary to have a clear ability to
measure progression if they were to be included.
There was debate about all other domains being core. Overall it was agreed that, although each domain is
important, ADLs, neuropsychiatric, quality of life and global are not core domains that should be selected
dependent on the type of study, and we have recommended the DAD, NPI, DEMQOL and CDR, respectively.
We also discussed the issue of informant-rated scales, and how the informant needs to have seen the
person regularly in the weeks prior to completing the scale, so, therefore, the availability of information for
each participant is required in study design.
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After the conference
With the core recommendations from the conference, we conducted a second electronic consultation with
the AS Research Network, the methods and results of which are detailed in Chapters 5 and 6. This additional
consultation confirmed the main recommendations from the conference.
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Chapter 8 Discussion
Findings
The main conclusions from the synthesis of the information at the consensus conference were that both
cognition and biological outcome measures should be included in the core set of outcomes, although all
domains are thought to be important. Most of the trials identified in the systematic review included only
participants with AD, so our recommendations are mainly for AD.
Cognition is included as a core domain because it is the fundamental symptom of dementia, and there
would be no purpose in modifying the underlying disease if this did not lead to cognition in an intervention
group being better than in a control group over time. The biological outcome measures are core as they are
the only way of being sure that the disease is being modified rather than the treatment being purely
symptomatic.
The PPI conclusions are that the most important consideration for people with dementia and their carers are
not what measures are used, but the overall burden of the study in terms of time, travel and inconvenience.
Recommendations of outcomes
Core domains
Within the cognitive domain, we recommend the use of either the ADAS-Cog or MMSE, as both have the
best psychometrics of the included measures. Cognitive measures were described as often distressing, by
both people with dementia and their families within the PPI consultation, as people are often aware that
they are deteriorating, although as cognition is a core symptom of dementia it not possible to avoid
measuring it. As one of the purposes of defining core measures is to make individual studies comparable
and meta-analysable, it would be helpful for a future study to formulate an algorithm to be able to
compare scores on both the ADAS-Cog and the MMSE and to consider developing algorithms specifically
for individual subtypes of dementia. This has recently been accomplished for the ACE-3 (Addenbrooke’s
Cognitive Examination – third edition)471 and the MMSE (Professor Gill Livingston, University College
London, 4 April 2016, personal communication). This should be possible as a recently published study of
the longitudinal cognitive decline of mild to moderate AD participants in placebo arms of 20 trials found
the trajectories of the ADAS-Cog and MMSE to be similar.472 We have longitudinal data from an earlier
study in which 224 participants completed the ADAS-Cog and the MMSE and for whom, therefore, data
are available.473
For biological outcomes it was agreed that serial structural MRI currently offers the best indication in a
biological outcome of disease progression, although it is not a perfect biomarker. As it would not require
as large a number as a cognitive outcome for satisfactory power, we recommend MRI as a core outcome,
but only as an optional part of the study. Therefore, people who want to be in the study but could not or
would not undergo MRI could be included. Some people are unable to undergo MRI because they have
a pacemaker or a fear of enclosed spaces or because it is too far for them to travel to the MRI scanner.
Thus, not wanting to undergo MRI should not put people off participating.
To power a full-scale trial on MRI, an early paper recommends 200 participants per trial arm,474 and a more
recent paper reduced this to 81 participants per trial arm.475 Despite needing a reduced number to power
a trial on MRI, the potential costs of both baseline and follow-up scans in a group of 162 participants are
expensive. The commercial cost of MRI in research starts from £365.76, although the NHS tariff is around £110.
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Non-core domains
The assumption of a recommendation of a core set of outcomes is that measures can be added to it,
but none can be taken away. Although we do not judge the domains of ADLs, global, neuropsychiatric
symptoms and quality of life to be core, they are still important outcomes and their need to be included
as a chosen outcome depends on the specific focus of individual trials. We have made recommendations
about which measures we would recommend within each of these domains. In addition, a decline in social
engagement can be one of the most important outcomes in mild to moderate dementia. There are no
current measures for this in the literature in dementia, but one has been developed (Gill Livingston,
University College London, 10 May 2016, personal communication; Sommerlad et al.476).
We judge ADLs to be an important domain, as functional impairment increases as dementia progresses,
it is often one of the first areas where symptoms are noticed and many problems within families arise as
people with dementia become more dependent but do not want to accept help.477 We recommend that
the measure used is a proxy measure as people with dementia can sometimes underestimate their functional
impairment, although sometimes they can be more accurate than a proxy (Linda Clare, University of Exeter,
25 May 2016, personal communication; Martyr and Clare478). As described in Chapter 6, Standardised
interviews, Activities of daily living, in view of the time taken, the acceptability and the psychometric properties,
we recommend that the DAD, a dementia-specific proxy ADL measure, is the best instrument to use.
Global outcomes are also important as they encompass and summarise the range of functions affected by
dementia, with a staging instrument thought to be better for disease modification trials than a multidomain
or clinician impression scale. For global outcomes we recommend the CDR, a staging instrument specific to
dementia, as it has the most satisfactory psychometric properties. In particular, we recommend the use
of the global CDR score over the sum of boxes, as using the sum of boxes makes the CDR more of a
multidomain scale rather than a staging one.
Neuropsychiatric symptoms are also an important domain, as most people with dementia will experience at
least one symptom over the course of their dementia. However, although important, they do not change in
line with disease progression; many neuropsychiatric symptoms are no worse or may improve as dementia
progresses from moderate to severe and, thus, the use of these symptoms to measure disease progression
might be misleading. They are distressing for people with dementia, their family and those around them,
and often lead to care home admission. Within this category we are therefore recommending that triallists
use the NPI, as this has acceptable psychometric properties in this domain and is the only measure included
in ongoing disease modification trials.
The domain of quality of life is important, as if, for example, a pharmacological intervention has a positive
impact on cognition, it is also possible that it would have a negative impact on quality of life, and then it
would be important to record this. From the conference we recommend using a dementia-specific measure,
the DEMQOL, as it has adequate psychometric properties and coverage of the domain. In addition, it can be
collected from both the person with dementia and a proxy.
It was suggested that we should have different outcomes recommended for different types of dementia,
particularly with cognitive tests, which are the most sensitive to the change within the specific cognitive
domain that is key to a particular type of dementia. However, because the majority of studies include only
participants with AD, it is not possible to make recommendations for the specific types of dementia. This is
something to be considered in future trials of disease-modifying drugs.
It was also suggested that we should have different core outcomes for different phases of trials (e.g. we
could recommend different measures within the domain for different phases of trials). However, the three
phases of trials do not always translate to non-pharmacological intervention trials.
We did not include outcomes that related solely to economics, carers or drug levels. Although all three
may be important outcomes in a disease modification trial, they are not necessarily core. Health economics
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is particularly relevant in Phase III trials, requiring data on costs and QALYs. We also did not include
measures of side effects, which were mentioned across all three focus groups. These will always be
measured as they are as relevant as measuring how effective a pharmacological intervention is.
Recommendations around completing outcomes
To ensure that side effects are measured accurately, an informant may also need to participate in the
study. Having an informant for each participant would also be useful to ensure that, if the intervention is
pharmacological, it is taken in adherence with the protocol, as medication management can be difficult for
people with dementia, and often caregivers provide support.479,480
Informants are also often involved in the completion of outcomes on behalf of the person with dementia they
care for. There was discussion around who completes outcomes at both the PPI consultation and consensus
conference and, although it is important that people with dementia should be enabled to complete measures,
informal carers also need to be involved. This is due to the nature of dementia, including deterioration.
Although this can mean that people with dementia who wish to participate in research are excluded
because they do not have a defined carer, it is by definition the case that most people living with mild to
moderate dementia have someone helping to care for them in some capacity, although not necessarily
living with them.
As we are recommending some measures that are informant based, either partly or fully, there also needs
to be a way to standardise who the informant is that is completing outcomes. It is important to consider
how pragmatic researchers can and should be in their identification of an informant (e.g. does this have
to be a carer/can this be a neighbour/friend/health professional). An informant should also be the most
reliable person available, in terms of both the information they give and their ability to commit to the full
duration of the trial,481 as when an informant is changed between study visits, the answers on outcomes
show greater variability than when the informant is the same.482 Future research should also consider how
to establish robust methods of using informant-supplied information for the completion of questionnaires,
and also how to supplement responses from participants, as this could be very useful in terms of ensuring
full data collection of all items and has the potential to expand the range of participants who can
contribute to this research area.
As part of the project, we also considered the practicalities of participants completing the core set of
outcomes, and how we can minimise any problems. We recommend that an outcome package at the very
maximum should take no longer than 90 minutes without a break for a person with dementia, which was
accepted by the people consulted within the PPI group. Researchers should aim for shorter time periods,
particularly dependent on the person’s comorbid health conditions and how they are on the day. The people
consulted at the focus groups also accepted that long assessments could take place over 1 day but be split
into several time periods, with breaks and refreshments, if necessary.
They also want researchers to be clear about why assessments are being done as this would allow them to
feel that their time is being well used. Despite giving informed or consultee consent at the beginning of the
trial, people are required to be reminded of participation and what it involves at the time the assessments
are happening. This is in line with process consent,483 which is the idea that consent runs throughout the
whole research process, not just at the start of the trial when informant consent is taken, and is of particular
importance in dementia research as a participant may lose capacity over the course of the trial period.
Patient and public involvement
A small but growing literature484–486 suggests that using qualitative methods to examine participant
perspectives can provide triallists with important insights that can inform the design and implementation of
clinical trials. A proactive approach to consider the design and development of clinical trials is needed at
this early stage in the development of potentially disease course-modifying treatments that respond to the
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wider challenges in the design and implementation of clinical trials, and also to understand the needs,
hopes and expectations of this patient population and their families.
The experiences and beliefs of our PPI group broadly reflect the wider literature. Reasons for refusals to
participate appear to vary according to the type of trial and the severity of treatment,487 with key factors
including inconvenience, difficulties with transport, too many clinic visits and time taken, as well as a
distrust of medicine or the hospital and worries about side effects.488,489 Much of the literature examining
trial participation has identified altruism, trust in recruiting clinicians and an expectation of personal benefit
as the main motivations for participation in trials.490,491
However, altruism may be overstated as a motivation for participants, and a small but increasing number
of studies using qualitative methods to examine the perspectives of clinical trial participants484–486 have
concluded that patients participate in a clinical trial because they believe that they are receiving personalised
care. One study486 found that, even when participants recalled the involvement of chance, most also held
other coexisting (and sometimes contradictory) views about how and why they had been allocated to the
treatment or intervention and believed that they would receive the best treatment for them. Similarly, a
number of studies have identified that personal benefits, hope, access to the most effective treatment,492 and
the enthusiasm and hopes of family and friends were often the driving force behind and key motivations for
participation.490 Such beliefs highlight the vulnerability of some groups and the risks that they are willing to
take if there is a chance of survival,493 and this may be an important factor for trials involving potentially
disease course-modifying treatments.
Future of biomarkers
Although outcomes, such as cognition, give an indication of clinical benefit, they do not necessarily
demonstrate if an intervention has disease-modifying properties, whereas a biomarker could.494 Change
in current biomarkers of AD, in particular, does not always translate to changes in disease, and the
improvement of current and development of new biomarkers are the key challenges in working towards a
disease-modifying treatment, even more so with the development of adaptive trial designs.19 Sensitive
biomarkers could enable trials of potential disease-modifying interventions to be shorter, as they would be
able to detect changes in disease progression; however, the development and validation of biomarkers
takes time.495 The development of biomarkers for dementia, particularly AD, is a hugely innovative field,
meaning that it may be important to consider other biomarkers as core outcomes in the future if they are
objective and reliable enough to show a potential disease-modifying effect. Ultimately, the choice of a
biological marker depends, in a pharmacological study, on the compound being tested, and also the
resources available.
When biomarkers are to be used in disease modification trials, it is also important to consider the impact this
will have on participants’ willingness to take part in the research. From the PPI consultation, participants
were generally enthusiastic about potentially invasive biological tests, but did also highlight how they may
put off potential participants because of side effects, misconceptions and anxiety. They supported our
recommendation that MRI should be optional rather than compulsory, and indicated that this would make
them more willing to take part in a trial. As biomarkers develop, consideration will need to be given to
reducing the side effects of the biological techniques, particularly CSF examination, as 30% of people in
memory clinics report side effects, although very rarely are these serious or long-lasting problems.496
Previous outcome recommendations
There have been previous recommendations related to the outcomes that should be used in disease
modification trials. The current US Food and Drug Administration guidelines for all types of clinical trials
for AD are that treatments must show efficacy on both a cognitive and a functional or global outcome
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measure.497 For disease modification trials, in particular, the US Food and Drug Administration draft
guidelines recommend that, as well as a benefit on clinical outcomes, a disease-modifying effect could be
shown via a reliable biomarker, or by an adaptive trial design, such as a randomised start design, that can
determine a long-lasting effect on disease course. Furthermore, the European Medicines Agency has
recently published draft guidelines around medical trials of treatments for dementia.498 These state that
disease modification should be demonstrated by a slowing decline of clinical symptoms and also be linked
to a change in validated biomarkers that reflect underlying disease pathology. These recommendations are
in line with, but not as detailed as, our recommendations. Around a decade ago, a European task force
reached consensus around a number of topics in dementia trials, including recommendations for the end
points of disease modification trials.499,500 They recommended measuring cognition, ADLs and global
functioning as core, and within the domains, respectively, recommended the measures of the ADAS-Cog,
ADCS-ADL and CDR sum of boxes.
Strengths and limitations
As part of the project, we have incorporated other research from members of our group around the
development of core outcome sets for dementia from perspectives other than disease modification.
The first is the recently published standard set of outcomes of what matters the most to people living with
dementia, developed by ICHOM.501 The second is funded by the JPND, and was a project to develop a set of
core outcomes to be used in psychosocial intervention trials of dementia.502,503 We also used references
gathered for a project about non-pharmacological interventions for dementia. We conducted additional
searches on top of those specified in the protocol, including for ongoing trials on two clinical trial registries.
We conducted both e-mail and face-to-face consultations with people living with dementia and carers,
and gained a wide variety of views around completing outcomes from the 18 participants. Although the
feedback from the PPI group was very useful, we conducted focus groups only in three locations, and the
overall number of people consulted was small, even including the second e-mail consultation. In addition,
all participants were part of the AS Research Network and/or a dementia PPI group, and were knowledgeable
about dementia. Although this meant that they were able to give informed views, they did not cover
the possible range of opinions, and only one-third of the participants had experience of participating in
research. Furthermore, context makes a huge difference, and advocacy group members often have different
ideas from the patient and carers attending memory clinics. The background of participants can also
influence ideas, with the majority of those who participate in PPI being from middle-class backgrounds and
of white ethnicity and thus not necessarily reflective of wider society,504 which is a potential limitation within
our PPI sample. In addition, we did not conduct detailed, in-depth, open-ended interviews and, therefore,
the information we gained was limited. Although there were three research team members present in each
location, with differing backgrounds (so views were not filtered through a single researcher’s perspective),
we did not do formal and independent thematic analyses. With more time and funding we would like to
have further widened the consultation to include, for example, the clinical research nurses who often run
dementia trials.
Many of the opinions arising from this consultation were contradictory. Thus, people suggested that they
wanted more importance on interpreting scores within the context of an individual’s experiences and
individualised instruments with more detail, but also wanted testing to be of shorter duration with fewer
questions. Overall, it appeared that people were saying that they wanted to be recognised as a full person
with an illness rather than to be summed up by declining scores on questionnaires. This is an important
message for researchers, although most will think they do this already, as well as being the only acceptable
way for health professionals to practise. Contextual information is of great importance in clinical practice
and, although it should be considered in trials, it is of less relevance if participants have been randomised as
those in each group have been matched for individual differences.
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We included outcomes that are informant rated, which will limit people living with dementia taking part if
they do not have an informant available. We also included only outcomes that have been or are currently
being used in trials. Outcomes are not perfect and there may be better measures in the future. It has been
suggested that one problem for disease modification trials is that outcomes need to be very sensitive in the
early stages of dementia, when subtle and slow changes occur.495 However, most people with dementia
do deteriorate cognitively over the period of trials, and drugs which modify the disease need to be able to
show a clinically important difference in cognitive deterioration, which would be seen in current measures.
This may not be true of MCI, but this was not part of the study presented here.
This project was delivered in 6 months with a very limited budget, so we included only, as specified in
the brief, mild to moderate dementia. We cannot make recommendations for disease modification trials
involving other stages of dementia, such as severe, prodromal or mild cognitive impairment. Work has been
completed around more appropriate measures to be used in other stages, such as those with dementia living
in long-term care.505 Similarly, we are unable to make recommendations for separate types of dementia,
such as vascular or frontotemporal dementia, as most of the trials included only participants with AD. This is
potentially a limitation of the outcome set for use in disease modification trials not focusing on participants
with AD; although as AD is the most common type of dementia, the outcome set would reflect those most
affected. If, and when, a disease modification treatment for AD is found, this could significantly decrease the
burden of dementia on public health by up to 50%, although more work is needed to address the disease
modification of the less prevalent types of dementia and reduce the burden of these.506
We have also not had time or resources to consult with regulators and pharmaceutical industries; however,
we have plans to do this in the future, possibly through collaboration with Alzheimer’s Research UK.
Similarly, we did not consider economic measures as outcomes and did not include health economists on
our team. This was because of the limitation in time and resources and the commissioning brief. Our
recommendations did not consider the financial cost in detail although it was mentioned in the discussion.
We did not attempt a cost analysis but are aware that MRI is expensive. If there are better biological
measures in the future this recommendation will be superseded.
We included the highest standard of trials, RCTs and then CCTs, that compared the intervention with a
control or another intervention. This means that we will have missed early-stage disease modification trials,
in which the dosage and safety are the main focuses, rather than the efficacy from the comparison of
interventions with each other or control groups. Despite including both ongoing and published trials, we
may also have missed a number of trials that have been completed but not yet published in an academic
journal article, whether a protocol or the study results. We did, however, conduct a large-scale systematic
review, screening 22,918 references, in the hope of picking up the majority of relevant trials. Most of the
trials included were conducted in English-speaking countries, with a large proportion conducted solely or
partly in the USA. We included many trials from countries where the native language was not English as
long as the trial was reported in English, and have reported whether or not validation of the measures has
been carried out in other languages, but are unable to make definitive recommendations about measures
in other languages. We excluded 30 full-text articles because they were not available in English.
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Chapter 9 Conclusions
A t present there are 81 different outcome measures used across disease modification trials, if weinclude published and ongoing trials. These include 72 questionnaire- or interview-based outcomes
and nine techniques for measuring biological markers. This illustrates the importance and difficulty of the
development of a consensus about a core set of the best available measures in allowing the comparison
and combination of disease modification trials.
The main conclusions from the synthesis of all the information at the consensus conference were that
cognition and biological markers are the only core outcome domains. For cognition we recommend the
ADAS-Cog or MMSE, and for a biological marker we recommend using MRI as an outcome, which is
optional for participants. This means that those who are unable or do not wish to undergo MRI can
still participate. Other biological outcome markers would be appropriate depending on the proposed
mechanism of action of the therapy, and selecting a universal set of biomarker outcome measures for all
studies was not possible. We have also made outcome recommendations for the important, but non-core,
domains of ADLs, global functioning, neuropsychiatric and quality of life, respectively, recommending the
DAD, CDR, NPI and DEMQOL.
We have reached our conclusions and recommendations through discussion at the consensus conference
based on the psychometric properties and suitability of the outcomes found within the systematic review,
in discussion with expert researchers and clinicians, and informed by the voluntary sector and patients and
families. We also considered the practicalities of the completion of the core outcome set, including timing,
breaks, travel and if the person with dementia and/or an informant completes the measures.
As the recommended measures are currently the best available, we expect that additional or alternative
outcome measures may supersede the current core set, particularly for biological markers where there is
considerable current research. The principles on which we have made our choices are laid out here and
they will not change.
Recommendations for future research
The recommendations throughout this report are in the most part for AD; therefore, there is a need to
extend the development of core outcome sets for other dementias. As we are recommending the use of
either the ADAS-Cog or MMSE, which are the most commonly used cognitive outcomes in the included
disease modification trials, and we wish to be able to directly compare scores on each item, it would be
useful to develop an algorithm to directly compare scores on both. Patients also feel that they are failing in
tests of cognition as they notice their deterioration over time. It was suggested that timed measures, which
estimate cognitive processing speed, should be further developed and validated against other measures,
so that they can be considered in terms of clinical significance and minimal clinically important difference.
These would mean that patients would be able to complete cognitive scales where they would not feel like
they were failing.
We are also recommending measures that are partly or fully rated by informants, so it would also be useful
to consider ways of making informant data more robust, including thinking about who the most appropriate
informant is. We did not make any economic recommendations; however, future research could consider
both QALYs and cost data.
Through PPI we gathered a wide variety of feedback about outcomes and trial participation; however, this
was not a full qualitative study and only a small number of people participated, which highlights the need
for further qualitative research. This could also include consultations with trial staff, such as clinical research
nurses, and to see how those that administer outcomes can influence participants’ attitudes towards them.
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Appendix 1 MEDLINE (via OvidSP) search
strategy
Search strategy
1. exp Alzheimer Disease/
2. exp Dementia, Vascular/
3. exp ‘Pick Disease of the Brain’/
4. exp Dementia, Multi-Infarct/
5. exp Cognition Disorders/ or exp Dementia/
6. dement*.mp.
7. alzheimer*.mp.
8. (lewy* and dement*).af.
9. multiple infarcts.mp.
10. exp Supranuclear Palsy, Progressive/
11. (pick adj5 disease).mp.
12. ‘Frontotemporal Dementia’.mp. or exp Frontotemporal Dementia/
13. (park* and dement*).af.
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. exp ‘Outcome Assessment (Health Care)’/
16. ‘outcome’.mp.
17. ‘instrument’.mp.
18. ‘measure’.mp.
19. outcome*.mp.
20. instrument*.mp.
21. measure*.mp.
22. 16 or 17 or 18 or 19 or 20 or 21
23. intervention.mp.
24. therap*.mp.
25. trial*.mp.
26. 23 or 24 or 25
27. control*.mp.
28. 22 or 26 or 27
29. limit 28 to english language
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Appendix 2 Disagreements on exclusion of
full texts
The raters disagreed on the inclusion of four full texts.
For the first paper,33 across the three raters there were two exclusions and one inclusion, with disagreement
about the trial’s aim being symptomatic or disease modification. After looking at a second paper (within the
database) that was referring to the same trial,32 it was much clearer that the aim of the trial was disease
modification, so we agreed by consensus to include the first paper.
For the second paper, there was disagreement between raters – two raters excluded and one included –
and we agreed to exclude, as it was a conference abstract.507
The third and fourth paper referred to the same trial,25,26 and across the three raters there was one include,
one undecided and one exclude. The raters could not reach a consensus, so we consulted with Gill Livingston
who decided it should be included as the intervention was aiming to change neuronal dysfunction in AD.
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Appendix 3 List of excluded studies and reasons
for exclusion
TABLE 15 Excluded studies and reasons for exclusion (n = 748)
Reference Reason for exclusion
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine
in patients with Parkinson’s disease dementia or dementia with Lewy bodies:
a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613–18
Not a disease modification trial
AbbVie. NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal Fluid
Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer’s
Disease and Mild Cognitive Impairment. URL: https://clinicaltrials.gov/ct2/show/
NCT02573740 (accessed 29 January 2016)
No quantitative outcome relating
to disease modification
Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with
probable Alzheimer’s disease. Neurology 2001;57:1515–17
Not a disease modification trial
Adami M, Scarpini E, Bruno G, Zappala G, Richarz U, Gaudig M, et al. Cessation versus
continuation of 12 months galantamine therapy in patients with Alzheimer’s disease:
a randomised, double blind, placebo controlled withdrawal trial. Alzheimers Dement
2011;1:S794
Not published in a peer-reviewed
journal article or is an ongoing
trial
Adamus WS, Leonard JP, Tröger W. Phase I clinical trials with WAL 2014, a new
muscarinic agonist for the treatment of Alzheimer’s disease. Life Sci 1995;56:883–90
No participants with mild or
moderate dementia
Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in
patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp 1998;59:837–45
Not a disease modification trial
Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of
rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin
2004;20:1747–52
Not a disease modification trial
Aguiar P, Monteiro L, Feres A, Gomes I, Melo A. Rivastigmine transdermal patch and
physical exercises for Alzheimer’s disease: a randomised clinical trial. Curr Alzheimer
Res 2014;11:532–7
Not a disease modification trial
Aguirre E, Spector A, Hoe J, Russell IT, Knapp M, Woods RT, et al. Maintenance
Cognitive Stimulation Therapy (CST) for dementia: a single-blind, multi-centre,
randomised controlled trial of Maintenance CST vs. CST for dementia. Trials
2010;11:46
Not a disease modification trial
Ahlin A, Nyback H, Junthe T, Ohman G, Nordgren I. Tetrahydroaminoacridine in
Alzheimer’s dementia: clinical and biochemical results of a double–blind crossover trial.
Hum Psychopharmacol 1991;6:109–18
Not a disease modification trial
Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM. Effects of low versus high
frequencies of repetitive transcranial magnetic stimulation on cognitive function and
cortical excitability in Alzheimer’s dementia. J Neurol 2012;259:83–92
Not a disease modification trial
Akanuma K, Meguro K, Meguro M, Sasaki E, Chiba K, Ishii H, et al. Improved social
interaction and increased anterior cingulate metabolism after group reminiscence with
reality orientation approach for vascular dementia. Psychiatry Res 2011;192:183–7
Not a disease modification trial
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.
Melissa officinalis extract in the treatment of patients with mild to moderate
Alzheimer’s disease: a double blind, randomised, placebo controlled trial. J Neurol
Neurosurg Psychiatry 2003;74:863–6
Not a disease modification trial
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s
disease: a double blind, randomised and placebo-controlled trial. J Clin Pharm Ther
2003;28:53–9
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine
transdermal patch on activities of daily living: item responder analyses. Int J Geriatr
Psychiatry 2011;26:356–63
Not a disease modification trial
Alva G, Isaacson R, Sadowsky C, Grossberg G, Meng X, Somogyi M. Efficacy of
higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer’s Disease
Assessment Scale-cognitive subscale: Domain and individual item analysis. Int J Geriatr
Psychiatry 2014;29:920–7
Not a disease modification trial
Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, et al.
Combination treatment in Alzheimer’s disease: results of a randomised, controlled trial
with cerebrolysin and donepezil. Curr Alzheimer Res 2011;8:583–91
Not a disease modification trial
Alvarez A, Iglesias O, Aleixandre M, Linares C, Figueroa J, Muresanu D, et al.
Cerebrolysin and combination therapy enhance serum BDNF in AD patients.
Alzheimer’s Dement 2014;10:774
Not published in a peer-reviewed
journal article or is an ongoing
trial
Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial:
association between the cholinesterase inhibitor donepezil and the cholinergic
precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury:
interim results. J Neurol Sci 2012;322:96–101
Not a disease modification trial
Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid
acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine.
Mech Ageing Dev 2001;122:2057–62
Not a disease modification trial
Amieva H, Dartigues JF. ETNA3, a clinical randomised study assessing three
cognitive-oriented therapies in dementia: rationale and general design. Rev Neurol
2013;169:752–6
Not a disease modification trial
Andersen F, Viitanen M, Halvorsen DS, Straume B, Wilsgaard T, Engstad TA. The effect
of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease.
A community based RCT with a two-by-two factorial design. BMC Neurol 2012;12:59
Not a disease modification trial
Andrade LP, Gobbi LT, Coelho FG, Christofoletti G, Costa JL, Stella F. Benefits of
multimodal exercise intervention for postural control and frontal cognitive functions
in individuals with Alzheimer’s disease: a controlled trial. J Am Geriatr Soc
2013;61:1919–26
Not a disease modification trial
Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O. Effectiveness of the
combination of memantine plus vitamin D on cognition in patients with Alzheimer
disease: a pre–post pilot study. Cogn Behav Neurol 2012;25:121–7
Not a RCT/CCT
Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of
memantine in community-based Alzheimer’s disease patients: an adaptation in Spain.
Eur J Health Econ 2006;7:137–44
Not a disease modification trial
Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, et al. The effects
of combine treatment of memantine and donepezil on Alzheimer’s disease patients
and its relationship with cerebral blood flow in the prefrontal area. Int J Geriatr
Psychiatry 2014;29:881–9
Not a disease modification trial
Arcoverde C, Deslandes A, Moraes H, Almeida C, Araujo NB, Vasques PE, et al.
Treadmill training as an augmentation treatment for Alzheimer’s disease: a pilot
randomised controlled study. Arq Neuropsiquiatr 2014;72:190–6
Not a disease modification trial
Arlt S, Muller-Thomsen T, Beisiegel U, Kontush A. Effect of one-year vitamin C- and
E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in
Alzheimer’s disease. Neurochem Res 2012;37:2706–14
Not a disease modification trial
Aronson S, Van Baelen B, Kavanagh S, Schwalen S. Optimal dosing of galantamine in
patients with mild or moderate Alzheimer’s disease: post hoc analysis of a randomised,
double-blind, placebo-controlled trial. Drugs Ageing 2009;26:231–9
Not a disease modification trial
Arrigo A, Moglia A, Borsotti L. A double-blind, placebo-controlled, crossover trial
with nicergoline in patients with senile dementia. Int J Clin Pharmacol Res
1982;2(Suppl. 1):33–41
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Ash E, Bregman N, Moore O, Korczyn A, Zangen A. Transcranial magnetic stimulation
of deep brain regions in Alzheimer’s disease. Alzheimer’s Dement 2014;10:P450
Not published in a peer-reviewed
journal article or is an ongoing
trial
Ash EL, Vakhapova V, Bova I, Simon E, Korem M, Eldad M, et al. Transcranial magnetic
stimulation of deep brain regions in Alzheimer’s disease: a pilot study. Ann Neurol
2012;72:S126
Not published in a peer-reviewed
journal article or is an ongoing
trial
Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, et al. MR spectroscopy
for assessment of memantine treatment in mild to moderate Alzheimer dementia.
J Alzheimers Dis 2011;26(Suppl. 3):331–6
Not a disease modification trial
Asp E, Cloutier F, Fay S, Cook C, Robertson ML, Fisk J, et al. Verbal repetition in
patients with Alzheimer’s disease who receive donepezil. Int J Geriatr Psychiatry
2006;21:426–31
Not a disease modification trial
Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, et al. High-dose
estradiol improves cognition for women with AD: results of a randomised study.
Neurology 2001;57:605–12
Not a disease modification trial
Atri A, Hendrix S, Pejovic V, Graham S. Extended-release daily memantine provides
increasing cumulative benefits across clinical domains over 24 weeks in patients with
moderate to severe Alzheimer’s disease: an analysis of area under the curve. Neurology
2014;82:P1-006
Not published in a peer-reviewed
journal article or is an ongoing
trial
Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients
with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for
combination therapy. Alzheimers Res Ther 2013;5:6
Not a disease modification trial
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of
combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:209–21
Not a disease modification trial
Auchus A, Brashear H, Salloway S, Korczyn A, De Deyn P, Gassmann-Mayer C.
Galantamine treatment of vascular dementia: a randomised trial. Neurology
2007;69:448–58
Not a disease modification trial
Avila R, Carvalho IA, Bottino CM, Miotto EC. Neuropsychological rehabilitation in mild
and moderate Alzheimer’s disease patients. Behav Neurol 2007;18:225–33
Not a disease modification trial
Bachynsky J, McCracken P, Lier D, Alloul K, Jacobs P. Propentofylline treatment for
Alzheimer disease and vascular dementia: an economic evaluation based on functional
abilities. Alzheimer Dis Assoc Disord 2000;14:102–11
Not a disease modification trial
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate
Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month
study. J Alzheimers Dis 2007;11:471–9
Not a disease modification trial
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten ECW, et al. Efficacy,
safety and tolerability of rivastigmine capsules in patients with probable vascular
dementia: the VantagE study. Curr Med Res Opin 2008;24:2561–74
Not a disease modification trial
Ban TA, Morey LC, Aguglia E, Batista R, Campanella G, Conti L, et al. Glycosaminoglycan
polysulfate in the treatment of old age dementias. Prog Neuropsychopharmacol Biol
Psychiatry 1991;15:323–42
Not a disease modification trial
Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH. Inositol treatment of Alzheimer’s
disease: a double blind, cross-over placebo controlled trial. Prog Neuropsychopharmacol
Biol Psychiatry 1996;20:729–36
Not a disease modification trial
Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus placebo
in hyperhomocysteinemic Parkinson’s disease dementia patients. Mov Disord
2008;23:1532–40
Not a disease modification trial
Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial
of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord
2000;11:230–7
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Batman MW. The effects of therapeutic aquatic exercise on patients with Alzheimer’s
Disease (elderly). Diss Abstr Int B Sci Eng 1999;60:2933
Not published in a peer-reviewed
journal article or is an ongoing
trial
Battaglia A, Annon K, Pamparana F, De Paolis C, Bonura ML, Stekke W, et al.
P-8–11 Nicergoline in the long term treatment of mild or moderate senile
dementia. A multicenter double-blind, randomised, placebo-controlled trial.
Eur Neuropsychopharmacol 1995;5:383
Not published in a peer-reviewed
journal article or is an ongoing
trial
Baum L, Lam CWK, Cheung SKK, Kwok T, Lui V, Tsoh J, et al. Six-month randomised,
placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with
Alzheimer disease. J Clin Psychopharmacol 2008;28:110–13
Not published in a peer-reviewed
journal article or is an ongoing
trial
Bayer AJ, Bokonjic R, Booya NH, Demarin V, Ersmark B, Fairbairn AF, et al. European
pentoxifylline multi-infarct dementia study. Eur Neurol 1996;36:315–21
Not a disease modification trial
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind,
placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for
Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:124–31
Not a disease modification trial
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Effects of
metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-
controlled, 6-month study. Alzheimer Dis Assoc Disord 1998;12:54–7
Not a disease modification trial
Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the
progression of cognitive decline in Alzheimer’s disease using mifepristone.
J Mol Neurosci 2002;19:201–6
Not a disease modification trial
Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative
dementia. A double-blind study of response to different dose level. Psychopharmacology
1985;87:147–51
Not a disease modification trial
Bentham PW. A double-blind placebo-controlled trial of L-tryptophan to assess the
degree of cognitive and behavioural improvement in patients with Alzheimer-type
dementia and to compare differential response in clinical sub-groups. Int Clin
Psychopharm 1990;5:261–72
Not a disease modification trial
Bergamaschini LC, Scarpini E, Rossi E, Galimberti D, Case A, Lucca U, et al.
[Randomised pilot study on the feasibility of Enoxaparin treatment in Alzheimer’s
disease.] Neurodegener Dis 2011;8:1
Full text unavailable in English
Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of
cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol
1994;9:161–8
Not a disease modification trial
Bergamasco B, Villardita C, Coppi R. Idebenone in the treatment of multi-infarct
dementia: a randomised, double-blind, placebo controlled multicentre trial.
Arch Gerontol Geriatr 1992;15:271–8
Not a disease modification trial
Beversdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW.
Donepezil in the treatment of dementia with Lewy bodies. Am J Geriatr Psychiatry
2004;12:542–3
Not a disease modification trial
Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study of
clonidine plus physostigmine in Alzheimer’s disease. Dementia 1994;5:243–6
Not a disease modification trial
Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP. Pentoxifylline in
cerebrovascular dementia. J Am Geriatr Soc 1992;40:237–44
Not a disease modification trial
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy
and tolerability of donepezil in vascular dementia: positive results of a 24-week,
multicenter, international, randomised, placebo-controlled clinical trial. Stroke
2003;34:2323–30
Not a disease modification trial
Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomised, double-blind, placebo-controlled,
multicenter study to evaluate the safety and tolerability of metrifonate in patients with
probable Alzheimer disease. The Metrifonate Study Group. Alzheimer Dis Assoc Disord
2000;14:39–45
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of
butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger
patients with Alzheimer’s disease. Pharmacogenet Genomics 2006;16:771–4
Not a disease modification trial
Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine
provides sustained benefits in patients with ‘advanced moderate’ Alzheimer’s disease
for at least 12 months. Dement Geriatr Cogn Disord 2003;15:79–87
Not a disease modification trial
Boada-Rovira M. [Human albumin grifols 5% in plasmapheresis: a new therapy
involving beta-amyloid mobilisation in Alzheimer’s disease.] Rev Neurol
2010;50(Suppl. 5):9–18
Full text unavailable in English
Boada-Rovira M, Lopez O, Nunez L, Ortiz P, Anaya F, Hernandez I, et al. A phase II
study to evaluate the efficacy and safety of plasma replacement with 5% albumin in
beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with
mild–moderate Alzheimer’s disease. Alzheimers Dement 2014;10:P274
Not published in a peer-reviewed
journal article or is an ongoing
trial
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of
xanomeline, a selective muscarinic receptor agonist, on cognitive function and
behavioural symptoms in Alzheimer disease. Arch Neurol 1997;54:465–73
Not a disease modification trial
Bogaert P, Grinsven R, Tolson D, Wouters K, Engelborghs S, Mussele S. Effects of
SolCos model-based individual reminiscence on older adults with mild to moderate
dementia due to Alzheimer disease: a pilot study. J Am Med Dir Assoc 2013;14:528
Not a disease modification trial
Bokde ALW, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, et al. Decreased
activation along the dorsal visual pathway after a 3-month treatment with galantamine
in mild Alzheimer disease: a functional magnetic resonance imaging study. J Clin
Psychopharmacol 2009;29:147–56
Not a disease modification trial
Bottino CMC, Carvalho IAM, Alvarez AMM, Avila R, Zukauskas PR, Bustamante SEZ,
et al. Cognitive rehabilitation combined with drug treatment in Alzheimer’s disease
patients: a pilot study. Clin Rehabil 2005;19:861–9
Not a disease modification trial
Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, et al. A
randomised, multicenter, placebo controlled trial of memantine for behavioural variant
FTD and semantic variant PPA. Alzheimers Dement 2012;1:P405
Not published in a peer-reviewed
journal article or is an ongoing
trial
Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, et al. A
26-week, multicenter, randomised, double blind, placebo controlled trial of memantine
for behavioural variant FTD and semantic variant PPA. Dement Geriatr Cogn Disord
2012;34:47–8
Not published in a peer-reviewed
journal article or is an ongoing
trial
Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, et al.
Memantine in patients with frontotemporal lobar degeneration: a multicentre,
randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12:149–56
Not a disease modification trial
Boxer A, Tartaglia M, Koestler M, Lasky A, Fine E, Heuer H, et al. A 12 week,
randomised, double-blind, placebo-controlled pilot clinical trial of davunetide 15 mg
intranasally twice daily for FTLD with predicted tau pathology (CBD,PNFA, PSP).
Dement Geriatr Cogn Disord 2010;30:28–9
Not published in a peer-reviewed
journal article or is an ongoing
trial
Breeze RW, Cox S, Rodgers-Cox J. Changes in P-300 latency as a result of
co-dergocrine mesylate therapy in patients with senile dementia. J Geriatr Psychiatry
1988;3:263–6
Not a disease modification trial
Brem A-K, Atkinson NJ, Seligson EE, Pascual-Leone A. Differential pharmacological
effects on brain reactivity and plasticity in Alzheimer’s disease. Front Psychiatry
2013;4:124
Not a disease modification trial
Brem AK, Schilberg L, Freitas C, Atkinson N, Seligson E, Pascual-Leone A. Effects of
cognitive training and rTMS in Alzheimer’s disease. Alzheimers Dement 2013;1:664
Not published in a peer-reviewed
journal article or is an ongoing
trial
Brem AK, Schilberg L, Freitas C, Atkinson N, Seligson E, Pascual-Leone A. Synergistic
effects of rTMS and cognitive training in Alzheimer’s Disease. J Neurol Sci
2013;333:e343
Not published in a peer-reviewed
journal article or is an ongoing
trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine
prolonged-release formulation in the treatment of mild to moderate Alzheimer’s
disease. Dement Geriatr Cogn Disord 2005;20:120–32
Not a disease modification trial
Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger
patients with Alzheimer’s disease: a reanalysis of a double-blind, placebo-controlled
study using the trilinear approach. Int Psychogeriatr 1998;10:193–203
Not a disease modification trial
Brown D, Spanjers K, Atherton N, Lowe J, Stonehewer L, Bridle C, et al. Development
of an exercise intervention to improve cognition in people with mild to moderate
dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072.
Physiotherapy 2015;101:126–34
Not a disease modification trial
Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, et al. Effect of age on
response to rivastigmine or donepezil in patients with Alzheimer’s disease. Curr Med
Res Opin 2006;22:483–94
Not a disease modification trial
Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and
donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a
2-year period. Curr Med Res Opin 2005;21:1317–27
Not a disease modification trial
Burgener SC, Yang Y, Gilbert R, Marsh-Yant S. The effects of a multimodal
intervention on outcomes of persons with early-stage dementia. Am J Alzheimers Dis
Other Demen 2008;23:382–94
Not a disease modification trial
Burke D. Donepezil or memantine improved cognitive functioning in moderate-to-
severe Alzheimer disease. ACP J Club 2012;156:1
Not published in a peer-reviewed
journal article or is an ongoing
trial
Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK. L-deprenyl
in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am
Geriatr Soc 1993;41:367–70
Not a disease modification trial
Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl
in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.
J Am Geriatr Soc 1993;41:1219–25
Not a disease modification trial
Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of
rivastigmine in patients with and without visual hallucinations in dementia associated
with Parkinson’s disease. Move Disord 2006;21:1899–907
Not a disease modification trial
Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years:
an open-label, multicentre study in patients with Alzheimer’s disease. Int J Geriatr
Psychiatry 2007;22:806–12
Not a disease modification trial
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of
donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr
Cogn Disord 1999;10:237–44
Not a disease modification trial
Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe
Alzheimer’s disease. Int J Geriatr Psychiatry 2004;19:243–9
Not a disease modification trial
Burns A GS, Perdomo C. Long-term use of donepezil may be safe and effective in
elderly AD patients. Brown Uni Geriatr Psychopharmacol Update 2007;11:3–4
Not a disease modification trial
Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, et al. Effects of a
newly developed cognitive intervention in amnestic mild cognitive impairment and mild
Alzheimer’s disease: a pilot study. J Alzheimers Dis 2011;25:679–94
Not a disease modification trial
Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in
Alzheimer disease: a randomised, placebo-controlled, double-blind, phase 2 trial.
Neurology 2015;84:2161–8
Not a disease modification trial
Camargo CH, Justus FF, Retzlaff G. The effectiveness of reality orientation in the
treatment of Alzheimer’s disease. Am J Alzheimers Dis Other Dement 2015;30:527–32
Not a disease modification trial
Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M. Effects of Ginkgo
biloba supplementation in Alzheimer’s disease patients receiving cholinesterase
inhibitors: data from the ICTUS study. Phytomedicine 2014;21:888–92
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Caramelli P, Laks J, Palmini ALF, Nitrini R, Chaves MLF, Forlenza OV, et al. Effects of
galantamine and galantamine combined with nimodipine on cognitive speed and
quality of life in mixed dementia: a 24-week, randomised, placebo-controlled
exploratory trial (the REMIX study). Arq Neuropsiquiatr 2014;72:411–17
Not a disease modification trial
Carlson MC, Tschanz JT, Norton MC, Welsh-Bohmer K, Martin BK, Breitner JC. H2
histamine receptor blockade in the treatment of Alzheimer disease: a randomised,
double-blind, placebo-controlled trial of nizatidine. Alzheimer Dis Assoc Disord
2002;16:24–30
Not a disease modification trial
Ceccato E, Vigato G, Bonetto C, Bevilacqua A, Pizziolo P, Crociani S, et al. STAM
protocol in dementia: a multicenter, single-blind, randomised, and controlled trial.
Am J Alzheimers Dis Other Demen 2012;27:301–10
Not a disease modification trial
Chan WC, Cheng ST, Shi L, Wang D, Lam LC-W. Would transcranial direct current
stimulation (tDCS) enhance the effects of working memory training in older adults
with mild neurocognitive disorder due to Alzheimer’s disease: study protocol for a
randomised controlled trial. Trials 2015;16:1–7
Not a disease modification trial
Chapman SB, Weiner MF, Rackley A, Hynan LS, Zientz J. Effects of cognitive-
communication stimulation for Alzheimer’s disease patients treated with donepezil.
J Speech Lang Hear R 2004;47:1149–63
Not a disease modification trial
Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R. AMPA
potentiator treatment of cognitive deficits in Alzheimer disease. Neurology
2007;68:1008–12
Not a disease modification trial
Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile
dementia of the Alzheimer type: A multicentre trial. BMJ 1990;300:495–9
Not a disease modification trial
Chen J, Huang Y, Wang SX, Li QS, Liang YJ, Guo YN. [18FDG PET cerebral function
imaging in 10 vascular dementia patients receiving needling at Baihui(DU20), Shuigou
(DU26) and Shenmen(HT7).] J South Med Uni 2006;26:610–12
Full text unavailable in English
Chen TS, Lang HC. Cost-effectiveness analysis of donepezil and rivastigmine for mild to
moderate Alzheimer’s disease in Taiwan. Value Health 2013;16:A104
Not published in a peer-reviewed
journal article or is an ongoing
trial
Chen WW, Tian AL, Zhai L, Zhai XL, Zhang YL. [Effect of the xingding allied piracetam
injection on improvement of cognitive function in patients with vascular dementia.]
Chin J Clin Rehabil 2005;9:231–3
Full text unavailable in English
Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al.
Testosterone improves spatial memory in men with Alzheimer disease and mild
cognitive impairment. Neurology 2005;64:2063–8
Not a disease modification trial
Cheung SK. The effects of the music-with-movement intervention of the cognitive
functions of people with moderate dementia. Diss Abstr Int B Sci Eng 2014;75
Not published in a peer-reviewed
journal article or is an ongoing
trial
Chiu C-C, Su K-P, Cheng T-C, Liu H-C, Chang C-J, Dewey ME, et al. The effects
of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive
impairment: a preliminary randomised double-blind placebo-controlled study.
Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1538–44
Not a disease modification trial
Choe YM, Kim KW, Jhoo JH, Ryu SH, Choo IH, Seo EH, et al. Multi-centre, randomised,
placebo-controlled, double-blind clinical trial of escitalopram on the progression
delaying effect in Alzheimer’s disease: Anmri study for atrophy delaying effect.
Alzheimers Dement 2014;10:P302
Not published in a peer-reviewed
journal article or is an ongoing
trial
Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, et al. Tolerability and efficacy of
memantine add-on therapy to rivastigmine transdermal patches in mild to moderate
Alzheimer’s disease: a multicenter, randomised, open-label, parallel-group study.
Curr Med Res Opin 2011;27:1375–83
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Chua KK, Wong A, Kwan P-L, Song JX, Chen LL, Chan A-T, et al. The efficacy and
safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer’s
disease: protocol for a randomised controlled trial. Trials 2015;16:199
Not a disease modification trial
Clare L, Linden DEJ, Woods RT, Whitaker R, Evans SJ, Parkinson CH, et al.
Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease:
a single-blind randomised controlled trial of clinical efficacy. Am J Geriatr Psychiatry
2010;18:928–39
Not a disease modification trial
Claus JJ, De Koning I, Van Harskamp F, Breteler MMB, Voet B, Gutzmann H, et al.
Lisuride treatment of Alzheimer’s disease: a preliminary placebo-controlled clinical trial
of safety and therapeutic efficacy. Clin Neuropharmacol 1998;21:190–5
Not a disease modification trial
Claxton A, Baker L, Hanson A, Cholerton B, Trittschuh E, Morgan A, et al. Long-acting
intranasal insulin detemir improves working memory for adults with mild cognitive
impairment or early-stage Alzheimer’s dementia. Alzheimers Dement
2013;9(Suppl. 1):P657
Not published in a peer-reviewed
journal article or is an ongoing
trial
Coelho FG, Andrade LP, Pedroso RV, Santos-Galduroz RF, Gobbi S, Costa JL, et al.
Multimodal exercise intervention improves frontal cognitive functions and gait in
Alzheimer’s disease: a controlled trial. Geriatr Gerontol Int 2013;13:198–203
Not a disease modification trial
Coker E. High-dose vitamin B supplements did not slow cognitive decline in patients
with mild to moderate Alzheimer disease. Evid Based Nurs 2009;12:57
Not published in a peer-reviewed
journal article or is an ongoing
trial
Comelli M, Lucca U, Spagnoli A. Statistical analysis of the clinical trial of a therapy for
Alzheimer’s disease. Univariate tests and logistic regression. Acta Neurologica
1990;12:222–30
Not a disease modification trial
Concari L, Gardini S, Dieci F, Copelli S, Ferrari Pellegrini F, Ghetti C, et al. Cognitive
and brain metabolism improvement after cognitive stimulation therapy Functional.
Neurology 2013;28:21–2
Not published in a peer-reviewed
journal article or is an ongoing
trial
Connelly P. High dose vitamin B supplementation does not slow cognitive decline in
mild to moderate Alzheimer’s disease. Evid Based Ment Health 2009;12:86
Not published in a peer-reviewed
journal article or is an ongoing
trial
Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind
placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in
Alzheimer’s disease. Int J Geriatr Psychiatry 2008;23:155–60
Not a disease modification trial
Cook C, Fay S, Rockwood K. Decreased initiation of usual activities in people with mild
to moderate Alzheimer’s disease: a descriptive analysis from the VISTA clinical trial. Int
Psychogeriatr 2008;20:952–63
Not a disease modification trial
Corey-Bloom J, Anand R, Veach J. A randomised trial evaluating the efficacy and safety
of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients
with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol
1998;1:55–65
Not a disease modification trial
Cornelli U. Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined
with antioxidants. Neurodegen Dis 2010;7:193–202
Not a disease modification trial
Corona GI SG, Frattini P, Cucchi ML, Zerbi F, Tosca P, Savoldi F. Preliminary data on
monoamine metabolic levels in cerebrospinal fluid and in urine during therapy in
dementia. IRCS J Med Sci 1983;11:923–4
Not a disease modification trial
Corona GL CM, Frattini P, Santagostino G, Schinelli S, Romani A, Pola A, et al. Clinical
and biochemical responses to therapy in Alzheimer’s disease and multi-infarct
dementia. Eur Arch Psychiatry Clin Neurosci 1989;239:79–86
Not a disease modification trial
Corrigan FM VRA, Horrobin DF. Essential fatty acids in Alzheimer’s disease. Ann NY
Acad Sci 1991;640:250–2
Not a disease modification trial
Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, et al. Improved
language performance in Alzheimer disease following brain stimulation. J Neurol
Neurosurg Psychiatry 2011;82:794–7
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Courtney C, Farrell D, Grey R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil
treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind
trial. Lancet 2004;363:2105–15
Not a disease modification trial
Cove J, Jacobi N, Donovan H, Orrell M, Stott J, Spector A. Effectiveness of weekly
cognitive stimulation therapy for people with dementia and the additional impact of
enhancing cognitive stimulation therapy with a carer training program. Clin Interv
Ageing 2014;9:2143–50
Not a disease modification trial
Craft S, Claxton A, Baker L, Cholerton B, Hanson A, Callaghan M, et al. Therapeutic
effects of long-acting intranasal insulin detemir for Alzheimer’s dementia or mild
cognitive impairment. Alzheimers Dement 2013;9(Suppl. 1):139–40
Not published in a peer-reviewed
journal article or is an ongoing
trial
Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer’s
disease. Psychopharmacol Bull 1991;28:61–6
Unable to find a copy of the full
text
Crook T, Wilner E, Rothwell A, Winterling D, McEntee W. Noradrenergic intervention in
Alzheimer’s disease. Psychopharmacol Bull 1991;28:67–70
Unable to find a copy of the full
text
Crumpacker DW. Retrospective evaluation of constructional praxis measurements
among APOE4(–) subjects enrolled in the study of AC-1202 (Axona) in mild to
moderate Alzheimer’s disease (AD). Am J Geriatr Psychiatry 2012;1:S129
Not published in a peer-reviewed
journal article or is an ongoing
trial
Cumbo E. Effects of levetiracetam, phenobarbital and lamotrigine on
neuropsychological performance and moodin patients with Alzheimer’s disease and
epilepsy. Epilepsia 2009;50:101
Not published in a peer-reviewed
journal article or is an ongoing
trial
Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. A
randomised, double-blind, placebo-controlled phase 2 study to evaluate the efficacy
and safety of crenezumab in patients with mild to moderate Alzheimer’s disease.
Alzheimers Dement 2014;10:P275
Not a disease modification trial
Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al.
Randomised, double-blind, parallel-group, 48-week study for efficacy and safety of a
higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer’s disease. Dement Geriatr
Cogn Disord 2012;33:341–53
Not a disease modification trial
Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment
of the cognitive deficits of Alzheimer’s disease. Neurology 1998;50:1214–21
Not a disease modification trial
Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch
skin tolerability: results of a 1-year clinical trial in patients with mild to moderate
Alzheimers disease. Clin Drug Investig 2010;30:41–9
Not a disease modification trial
Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine
transdermal patch and capsule on aspects of clinical global impression of change
in Alzheimer’s disease: a retrospective analysis. Dement Geriatr Cogn Disord
2010;29:406–12
Not a disease modification trial
Cummings J, Grossberg G, Alva G, Caputo A, Downs P, Strohmaier C. High-dose
13.3 MG/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental
activities of daily living: individual item analysis. Alzheimers Dement 2012;8(Suppl. 1):P604
Not published in a peer-reviewed
journal article or is an ongoing
trial
Cummings J, Hendrix S, Miller M, Pejovic V, Graham S, Tocco M. Extended-release
memantine (28 mg, once daily) and sustained behavioural improvement: post hoc
responder analysis from a randomised trial in patients with moderate to severe
Alzheimer’s disease. Neurology 2012;78:P04.197
Not published in a peer-reviewed
journal article or is an ongoing
trial
Cutler NR, Sramek JJ, Murphy MF, Nash RJ. Implications of the study population
in the early evaluation of anticholinesterase inhibitors for Alzheimer’s disease.
Ann Pharmacother 1992;26:1118–22
Not a disease modification trial
D’Amico F, Rehill A, Knapp M, Aguirre E, Donovan H, Hoare Z, et al. Maintenance
cognitive stimulation therapy: an economic evaluation within a randomised controlled
trial. J Am Med Dir Assoc 2015;16:63–70
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al. Inhibition of
acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients
treated with galantamine. Neurobiol Ageing 2008;29:168–84
Not a disease modification trial
Darreh-Shori T ML, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N,
Minthon L, et al. Changes in the activity and protein levels of CSF acetylcholinesterases
in relation to cognitive function of patients with mild Alzheimer’s disease following
chronic donepezil treatment. J Neural Transm 2006;113:1791–801
Not a disease modification trial
Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential
increase in cerebrospinal fluid-acetylcholinesterase after treatment with
acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett
2001;300:157–60
Not a disease modification trial
Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind,
placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine
Collaborative Study Group. N Engl J Med 1992;327:1253–9
Not a disease modification trial
Davis RN, Massman PJ, Doody RS. Cognitive intervention in Alzheimer disease:
a randomised placebo-controlled study. Alzheimer Dis Assoc Disord 2001;15:1–9
Not a disease modification trial
de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, et al.
The effect of Souvenaid on functional brain network organisation in patients with mild
Alzheimer’s disease: a randomised controlled study. PLOS ONE 2014;27;9:e86558
Not a disease modification trial
Dean R, Siemers E, Carlson C, Estergard W, Sundell K, Henley D, et al. Effects
of solanezumab versus placebo administration on biomarkers in people with
mild to moderate Alzheimer’s disease: results from two phase III clinical trials.
Alzheimers Dement 2013;9(Suppl. 1):P283
Not published in a peer-reviewed
journal article or is an ongoing
trial
Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Treatment of Alzheimer’s disease
with stabilised oral nicotinamide adenine dinucleotide: a randomised, double-blind
study. Drugs Exp Clin Res 2004;30:27–33
Not a disease modification trial
Derouesne C, Renault B, Gueguen B, Van Der Linden M, Lacomblez L, Homeyer P,
et al. Neuropsychophysiological evaluation of three doses of S 12024–2 in mild
to moderate Alzheimer’s disease. Clin Drug Investig 1997;14:301–6
Not a disease modification trial
Desire L, Marcade M, Peillon H, Drouin D, Sol O, Pando M. Clinical trials of EHT 0202,
a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer’s disease.
Alzheimers Dement 2009;1:255–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al.
Donepezil in patients with subcortical vascular cognitive impairment: a randomised
double-blind trial in CADASIL. The Lancet Neurol 2008;7:310–18
Not a disease modification trial
Di Lorenzo F. D2 agonist administration restores altered cortical plasticity in Alzheimer’s
disease patients. Clin Neurophysiol 2014;125:S66
Not published in a peer-reviewed
journal article or is an ongoing
trial
Di Lorenzo F, Martorana A, Bonn S, Caltagirone C, Koch G. D2 agonist administration
restores impaired LTP-like cortical plasticity in AD patients. Clin Neurophysiol
2013;124:e139–40
Not published in a peer-reviewed
journal article or is an ongoing
trial
Diehl-Schmid J, Hardlund J, Bentham P, Wischik CM. The first disease-modifying drug
trial in frontotemporal dementia: initial experiences. Alzheimers Dement 2014;10:138
Not published in a peer-reviewed
journal article or is an ongoing
trial
Doggrell SA. Is memantine a breakthrough in the treatment of moderate-to-severe
Alzheimer’s disease? Expert Opin Pharmacother 2003;4:1857–60
Not a disease modification trial
Dong GS, Li X, Jiang QH, Yang HQ. [Effects of donepezil treatment on platelets and
secretase activities in Alzheimer’s disease patients.] Zhonghua Yi Xue Za Zhi
2011;91:3341–5
Full text unavailable in English
D’Onofrio G, Sancarlo D, Addante F, Ciccone F, Cascavilla L, Paris F, et al. A pilot
randomised controlled trial evaluating an integrated treatment of rivastigmine
transdermal patch and cognitive stimulation in patients with Alzheimer’s disease.
Int J Geriatr Psychiatry 2015;30:965–75
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Doody R, Galvin J, Farlow M, Shah R, Doraiswamy PM, Ferris S, et al. A new 26-week,
double-blind, randomised, placebo-controlled, study of AC-1204 (caprylic triglyceride)
in mild to moderate Alzheimer’s disease: presentation of study design. J Nutr Health
Ageing 2012;16:868
Not published in a peer-reviewed
journal article or is an ongoing
trial
Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety
of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s
disease: a subgroup analysis in patients already taking or not taking concomitant
memantine. Dement Geriatr Cogn Disord 2012;33:164–73
Not a disease modification trial
Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter,
phase 3, extension study of the safety and efficacy of donepezil in patients with
Alzheimer disease. Arch Neurol 2001;58:427–33
Not a disease modification trial
Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Dimebon
found safe and effective in mild to moderate Alzheimer’s disease. Brown Uni Geriatr
Psychopharmacol Update 2008;12:1–6
Not a disease modification trial
Doran MD. A Randomised 26 week Double-Blind Placebo Controlled Trial to Evaluate
the Safety and Efficacy of Galantamine in the Treatment of Dementia Secondary to
Cerebrovascular Disease. London: National Research Register; 2003
Not published in a peer-reviewed
journal article or is an ongoing
trial
Dorn M. Effect of Nimodipine on the Well-Being, Symptoms and Efficiency of
Ambulatory Patients with Cerebrovascular Disorders. Stuttgart: Schattauer; 1985
Not published in a peer-reviewed
journal article or is an ongoing
trial
Dubois B, McKeith I, Orgogozo J-M, Collins O, Meulien D. A multicentre, randomised,
double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety
of two doses of metrifonate in patients with mild to moderate Alzheimer’s disease:
The MALT Study. Int J Geriatr Psychiatry 1999;14:973–82
Not a disease modification trial
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil
in Parkinson’s disease dementia: a randomised, double-blind efficacy and safety study.
Move Dis 2012;27:1230–8
Not a disease modification trial
Dukoff R, Friz J, Lasser, Lev JPK, Sunderland T. A Comparison of Effects of Tacrine
with Scopolamine Versus Tacrine with Placebo in Patients with Alzheimer’s Disease
Conference Abstract. 11th Annual Meeting of the American Association for Geriatric
Psychiatry San Diego, CA, USA, 8–11 March 1998
Not published in a peer-reviewed
journal article or is an ongoing
trial
Dysken M, Kuskowski M, Love S. Ondansetron in the treatment of cognitive decline in
Alzheimer dementia. Am J Geriatr Psychiatry 2002;10:212–15
Not a disease modification trial
Dysken MW, Guarino PD, Vertrees JE, Asthana S, Sano M, Llorente M, et al. Vitamin E
and memantine in Alzheimer’s disease: clinical trial methods and baseline data.
Alzheimers Dement 2014;10:36–44
Not a disease modification trial
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, et al. Milacemide:
a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc
1992;40:503–6
Not a disease modification trial
Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of
vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA
cooperative randomised trial. JAMA 2014;311:33–44
Not a disease modification trial
Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Acta Neurol Scand
1992;85:75–80
Not a disease modification trial
Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, et al. Pilot randomised controlled
study of a histamine receptor inverse agonist in the symptomatic treatment of
Alzheimer’s disease. Alzheimers Dement 2011;1:S300
Not published in a peer-reviewed
journal article or is an ongoing
trial
Eisdorfer CJ, Wilkie FL. The effect of magnesium pemoline on cognition and behaviour.
J Gerontol 1968;23:283–8
Not a disease modification trial
Eliasova I, Anderkova L, Marecek R, Rektorova I. Non-invasive brain stimulation of the
right inferior frontal gyrus may improve attention in early Alzheimer’s disease: a pilot
study. J Neurol Sci 2014;346:318–22
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or
mixed dementia: results of a multicenter, double-blind trial. Clin Ther 2000;22:834–44
Not a disease modification trial
Emre M, Aarsland D, Albanese A, Byrne E, Deuschl G, De Deyn PP, et al. Rivastigmine
for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–18
Not a disease modification trial
Emre M, Poewe W, Deyn PP, Barone P, Kulisevsky J, Pourcher E, et al. Long-term safety
of rivastigmine in Parkinson disease dementia: an open-label, randomised study. Clin
Neuropharmacol 2014;37:9–16
Not a disease modification trial
Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine
for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a
randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969–77
Not a disease modification trial
Eriksdotter M, Vedin I, Falahati F, Freund-Levi Y, Hjorth E, Faxen-Irving G, et al. Plasma
fatty acid profiles in relation to cognition and gender in Alzheimer’s Disease patients
during oral omega-3 fatty acid supplementation: The OmegAD Study. J Alzheimers Dis
2015;48:805–12
Not a disease modification trial
Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, et al.
Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder
analyses from a randomised, controlled trial (GAL-INT-6). J Psychopharmacol
2008;22:761–8
Not a disease modification trial
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of
galantamine in probable vascular dementia and Alzheimer’s disease combined with
cerebrovascular disease: a randomised trial. Lancet 2002;359:1283–90
Not a disease modification trial
Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, et al. An open-
label extension trial of galantamine in patients with probable vascular dementia and
mixed dementia. Clin Ther 2003;25:1765–82
Not a disease modification trial
Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer’s
disease and concurrent hypertension. Int J Clin Prac 2002;56:791–6
Not a disease modification trial
Etienne P, Dastoor D, Gauthier S, Ludwick R, Collier B. Alzheimer disease: lack of effect
of lecithin treatment for 3 months. Neurology 1981;31:1552–4
Not a disease modification trial
Fabbrini G, Martucci N, Battaglia A, Pamparana F, Annoni K. Nicergoline in the
Treatment of Dementia: The Effects on Cerebral Blood Flow Measured by SPECT
Conference Abstract. 8th European College of Neuropsychopharmacology Congress
Venice, Italy, 30 September–4 October 1995
Not published in a peer-reviewed
journal article or is an ongoing
trial
Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, et al. Evaluation
of cycloserine in the treatment of Alzheimer’s disease. J Geriatr Psychiatry Neurol
1995;8:226–30
Not a disease modification trial
Falsaperla A, Monici Preti PA, Oliani C. Selegiline versus oxiracetam in patients with
Alzheimer-type dementia. Clin Ther 1990;12:376–84
Not a disease modification trial
Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J.
A controlled trial of tacrine in Alzheimer’s disease. The Tacrine Study Group.
JAMA 1992;268:2523–9
Not a disease modification trial
Farlow MR. Rivastigmine three times daily improves cognition and response in
Alzheimer’s disease. Evid Based Ment Health 2007;10:116
Not a disease modification trial
Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating
rivastigmine transdermal patches with concomitant memantine in mild to moderate
Alzheimer’s disease: a post hoc analysis. Curr Med Res Opin 2010;26:263–9
Not a disease modification trial
Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy
of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur
Neurol 2000;44:236–41
Not a RCT/CCT
Farlow MR, Doraiswamy M, Meng X, Somogyi M. The effect of vascular risk factors on
the efficacy of rivastigmine patch and capsule in Alzheimer’s disease. Am J Geriatr
Psychiatry 2011;1:S120
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness
and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in
moderate to severe Alzheimer’s disease: a 24-week, randomised, double-blind study.
Clin Ther 2010;32:1234–51
Not a disease modification trial
Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, et al.
Comparing the efficacy and safety of Crocus sativus L. with memantine in patients
with moderate to severe Alzheimer’s disease: a double-blind randomised clinical trial.
Hum Psychopharmacol 2014;29:351–9
Not a disease modification trial
Feldman H, Coric V, Sperling R, Greenberg S, Bronen R, Sorensen AG, et al. Cerebral
microbleeds in a phase 2 clinical trial of mild to moderate Alzheimer’s disease with the
gamma secretase inhibitor BMS-708163. Alzheimers Dement 2011;1:S375
Not published in a peer-reviewed
journal article or is an ongoing
trial
Feldman H, Gauthier S, Hecker J, VelIas B, Emir B, Mastey V, et al. Efficacy of
donepezil on maintenance of activities of daily living in patients with moderate to
severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc
2003;51:737–44
Not a disease modification trial
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation
of donepezil in moderate to severe Alzheimer disease. Neurology 2004;63:644–50
Not a disease modification trial
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week,
randomised, double-blind study of donepezil in moderate to severe Alzheimer’s
disease. Neurology 2001;57:613–20
Not a disease modification trial
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al.
Randomised controlled trial of atorvastatin in mild to moderate Alzheimer disease:
LEADe. Neurology 2010;74:956–64
Not a disease modification trial
Feldman HH, Lane R, Study G. Rivastigmine: a placebo controlled trial of twice daily
and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg
Psychiatry 2007;78:1056–63
Not a disease modification trial
Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe
Alzheimer disease: an analysis of the treatment effects of memantine in patients
receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006;20:263–8
Not a disease modification trial
Ferris SH, Schmitt FA, Saxton J, Richardson S, MacKell J, Sun Y. Analysing the impact of
23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer’s
disease. Alzheimers Res Ther 2011;3:22
Not a disease modification trial
Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, et al. Oxytocin for
frontotemporal dementia: a randomised dose-finding study of safety and tolerability.
Neurology 2015;84:174–81
Not a disease modification trial
Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, Friedmann A, Russmann DL.
Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 1996;34:29–35
Not a disease modification trial
Fischhof PK, Saletu B, Ruther E, Litschauer G, Moslinger-Gehmayr R, Herrmann WM.
Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type
(SDAT) and multi-infarct dementia (MID). Neuropsychobiology 1992;26:65–70
Not a disease modification trial
Fisman M. Double blind study of lecithin in patients with Alzheimer’s disease.
Can J Psychiatry 1981;26:426–8
Not a disease modification trial
Fleisher A, Tariot P, Truran D, Mai J, Aisen P, Cummings J, et al. Brain volume
changes with divalproex sodium in Alzheimer’s disease. Neuropsychopharmacology
2010;35:S318–19
Not published in a peer-reviewed
journal article or is an ongoing
trial
Flicker C, Ferris SH, Kalkstein D, Serby M. A double-blind, placebo–controlled crossover
study of ganglioside GM1 treatment for Alzheimer’s disease. Am J Geriatr Psychiatry
1994;151:126–9
Not a disease modification trial
Foerster S, Buschert VC, Buchholz HG, Teipel SJ, Zach C, Hampel H, et al. Positive
effects of a 6-month stage-specific cognitive intervention program on brain metabolism
in subjects with amnestic mild cognitive impairment (AMCI) and mild Alzheimer’s
disease (AD). Alzheimers Dement 2009;1:205–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Forbes D. Cognitive stimulation therapy improved cognition and quality of life in
dementia. Evid Based Nurs 2004;7:54–5
Not a disease modification trial
Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer’s disease
to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Eur J Neurol 1999;6:423–9
Not a disease modification trial
Forette F, Gracon S, de Rotrou J, Hervy MP, Lechevalier B, Micas M, et al.
A double-blind, placebo-controlled, enriched population study of tacrine in patients
with Alzheimer’s disease. Eur J Neurol 1995;2:229–38
Not a disease modification trial
Forster S, Buschert VC, Buchholz H-G, Teipel SJ, Friese U, Zach C, et al. Effects of a
6-month cognitive intervention program on brain metabolism in amnestic mild
cognitive impairment and mild Alzheimer’s disease. J Alzheimers Dis 2011;25:695–706
Not a disease modification trial
Forster S, Buschert VC, Buchholz HG, Teipel SJ, Rominger A, La Fougere C, et al.
Attenuation of cerebral metabolic decline in patients with amnestic mild cognitive
impairment (aMCI) or mild Alzheimers disease (AD) joining a six-month stage-specific
cognitive intervention program. Nuklear Medizin 2010;49:A53
Not published in a peer-reviewed
journal article or is an ongoing
trial
Förster S, Buschert VC, Teipel SJ, Friese U, Buchholz HG, Drzezga A, et al. Effects of a
6-month cognitive intervention on brain metabolism in patients with amnestic MCI and
mild Alzheimer’s disease. J Alzheimers Dis 2011;26(Suppl. 3):337–48
Not a disease modification trial
Foroutanpour K. A Phase II, Single Centre, Randomised, Double-Blind, Placebo-
Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Three Different
Dosages of Cerebrolysin in Patients with Probable Alzheimer’s Disease. PRA
International Report prepared for EBEWE Pharma. Vienna: EBEWE Pharma; 2003
Not published in a peer-reviewed
journal article or is an ongoing
trial
FORUM Pharmaceuticals Inc. NCT02149160 Study to Assess the Safety, Tolerability,
and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to
Moderate Frontotemporal Dementia With Granulin Mutation. URL: https://clinicaltrials.
gov/ct2/show/NCT02149160 (accessed 29 January 2016)
No quantitative outcome relating
to disease modification
Francois C, Sintonen H, Sulkava R, Rive B. Cost-effectiveness of memantine in
moderately severe to severe Alzheimer’s disease: a Markov model in Finland. Clin Drug
Investig 2004;24:373–84
Not a disease modification trial
Freedman M, Rewilak D, Xerri T, Cohen S, Gordon A, Shandling M, et al. L-deprenyl in
Alzheimer’s disease: cognitive and behavioural effects. Neurology 1998;50:660–8
Not a disease modification trial
Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxen Irving G, Schultzberg M, et al. Effects
of supplementation with omega-3 fatty acids on oxidative stress and inflammation
in patients with Alzheimer’s disease: the OmegAD study. J Alzheimers Dis
2014;42:823–31
Not a disease modification trial
Frolich L. High-dose rivastigmine patch: results from the optima study. Neurobiol
Ageing 2012;33:S12
Not published in a peer-reviewed
journal article or is an ongoing
trial
Frolich L, Ashwood T, Nilsson J, Eckerwall G. Effects of AZD3480 on cognition in
patients with mild to moderate Alzheimer’s disease: a phase IIb dose-finding study.
J Alzheimers Dis 2011;24:363–74
Not a disease modification trial
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Not a disease modification trial
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Not a disease modification trial
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Not published in a peer-reviewed
journal article or is an ongoing
trial
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Not a disease modification trial
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Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer’s
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Not a disease modification trial
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Not a disease modification trial
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Not a disease modification trial
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tolerability of memantine extended release added to stable donepezil regimen in
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Not published in a peer-reviewed
journal article or is an ongoing
trial
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with moderate to severe Alzheimer’s disease and alleviates caregiver burden.
Evid Based Ment Health 2004;7:20–1
Not a disease modification trial
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trial
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Hashimoto M, Yamashita K, Kato S, Tamai T, Matsumoto I, Tanabe Y, et al. Beneficial
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journal article or is an ongoing
trial
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journal article or is an ongoing
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Not a disease modification trial
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Not a disease modification trial
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Not published in a peer-reviewed
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trial
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Not a disease modification trial
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Not a disease modification trial
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Not a disease modification trial
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Not published in a peer-reviewed
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trial
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Not a disease modification trial
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of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands.
Neuropsychiatr Dis Treat 2011;7:313–17
Not a disease modification trial
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Not a disease modification trial
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2012;366:893–903
Not a disease modification trial
Huang WW, Zhang LH, Zhang H, Kong L. [Effects of hydrochloric donepezil in
improving cognition and daily life ability in patients with Alzheimer disease.] Chin J Clin
Rehabil 2004;8:5378–9
Full text unavailable in English
Huang Y, Chen J, Htut WM, Lai X, Wik G. Acupuncture increases cerebral glucose
metabolism in human vascular dementia. Int J Neurosci 2007;117:1029–37
Not a disease modification trial
Huff FJ. Preliminary evaluation of besipirdine for the treatment of Alzheimer’s disease.
Besipirdine Study Group. Ann NY Acad Sci 1996;777:410–14
Not a disease modification trial
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Huff FJ, Antuono P, Murphy M, Beyer J, Dobson C. Potential clinical use of an
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Not a disease modification trial
Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB. Improving response inhibition
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Not a disease modification trial
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Not a disease modification trial
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Not a disease modification trial
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Not a disease modification trial
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Not a disease modification trial
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Not published in a peer-reviewed
journal article or is an ongoing
trial
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Not published in a peer-reviewed
journal article or is an ongoing
trial
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eptastigmine for the treatment of patients with Alzheimer’s disease. Neurology
1999;52:700–8
Not a disease modification trial
Imbimbo BP, Nicoli M, Martini C, Tomelleri GP, Martelli P, Ferrari GP, et al.
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Not a disease modification trial
Imbimbo BP, Troetel WM, Martelli P, Lucchelli F. A 6-month, double-blind,
placebo-controlled trial of eptastigmine in Alzheimer’s disease. Dement Geriatr
Cogn Disord 2000;11:17–24
Not a disease modification trial
Imbimbo BP, Verdelli G, Martelli P, Marchesini D. Two-year treatment of Alzheimer’s
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Not a disease modification trial
Imbriano L, Podda L, Rendace L, Lucchese F, Campanelli A, D’Antonio F, et al.
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clinical study. Funct Neurol 2013;28:36–7
Not published in a peer-reviewed
journal article or is an ongoing
trial
Ishizaki J, Meguro K, Ohe K, Kimura E, Tsuchiya E, Ishii H, et al. Therapeutic
psychosocial intervention for elderly subjects with very mild Alzheimer disease in a
community: the tajiri project. Alzheimer Dis Assoc Disord 2002;16:261–9
Not a disease modification trial
Isik AT, Bozoglu E. Acetylcholinesterase inhibition and insulin resistance in late onset
Alzheimer’s disease. Int Psychogeriatr 2009;21:1127–33
Not a disease modification trial
Ito T, Meguro K, Akanuma K, Ishii H, Mori E. A randomised controlled trial of the
group reminiscence approach in patients with vascular dementia. Dement Geriatr Cogn
Disord 2007;24:48–54
Not a disease modification trial
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Not a disease modification trial
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Not published in a peer-reviewed
journal article or is an ongoing
trial
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Alzheimer’s disease. Evid Based Ment Health 2003;6:110
Not published in a peer-reviewed
journal article or is an ongoing
trial
Jann MW, Cyrus PA, Eisner LS, Margolin DI, Griffin T, Gulanski B. Efficacy and safety
of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the
symptomatic treatment of Alzheimer’s disease: a randomised, double-masked,
placebo-controlled trial. Metrifonate Study Group. Clin Ther 1999;21:88–102
Not a disease modification trial
Jelcic N, Agostini M, Meneghello F, Busse C, Parise S, Galano A, et al. Feasibility and
efficacy of cognitive telerehabilitation in early Alzheimer’s disease: a pilot study.
Clin Interv Ageing 2014;9:1605–11
Not a disease modification trial
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randomised controlled trial. Neurorehabil Neural Repair 2012;26:949–56
Not a disease modification trial
Jeong YH WR, Park CH, Suh YH. Therapeutic potentials of mefenamic acid for the
treatment of Alzheimer’s disease. Neurobiol Ageing 2004;25:s589
Not published in a peer-reviewed
journal article or is an ongoing
trial
Jesso S, Diodati D, Morlog D, Pasternak S, Kertesz A, Finger E. A randomised,
double-blind, placebo controlled, cross-over study of the effects of oxytocin in patients
with frontotemporal dementia. Dement Geriatr Cogn Disord 2010;30:98
Not a disease modification trial
Jhee SS, Fabbri L, Piccinno A, Monici P, Moran S, Zarotsky V, et al. First clinical
evaluation of ganstigmine in patients with probable Alzheimer’s disease.
Clin Neuropharmacol 2003;26:164–9
Not a disease modification trial
Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. Patterns of clinically
detectable treatment effects with galantamine: a qualitative analysis. Dement Geriatr
Cogn Disord 2003;15:26–33
Not a disease modification trial
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Not a RCT/CCT
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therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s
disease. CNS drugs 2006;20:311–25
Not a disease modification trial
Johnsen K, Brynne N, Annas P, Hannesdottir K, Alexander R, Segerdahl M. The effects of
AZD1446 (A neuronal nicotinic receptor agonist) on quantified electroencephalography
(QEEG) in patients with mild to moderate Alzheimer’s disease. Quantitative
measurements using a QEEG cholinergic index. J Nutr Health Ageing 2013;17:834
Not published in a peer-reviewed
journal article or is an ongoing
trial
Johnson KH. Donepezil minimally effective for patients with vascular dementia. J Fam
Pract 2004;53:181–2
Not a disease modification trial
Johnson NA, Rademaker A, Weintraub S, Gitelman D, Wienecke C, Mesulam M.
Pilot trial of memantine in primary progressive aphasia. Alzheimer Dis Assoc Disord
2010;24:308
Not published in a peer-reviewed
journal article or is an ongoing
trial
Jolkkonen JT, Soininen HS, Riekkinen PJ. The effect of an ACTH4–9 analogue
(Org2766) on some cerebrospinal fluid parameters in patients with Alzheimer’s disease.
Life Sci 1985;37:585–90
Not a disease modification trial
Jones RW, McCrone P, Guilhaume C. Cost-effectiveness of memantine in Alzheimer’s
disease: an analysis based on a probabilistic Markov model from a UK perspective.
Drugs Ageing 2004;21:607–20
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A
multinational, randomised, 12-week study comparing the effects of donepezil and
galantamine in patients with mild to moderate Alzheimer’s disease. Int J Geriatr
Psychiatry 2004;19:58–67
Not a disease modification trial
Jorgenson S BA, Andersen J, Jensen HV, Olafsson K, Arup P, Moller SE. Fluvoxamine
treatment of dementia: tryptophan levels. Biol Psychiatry 1993;34:587–8
Not published in a peer-reviewed
journal article or is an ongoing
trial
Jubert J, Navarra J, Canals R, Balaguer M. [Neuropsychologic evaluation of the action
of oxovinca in the syndrome of diffuse deterioration of vascular origin.] Med Clín
1980;75:115–21
Full text unavailable in English
Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, et al. PET imaging
of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-
treated patients with AD. Neurobiol Ageing 2008;29:1204–17
Not a disease modification trial
Kalman J, Juhasz A, Rimanoczy A, Palotas A, Palotas M, Szabo Z, et al. Lack of
influence of the apolipoprotein E genotype on the outcome of selegiline treatment in
Alzheimer’s disease. Dement Geriatr Cogn Disord 2003;16:31–4
Not a disease modification trial
Kamphuis P, Verhey F, Olde Rikkert M, Twisk J, Swinkels S, Scheltens P. Efficacy of a
medical food on cognition in Alzheimer’s disease: results from secondary analyses of a
randomised, controlled trial. J Nutr Health Ageing 2011;15:720–4
Not a disease modification trial
Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat
analyses of a 24-week, multi-centre, double-blind, placebo-controlled, randomised trial.
Pharmacopsychiatry 2003;36:297–303
Not a disease modification trial
Karaman Y, Erdogan F, Köseoglu E, Turan T, Ersoy AO. A 12-month study of the
efficacy of rivastigmine in patients with advanced moderate Alzheimer’s disease.
Dement Geriatr Cogn Disord 2005;19:51–6
Not a disease modification trial
Keller C, Kadir A, Forsberg A, Porras O, Nordberg A. Long-term effects of galantamine
treatment on brain functional activities as measured by PET in Alzheimer’s disease
patients. J Alzheimers Dis 2011;24:109–23
Not a disease modification trial
Kemp PM, Holmes C, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, et al.
A randomised placebo controlled study to assess the effects of cholinergic treatment
on muscarinic receptors in Alzheimer’s disease. J Neurol Neurosurg Psychiatry
2003;74:1567–70
Not a disease modification trial
Kennelly S, Abdullah L, Crawford F, Mullan M, Kenny RA, Lawlor B. APOE E4
genotype-specific short-term cognitive benefits of treatment with the antihypertensive
nilvadipine in Alzheimer’s patients-an open-label trial. Ir J Med Sci 2011;180:S325
Not published in a peer-reviewed
journal article or is an ongoing
trial
Kennelly S, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, et al. Demonstration
of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug
nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry
2011;26:1038–45
Not a disease modification trial
Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in
frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn
Disord 2008;25:178–85
Not a disease modification trial
Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, et al. Phase II
crossover trial of varenicline in mild to moderate Alzheimer’s disease. Dement Geriatr
Cogn Disord 2014;37:232–45
Not a disease modification trial
Koch HJ, Szecsey A. A randomised controlled trial of prednisone in Alzheimer’s disease.
Neurology 2000;55:1067
Not published in a peer-reviewed
journal article or is an ongoing
trial
Knapp MJ, Gracon SI, Davis CS, Solomon PR, Pendlebury WW, Knopman DS. Efficacy
and safety of high-dose tacrine: a 30-week evaluation. Alzheimer Dis Assoc Disord
1994;8(Suppl. 2):22–31
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI.
A 30-week randomised controlled trial of high-dose tacrine in patients with
Alzheimer’s disease. JAMA 1994;271:985–91
Not a disease modification trial
Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term
tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine
Study Group. Neurology 1996;47:166–77
Not a disease modification trial
Knott V, Engeland C, Mohr E, Mahoney C, Ilivitsky V. Acute nicotine administration in
Alzheimer’s disease: an exploratory EEG study. Neuropsychobiology 2000;41:210–20
Not a disease modification trial
Knott V, Mohr E, Mahoney C, Engeland C, Ilivitsky V. Effects of acute nicotine
administration on cognitive event-related potentials in tacrine-treated and non-treated
patients with Alzheimer’s disease. Neuropsychobiology 2002;45:156–60
Not a disease modification trial
Kolykhalov IV, Gavrilova SI, Kalyn Ia B, Selezneva ND, Fedorova Ia B. [Efficacy, safety
and tolerability of a single dose of akatinol memantine in comparison to two-doses in
patients with moderately expressed and moderately severe dementia in Alzheimer’s
disease.] Zh Nevrol Psikhiatr Im S S Korsakova 2012;112:35–9
Full text unavailable in English
Krishnan K, Charles H, Doraiswamy P, Mintzer J, Weisler R, Yu X, et al. Randomised,
placebo-controlled trial of the effects of donepezil on neuronal markers and
hippocampal volumes in Alzheimer’s disease. Am J Geriatr Psychiatry 2003;160:2003–11
Not a disease modification trial
Kruntoradova K, Mandelikova M, Mlcoch T, Dolezal T. Cost-effectiveness analysis of
Ginkgo biloba extract (EGB761-tanakan) for the treatment of dementia in the Czech
Republic. Value Health 2015;18:A756
Not published in a peer-reviewed
journal article or is an ongoing
trial
Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of
Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur J
Neurol 2000;7:159–69
Not a disease modification trial
Kwak YS, Um SY, Son TG, Kim DJ. Effect of regular exercise on senile dementia
patients. Int J Sports Med 2008;29:471–4
Not a disease modification trial
Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, et al. A randomised placebo
controlled trial of homocysteine lowering to reduce cognitive decline in older
demented people. Clinical Nutrition 2011;30:297–302
Not a disease modification trial
Kwon JC, Kim EG, Kim JW, Kwon Oh D, Yoo BG, Yi HA, et al. A multicenter,
open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in
Binswanger-type subcortical vascular dementia. Am J Alzheimers Dis Other Demen
2009;24:293–301
Not a disease modification trial
Kyowa Hakko Kirin Pharma, Inc. NCT02127476 A Study of Single and Multiple Doses
of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer’s Disease.
URL: https://clinicaltrials.gov/ct2/show/NCT02127476 (accessed 29 January 2016)
No quantitative outcome relating
to disease modification
Kyowa Hakko Kirin Pharma, Inc. NCT02377713 A Single Dose Study of KHK6640 in
Japanese Patients With Alzheimer’s Disease. URL: https://clinicaltrials.gov/ct2/show/
NCT02377713 (accessed 29 January 2016)
No quantitative outcome relating
to disease modification
Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, et al. HIV-1 reverse
transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS
dementia complex treated with abacavir. AIDS 2001;15:747–51
Not a disease modification trial
Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and
the effect of memantine in dementia with Lewy bodies and Parkinson’s disease
dementia. Dement Geriatr Cogn Disord 2011;32:227–34
Not a disease modification trial
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, et al.
A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease.
Annals Neurol 2010;68:521–34
Not a disease modification trial
Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-
controlled, double-blind, randomised trial of an extract of Ginkgo biloba for dementia.
JAMA 1997;278:1327–32
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Leach L. Cognitive stimulation therapy improves cognition and quality of life in older
people with dementia. Evid Based Ment Health 2004;7:19
Not a disease modification trial
Lee DA, Ngo LY, Adamiak B, Gelmont D. A confirmatory phase 3 randomised,
double-blind, placebo-controlled study of the safety and effectiveness of immune
globulin intravenous (human), 10% solution (gammagard liquid/kiovig) for the
treatment of mild to moderate Alzheimer’s disease. Alzheimers Dement
2011;1:S783–4
Not published in a peer-reviewed
journal article or is an ongoing
trial
Lee DY, Kim KW, Jhoo JH, Ryu SH, Choo H, Seo EH, et al. A multicenter, randomised,
placebo-controlled, double-blind clinical trial of escitalopram on its atrophydelaying
effect in Alzheimer’s disease. Alzheimers Dement 2012;8(Suppl. 1):603
Not published in a peer-reviewed
journal article or is an ongoing
trial
Lee GY, Yip CC, Yu EC, Man DW. Evaluation of a computer-assisted errorless
learning-based memory training program for patients with early Alzheimer’s disease
in Hong Kong: a pilot study. Clin Interv Ageing 2013;8:623–33
Not a disease modification trial
Lefevre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, et al. Pharmacokinetics
and pharmacodynamics of the novel daily rivastigmine transdermal patch compared
with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther
2008;83:106–14
Not a disease modification trial
Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, et al. Adaptive,
dose-finding Phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to
moderate Alzheimer disease. Alzheimer Dis Assoc Disord 2015;29:192–9
Not a disease modification trial
Leroi I, Atkinson R, Overshott R. Memantine improves goal attainment and reduces
caregiver burden in Parkinson’s disease with dementia. Int J Geriatr Psychiatry
2014;29:899–905
Not a disease modification trial
Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al. Randomised
placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease.
Int J Geriatr Psychiatry 2004;19:1–8
Not a disease modification trial
Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomised controlled trial of
memantine in dementia associated with Parkinson’s disease. Move Dis
2009;24:1217–21
Not a disease modification trial
Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. [Efficacy and safety of
memantine in dementia with Lewy bodies.] Zh Nevrol Psikhiatr Im S S Korsakova
2008;108:39–46
Full text unavailable in English
Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. Efficacy and safety of
memantine in Lewy body dementia. Neurosci Behav Physiol 2009;39:597–604
Not a disease modification trial
Levy A, Brandeis R, Treves TA, Meshulam Y, Mawassi F, Feiler D, et al. Transdermal
physostigmine in the treatment of Alzheimer’s disease. Alzheimer Dis Assoc Disord
1994;8:15–21
Not a disease modification trial
Li CH, Liu CK, Yang YH, Chou MC, Chen CH, Lai CL. Adjunct effect of music therapy
on cognition in Alzheimer’s disease in Taiwan: a pilot study. Neuropsychiatr Dis Treat
2015;11:291–6
Not a disease modification trial
Liang E, Wagg J, Kurth M, Abushakra S. Effects of ELND005 (scyllo-inositol) on
neuropsychiatric symptoms (NPS) in mild/moderate AD: correlations of ELND005
exposures to neuropsychiatric outcomes in a 78-week phase 2 study. J Nutr Health
Ageing 2012;16:839
Not published in a peer-reviewed
journal article or is an ongoing
trial
Liang J, Li F, Wei C, Song H, Wu L, Tang Y, et al. Rationale and design of a
multicenter, phase 2 clinical trial to investigate the efficacy of traditional Chinese
medicine SaiLuoTong in vascular dementia. J Stroke Cerebrovasc Dis 2014;23:2626–34
Not a disease modification trial
Liang P, Wang Z, Qian T, Li K. Acupuncture stimulation of Taichong (Liv3) and Hegu
(LI4) modulates the default mode network activity in Alzheimer’s disease. Am J
Alzheimers Dis Other Demen 2014;29:739–48
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Likitjaroen Y, Meindl T, Friese U, Wagner M, Buerger K, Hampel H, et al. Longitudinal
changes of fractional anisotropy in Alzheimer’s disease patients treated with
galantamine: a 12-month randomised, placebo-controlled, double-blinded study.
Eur Arch Psychiatry Clin Neurosci 2012;262:341–50
Not a disease modification trial
Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Benzoate, a D-amino
acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a
randomised, double-blind, placebo-controlled trial. Biol Psychiatry 2014;75:678–85
Not a disease modification trial
Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Enhancement of NMDA
neurotransmission for the treatment of early-phase Alzheimer’s disease. J Neurochem
2014;130:34
Not published in a peer-reviewed
journal article or is an ongoing
trial
Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomised
placebo-controlled trial of donepezil in patients with progressive supranuclear palsy.
Neurology 2001;57:467–73
No participants with mild or
moderate dementia
Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B. Effects of fluoxetine on brain-derived
neurotrophic factor serum concentration and cognition in patients with vascular
dementia. Clin Interv Ageing 2014;9:411–18
Not a disease modification trial
Liu-Seifert H, Andersen S, Holdridge K, Siemers E. Delayed-start analyses of
solanezumab phase 3 studies in mild Alzheimer’s disease. Neurology 2015;84:P7.108
Not published in a peer-reviewed
journal article or is an ongoing
trial
Livingston GA, Sax KB, McClenahan Z, Blumenthal E, Foley K, Willison J, et al.
Acetyl-l-carnitine in dementia. Int J Geriatr Psychiatry 1991;6:853–60
Not a disease modification trial
Lloret A, Badía MC, Mora NJ, Pallardó FV, Alonso MD, Viña J. Vitamin E paradox in
Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental.
J Alzheimers Dis 2009;17:143–9
Not a disease modification trial
Loeb MB, Molloy D, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A
randomised, controlled trial of doxycycline and rifampin for patients with Alzheimer’s
disease. J Am Geriatr Soc 2004;52:381–7
Not a disease modification trial
Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al.
The effect of cholinesterase inhibitors on the regional blood flow in patients with
Alzheimer’s disease and vascular dementia. J Neurol Sci 2003;216:119–26
Not a disease modification trial
Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M,
Vilalta-Franch M, et al. Differential efficacy of treatment with acetylcholinesterase
inhibitors in patients with mild and moderate Alzheimer’s disease over a 6-month
period. Dement Geriatr Cogn Disord 2005;19:189–95
Not a disease modification trial
Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and
dementia: a randomised, controlled trial of antioxidant supplementation. Am J Med
Genet A 2011;155A:1939–48
Not a disease modification trial
Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, et al. Preliminary
results suggest testosterone therapy may benefit older patients with AD. Brown Uni
Geriatr Psychopharmacol Update 2006;10:1–7
Not a disease modification trial
Lucas P, Li D, Lobello K, Liu E, Brashear HR, Styren S. Intravenous bapineuzumab in
mild to moderate Alzheimer’s disease: results from two double-blind, placebo-
controlled phase 3 trials. J Nutr Health Ageing 2013;17:806–7
Not published in a peer-reviewed
journal article or is an ongoing
trial
Lucca U TM, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in
Alzheimer’s disease. Biol Psychiatry 1994;36:854–6
Not a disease modification trial
Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine
treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004;12:473–82
Not a disease modification trial
Magdolna P, Anna J, Agnes F, Gergely D, Csilla FO, Tamas HL, et al. [Achetylcholinesterase
(AchE) inhibition and serum lipokines in Alzheimer’s disease: Friend or foe?]
Neuropsychopharmacol Hung 2012;14:19–27
Full text unavailable in English
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Maher-Edwards G, Watson C, Ascher J, Barnett C, Boswell D, Davies J, et al.
Two randomised controlled trials of SB742457 in mild to moderate Alzheimer’s
disease. Alzheimers Dement 2015;1:23–36
Not a disease modification trial
Maher-Edwards G, Zvartau-Hind M, Hunter A, Gold M, Hopton G, Jacobs G, et al.
Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457,
in Alzheimer’s disease. Curr Alzheimer Res 2010;7:374–85
Not a disease modification trial
Maina G, Fiori L, Torta R, Fagiani M, Ravizza L, Bonavita E, et al. Oxiracetam in the
treatment of primary degenerative and multi-infarct dementia: a double-blind,
placebo-controlled study. Neuropsychobiology 1989;21:141–5
Not a disease modification trial
Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS. Efficacy of tacrine
and lecithin in mild to moderate Alzheimer’s disease: double blind trial. BMJ
1994;308:879–83
Not a disease modification trial
Marek GJ, Katz DA, Meier A, Greco NT, Zhang W, Liu W, et al. Efficacy and safety
evaluation of HSD-1 inhibitor ABT-384 in Alzheimer’s disease. Alzheimers Dement
2014;10(Suppl.):364–73
Not a disease modification trial
Marek G, Katz D, Meier A, Greco N, Zhang W, Liu W, et al. Evaluation of the efficacy
and safety of the HSD-1 inhibitor ABT-384 in mild to moderate Alzheimer’s disease.
Alzheimers Dement 2012;8(Suppl. 1):602
Not published in a peer-reviewed
journal article or is an ongoing
trial
Marin DB, Bierer LM, Lawlor BA, Ryan TM, Jacobson R, Schmeidler J, et al. L-deprenyl
and physostigmine for the treatment of Alzheimer’s disease. Psychiatry Res
1995;58:181–9
Not a disease modification trial
Marsh L, Biglan K, Williams JR. Randomised placebo-controlled trial of memantine for
dementia in Parkinson’s disease. Parkinsonism Relat Disord 2009;15:S82
Not published in a peer-reviewed
journal article or is an ongoing
trial
Maruyama M, Tomita N, Iwasaki K, Ootsuki M, Matsui T, Nemoto M, et al. Benefits of
combining donepezil plus traditional Japanese herbal medicine on cognition and brain
perfusion in Alzheimer’s disease: a 12-week observer-blind, donepezil monotherapy
controlled trial. J Am Geriatr Soc 2006;54:869–71
Not published in a peer-reviewed
journal article or is an ongoing
trial
Masterman D, Awipi T, Ashford E, Nave S, Yoo K, Vellas B, et al. A nicotinic-alpha-7
partial agonist as adjunctive therapy to stable donepezil. J Nutr Health Ageing
2012;16:838–9
Not published in a peer-reviewed
journal article or is an ongoing
trial
Matsuda O. Cognitive stimulation therapy for Alzheimer’s disease: the effect of
cognitive stimulation therapy on the progression of mild Alzheimer’s disease in patients
treated with donepezil. Int Psychogeriatr 2007;19:241–52
Not a disease modification trial
Matsuda O, Shido E, Hashikai A, Shibuya H, Kouno M, Hara C, et al. Short-term effect
of combined drug therapy and cognitive stimulation therapy on the cognitive function
of Alzheimer’s disease. Psychogeriatrics 2010;10:167–72
Not a disease modification trial
Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract
EGb 761 in dementia of the Alzheimer type. J Psychiat Res 1997;31:645–55
Not a disease modification trial
McCarney R, Fisher P, Iliffe S, Haselen R, Griffin M, Meulen J, et al. Ginkgo biloba for
mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-
group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008;23:1222–30
Not a disease modification trial
McCarney R, Warner J, Iliffe S, Haselen R, Griffin M, Fisher P. The Hawthorne Effect:
a randomised, controlled trial. BMC Med Res Methodol 2007;7:30
Not a disease modification trial
McKeith I, Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine
in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled
international study. Lancet 2000;356:2031–6
Not a disease modification trial
McKeith IG. The clinical trial protocol of the Metrifonate in Alzheimer’s Trial (MALT).
Dement Geriatr Cogn Disord 1998;9(Suppl. 2):2–7
Not a disease modification trial
McShane RH. Memantine plus donepezil improves physical and mental health in
people with Alzheimer’s disease. Evid Based Ment Health 2004;7:76
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Mellow AM, Sunderland T, Cohen RM, Lawlor BA, Hill JL, Newhouse PA, et al. Acute
effects of high-dose thyrotropin releasing hormone infusions in Alzheimer’s disease.
Psychopharmacology 1989;98:403–7
Not a disease modification trial
Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M. Donepezil treatment of vascular
dementia. Ann NY Acad Sci 2002;977:482–6
Not a disease modification trial
Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomised clinical trial of
daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc
1989;37:549–55
Not a disease modification trial
Minthon L, Edvinsson L, Gustafson L. Tacrine treatment modifies cerebrospinal fluid
neuropeptide levels in Alzheimer’s disease. Dementia 1994;5:295–301
Not a disease modification trial
Minthon L, Gustafson L, Dalfel G, Hagberg B, Nilsson K, Risberg J, et al. Oral
tetrahydroaminoacridine treatment of Alzheimer’s disease evaluated clinically and by
regional cerebral blood flow and EEG. Dementia 1993;4:32–42
Not a disease modification trial
Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer’s
disease: comparison of patients previously treated with acetylcholinesterase inhibitors
to patients with no prior exposure. Int J Geriatr Psychiatry 2003;18:292–7
Not a disease modification trial
Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Memantine versus
donepezil in mild to moderate Alzheimer’s disease: a randomised trial with magnetic
resonance spectroscopy. Eur J Neurol 2010;17:405–12
Not a disease modification trial
Modrego PJ, Pina MA, Fayed N, Díaz M. Changes in metabolite ratios after treatment
with rivastigmine in Alzheimer’s disease: a nonrandomised controlled trial with
magnetic resonance spectroscopy. CNS Drugs 2006;20:867–77
Not a disease modification trial
Moebius H, Loewen G, Dgetluck N, Hilt D. A randomised, double-blind,
placebo-controlled, 24-week, phase 2b outcomes study of 3 different doses
of encenicline or placebo in subjects with mild to moderate probable Alzheimer’s
disease. Neurology 2015;84:P7.100
Not published in a peer-reviewed
journal article or is an ongoing
trial
Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T. Cognitive and
quantified electroencephalographic correlates of cycloserine treatment in Alzheimer’s
disease. Clin Neuropharmacol 1995;18:28–38
Not a disease modification trial
Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, et al. Treatment
of Alzheimer’s disease with sabeluzole: functional and structural correlates.
Clin Neuropharmacol 1997;20:338–45
Not a disease modification trial
Mohs RC, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al. A 1-year, placebo-
controlled preservation of function survival study of donepezil in AD patients.
Neurology 2001;57:481–8
Not a disease modification trial
Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with
Alzheimer disease: 6-month, randomised, double-blind, placebo-controlled,
parallel-trial study. Am J Geriatr Psychiatry 2009;17:752–9
Not a disease modification trial
Mok V, Wong A, Ho S, Leung T, Lam WWM, Wong KS. Rivastigmine in Chinese
patients with subcortical vascular dementia. Neuropsychiatr Dis Treat 2007;3:943–8
Not a disease modification trial
Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild
compared to moderate Alzheimer’s disease: implications for early diagnosis and
treatment. Geriatric Arch Gerontol Geriatr 2011;52:18–22
Not a disease modification trial
Moller HJ, Hampel H, Hegerl U, Schmitt W, Walter K. Double-blind, randomised,
placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine
patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry
1999;32:99–106
Not a disease modification trial
Moller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthine derivative
propentofylline in dementia. Pharmacopsychiatry 1994;27:159–65
Not a disease modification trial
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Reference Reason for exclusion
Molloy DW, Standish TI, Almeida E, DiLoreto P, Lam-Au C, Guyatt GH. Doxycycline and
rifampin for Alzheimer’s disease – The DARAD clinical trial. Eur Geriatr Med 2010;1:S3
Not published in a peer-reviewed
journal article or is an ongoing
trial
Moreno Moreno MDJ. Cognitive improvement in mild to moderate Alzheimer’s
dementia after treatment with the acetylcholine precursor choline alfoscerate:
a multicenter, double-blind, randomised, placebo-controlled trial. Clin Ther
2003;25:178–93
Not a disease modification trial
Moretti DV. Alpha rhythm oscillations and MMSE scores are differently modified by
transdermal or oral rivastigmine in patients with Alzheimer’s disease. Am J
Neurodegener Dis 2014;3:72–83
Not a disease modification trial
Moretti DV, Frisoni GB, Giuliano B, Zanetti O. Comparison of the effects of transdermal
and oral rivastigmine on cognitive function and EEG markers in patients with
Alzheimer’s disease. Front Ageing Neurosci 2014;6:179
Not a disease modification trial
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical
vascular dementia: an open 22-month study. J Neurol Sci 2002;203–204:141–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical
vascular dementia: a randomised, controlled, open 12-month study in 208 patients.
Am J Alzheimers Dis Other Demen 2003;18:265–72
Not a disease modification trial
Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Ukmar M, et al. Rivastigmine
superior to aspirin plus nimodipine in subcortical vascular dementia: an open,
16-month, comparative study. Int J Clin Pract 2004;58:346–53
Not a disease modification trial
Moretti R, Torre P, Antonello RM, Cazzato G, Pizzolato G. Different responses to
rivastigmine in subcortical vascular dementia and multi-infarct dementia. Am J
Alzheimers Dis Other Demen 2008;23:167–76
Not a disease modification trial
Morgan J, Sethi KD. Rivastigmine for dementia associated with Parkinson’s disease.
Curr Neurol Neurosci Rep 2005;5:263–5
Not a disease modification trial
Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomised,
placebo-controlled trial. Annals Neurol 2012;72:41–52
Not a disease modification trial
Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil
use for dementia with Lewy bodies: results from an open-label extension of Phase III
trial. Alzheimers Res Ther 2015;7:5
Not a disease modification trial
Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with
dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry
Clin Neurosci 2006;60:190–5
Not a disease modification trial
Morillas-Ruiz JM, Rubio-Perez JM, Albaladejo MD, Zafrilla P, Parra S, Vidal-Guevara ML.
Effect of an antioxidant drink on homocysteine levels in Alzheimer’s patients. J Neurol
Sci 2010;299:175–8
Not a disease modification trial
Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits
cognitive, behavioural, and global function in patients with Alzheimer’s disease.
Neurology 1998;5:1222–30
Not a disease modification trial
Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C. Methanesulfonyl fluoride
(MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment
of senile dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1999;13:20–5
Not a disease modification trial
Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, et al. Effectiveness
and safety of cholinesterase inhibitors in elderly subjects with Alzheimer’s disease:
a ‘real world’ study. Arch Gerontol Geriatr 2004;38(Suppl.):297–307
Not a disease modification trial
Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does serotonin augmentation
have any effect on cognition and activities of daily living in Alzheimer’s dementia? A
double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2007;27:484–7
Not a disease modification trial
continued
DOI: 10.3310/hta21260 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 26
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Webster et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
163
TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Mulnard RA, Cotman CW, Kawas C, Dyck CH, Sano M, Doody R, et al. Oestrogen
replacement therapy for treatment of mild to moderate Alzheimer disease:
a randomised controlled trial. JAMA 2000;283:1007–15
Not a disease modification trial
Muniza R, Serraa CM, Reisberga B, Rojo JM, del Ser T, Casanova JP, et al.
Cognitive-motor intervention in Alzheimer’s disease: long-term results from the Maria
Wolff trial. J Alzheimers Dis 2015;45:295–304
Not a disease modification trial
Muratorio A, Bonuccelli U, Nuti A, Battistini N, Passero S, Caruso V, et al. A
neurotropic approach to the treatment of multi-infarct dementia using L-alpha-
glycerylphosphorylchlorine. Curr Ther Res Clin Exp 1992;52:741–52
Not a disease modification trial
Na HR, Kim S, Choi SH, Yang DW, Bae HJ, Kim JE, et al. Donepezil treatment in
Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary
report. Geriatr Gerontol Int 2011;11:90–7
Not a disease modification trial
Naber D, Greenspan A, Schreiner A. Efficacy and safety of risperidone in the treatment
of elderly patients suffering from organic brain disease (organic brain syndrome):
results from a double-blind, randomised, placebo-controlled clinical trial.
Psychopharmacology 2007;191:1027–9
No participants with mild or
moderate dementia
Nadeau SE, Malloy PF, Andrew ME. A crossover trial of bromocriptine in the treatment
of vascular dementia. Ann Neurol 1988;24:270–2
Not a disease modification trial
Nakamura Y, Strohmaier C, Tamura K, Kataoka N, Nakano M, Oda S, et al.
A 24-week, randomised, controlled study to evaluate the tolerability, safety and
efficacy of 2 different titration schemes of the rivastigmine patch in Japanese patients
with mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord Extra
2015;5:361–74
Not a disease modification trial
Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride
preserves regional cerebral blood flow in patients with Alzheimer’s disease. J Nucl Med
2001;42:1441–5
Not a disease modification trial
Nakasujja N, Miyahara S, Evans S, Lee A, Musisi S, Katabira E, et al. Randomised trial of
minocycline in the treatment of HIV-associated cognitive impairment. Neurology
2013;80:196–202
Not a disease modification trial
Nakatsuka M, Nakamura K, Hamanosono R, Takahashi Y, Kasai M, Sato Y, et al.
A cluster randomised controlled trial of nonpharmacological interventions for old-old
subjects with a clinical dementia rating of 0.5: The Kurihara Project. Dement Geriatr
Cogn DisordExtra 2015;5:221–32
Not a disease modification trial
Nappi G, Bono G, Merlo P, Borromei A, Caltagirone C, Lomeo C, et al. Long-term
nicergoline treatment of mild to moderate senile dementia. Results of a multicentre,
double-blind, placebo-controlled study. Clin Drug Investig 1997;13:308–16
Not a disease modification trial
Napryeyenko O, Borzenko I. Ginkgo biloba special extract in dementia with
neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial.
Arzneimittelforschung 2007;57:4–11
Not a disease modification trial
Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba
extract EGb 761 by type of dementia: analyses of a randomised controlled trial.
J Neurol Sci 2009;283:224–9
Not a disease modification trial
Nasab NM, Bahrammi MA, Nikpour MR, Rahim F, Naghibis SN. Efficacy of rivastigmine
in comparison to ginkgo for treating Alzheimer’s dementia. J Pak Med Assoc
2012;62:677–80
Not a disease modification trial
Nascimento CMC, Teixeira CVL, Gobbi LTB, Gobbi S, Stella F. [A controlled clinical trial
on the effects of exercise on neuropsychiatric disorders and instrumental activities in
women with Alzheimer’s disease.] Braz J Phys Ther 2012;16:197–204
Not a disease modification trial
Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al. A phase I/II trial
of nimodipine for HIV-related neurological complications. Neurology 1998;51:221–8
Not a disease modification trial
Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al.
Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s
disease. Neurology 1999;52:1138–45
Not a disease modification trial
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Reference Reason for exclusion
Nicholas T, Knebel W, Gastonguay MR, Bednar MM, Billing CB, Landen JW, et al.
Preliminary population pharmacokinetic modelling of pf-04360365, a humanised
anti-amyloid monoclonal antibody, in patients with mild to moderate Alzheimer’s
disease. Alzheimers Dement 2009;1:253
Not published in a peer-reviewed
journal article or is an ongoing
trial
Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al.
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Curr Alzheimer Res 2009;6:4–14
Not a disease modification trial
Novak G, Brashear HR, Di J, Werth J, Booth K, Margolin R, et al. Efficacy and safety of
monthly subcutaneous bapineuzumab. Alzheimers Dement 2014;10:25
Not published in a peer-reviewed
journal article or is an ongoing
trial
Novak PH, Moessler H, Gusev EI, Guekht AB. Cerebrolysin in vascular dementia:
a randomised, placebo controlled study. Alzheimers Dement 2009;1:249
Not published in a peer-reviewed
journal article or is an ongoing
trial
O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, et al. Economic
evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am
Geriatr Soc 1999;47:570–8
Not a disease modification trial
O’Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, et al. Effects of
centrally acting angiotensin-converting enzyme inhibitors on functional decline in
patients with Alzheimer’s disease. J Alzheimers Dis 2014;40:595–603
Not a disease modification trial
Ohnishi T, Sakiyama Y, Okuri Y, Kimura Y, Sugiyama N, Saito T, et al. The prediction of
response to galantamine treatment in patients with mild to moderate Alzheimer’s
disease. Curr Alzheimer Res 2014;11:110–18
Not a disease modification trial
Olazarán J, Muñiz R. Cognitive intervention in the initial stages of Alzheimer’s disease.
Res Pract Alzheimers Dis 2006;11:376–80
Not a disease modification trial
Olazarán J, Muñiz R, Reisberg B, Peña-Casanova J, Ser T, Cruz-Jentoft AJ, et al.
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer
disease. Neurology 2004;63:2348–53
Not a disease modification trial
Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, et al. Reality
orientation therapy combined with cholinesterase inhibitors in Alzheimer’s disease:
randomised controlled trial. Br J Psychiatry 2005;187:450–5
Not a disease modification trial
Orgeta V, Leung P, Yates L, Kang S, Hoare Z, Henderson C, et al. Individual cognitive
stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness
pragmatic, multicentre, randomised controlled trial. Health Technol Assess 2015;19(64)
Not a disease modification trial
Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of
memantine in patients with mild to moderate vascular dementia: a randomised,
placebo-controlled trial (MMM 300). Stroke 2002;33:1834–9
Not a disease modification trial
Orrell M, Aguirre E, Spector A, Hoare Z, Woods RT, Streater A, et al. Maintenance
cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic
randomised controlled trial. Br J Psychiatry 2014;204:454–61
Not a disease modification trial
Orrell M, Yates LA, Burns A, Russell I, Woods RT, Hoare Z, et al. Individual cognitive
stimulation therapy for dementia (iCST): study protocol for a randomised controlled
trial. Trials 2012;13:172
Not a disease modification trial
Ortega L, Yassuda M, Nunes P, Aprahamian I, Santos F, Santos G, et al. The effects of
a multiprofessional cognitive and functional rehabilitation program for patients with
mild Alzheimer’s disease. Alzheimers Dement 2011;1:S660–1
Not published in a peer-reviewed
journal article or is an ongoing
trial
Othman A, Meier A, William Ritchie C, Florian H, Gault LM, Tang Q. Efficacy and safety
of the ALPHA7 agonist ABT-126 as a monotherapy treatment in mild to moderate
Alzheimer’s dementia: results of a phase 2b trial. Alzheimers Dement 2014;10:P137
Not published in a peer-reviewed
journal article or is an ongoing
trial
Ott BR, Blake LM, Kagan E, Resnick M. Open label, multicenter, 28-week extension
study of the safety and tolerability of memantine in patients with mild to moderate
Alzheimer’s disease. J Neurol 2007;254:351–8
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Paasschen J, Clare L, Yuen KS, Woods RT, Evans SJ, Parkinson CH, et al. Cognitive
rehabilitation changes memory-related brain activity in people with Alzheimer disease.
Neurorehabil Neural Repair 2013;27:448–59
Not a disease modification trial
Panisset M, Gauthier S, Moessler H, Windisch M. Cerebrolysin in Alzheimer’s disease:
a randomised, double-blind, placebo-controlled trial with a neurotrophic agent.
J Neural Transm 2002;109:1089–104
Not a disease modification trial
Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T. The Scandinavian
Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in
multi-infarct dementia. J Neurol Sci 2000;175:116–23
Not a disease modification trial
Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al. Efficacy and
safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the
Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124–34
Not a disease modification trial
Pantoni L, Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, et al. Efficacy and safety
of nimodipine in subcortical vascular dementia: a randomised placebo-controlled trial.
Stroke 2005;36:619–24
Not a disease modification trial
Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bartorelli L, et al. Posatirelin for
the treatment of late-onset Alzheimer’s disease: a double-blind multicentre study vs
citicoline and ascorbic acid. Acta Neurol Scand 1995;92:135–40
Not a disease modification trial
Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Huls C, Zetterberg H, et al.
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment
with AChE inhibitors in Alzheimer’s disease. Acta Neurol Scand 2011;124:122–9
Not a disease modification trial
Paskavitz JF, Gunstad JJ, Samuel JE. Clock drawing and frontal lobe behavioural effects
of memantine in Alzheimer’s disease: a rater-blinded study. Am J Alzheimers Dis Other
Dement 2006;21:454–9
Not a disease modification trial
Pasinetti G, Rosenberg P. Repurposing anti-hypertensive drugs for Alzheimer’s disease.
Alzheimers Dement 2012;1:707–P8
Not published in a peer-reviewed
journal article or is an ongoing
trial
Pasinetti GM, Rosenberg P. Repurposing cardiovascular drugs as Alzheimer’s disease
modifying agents. J Nutr Health Ageing 2012;16:822
Not published in a peer reviewed
journal article or an ongoing trial
Patel KR. Biogen’s Aducanumab raises hope that Alzheimer’s can be treated at its
source. Manag Care 2015;24:19
Not published in a peer-reviewed
journal article or is an ongoing
trial
Peng DT, Xu XH, Wang LN. [Efficiency and safety assessment of donepezil for treating
mild and moderate Alzheimer disease.] Chin J Clin Rehabil 2005;9:170–2
Full text unavailable in English
Perryman KM, Fitten LJ. Quantitative EEG during a double-blind trial of THA and
lecithin in patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 1991;4:127–33
Not a disease modification trial
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine
treatment in mild to moderate Alzheimer disease: a 24-week randomised, controlled
trial. Am J Geriatr Psychiatry 2006;14:704–15
Not a disease modification trial
Petit H, Doody RS, Pratt RD. Donepezil Improves Cognition and Global Function in
Alzheimer’s Disease: Results from us and Multinational Phase III Clinical Trials.
11th European College of Neuropsychopharmacology Congress Paris, France,
31 October–4 November 1998
Not published in a peer-reviewed
journal article or is an ongoing
trial
Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and
neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging
1995;16:1–4
Not a disease modification trial
Pfizer. NCT00912288 A Phase 3, Multi-Centre, Randomised, Double-Blind, Placebo-
Controlled 26-Week Trial to Evaluate the Efficacy and Safety of Dimebon in Patients
with Moderate-to-Severe Alzheimer’s Disease. URL: http://clinicaltrials.gov/show/
NCT00912288 (accessed 29 January 2016)
Not published in a peer-reviewed
journal article or is an ongoing
trial
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Reference Reason for exclusion
Phillips MA, Childs CE, Calder PC, Rogers PJ. No effect of omega-3 fatty acid
supplementation on cognition and mood in individuals with cognitive impairment
and probable Alzheimer’s disease: a randomised controlled trial. Int J Mol Sci
2015;16:24600–13
Not a disease modification trial
Pirttilä T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of
galantamine in patients with mild to moderate Alzheimer’s disease: multicenter trial.
Eur J Neurol 2004;11:734–41
Not a disease modification trial
Pitkälä KH, Pöysti MM, Laakkonen M-L, Tilvis RS, Savikko N, Kautiainen H, et al. Effects
of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomised controlled trial.
JAMA Intern Med 2013;173:894–901
Not a disease modification trial
Pitkala K, Raivio M, Laakkonen ML, Tilvis R, Kautiainen H, Strandberg T. Effects of
intensive exercise intervention on Alzheimer’s patients – a randomised, controlled trial.
Eur Geriatr Med 2011;2:S59
Not published in a peer-reviewed
journal article or is an ongoing
trial
Pitkala KH, Raivio MM, Laakkonen ML, Tilvis RS, Savikko N, Kautiainen H, et al.
Effectiveness and costs of intensive exercise intervention on Alzheimer’s patients –
a randomised, controlled trial. Eur Geriatr Med 2013;4:S8
Not published in a peer-reviewed
journal article or is an ongoing
trial
Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, et al. Long-term benefits of
rivastigmine in dementia associated with Parkinson’s disease: an active treatment
extension study. Move Dis 2006;21:456–61
Not a disease modification trial
Pomara N, Block R, Abraham J. Combined cholinergic precursor treatment and
dihydroergotoxine mesylate in Alzheimer’s disease. IRCS J Med Sci 1983;11:1048–9
Not a disease modification trial
Pomara N, Ott BR, Peskind E, Resnick E. Memantine treatment of cognitive symptoms
in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled
randomised trail. Alzheimer Dis Assoc Disord 2007;21:60–4
Not a disease modification trial
Poole Hoffmann V, Case M, Hake AM. Effects of treatment with solanezumab in
patients with Alzheimer’s disease who receive current standard of care. J Nutr Health
Ageing 2013;17:847–8
Not published in a peer-reviewed
journal article or is an ongoing
trial
Poon P, Hui E, Dai D, Kwok T, Woo J. Cognitive intervention for community-dwelling
older persons with memory problems: telemedicine versus face-to-face treatment.
Int J Geriatr Psychiatry 2005;20:285–6
Not a disease modification trial
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients
with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor:
a randomised, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83–9
Not a disease modification trial
Potkin SG, Alva G, Gunay I, Koumaras B, Chen M, Mirski D. A pilot study evaluating
the efficacy and safety of rivastigmine in patients with mixed dementia. Drugs Ageing
2006;23:241–9
Not a disease modification trial
Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebo-controlled trial of
donepezil in patients with Down syndrome and Alzheimer’s disease – pilot study.
Int J Geriatr Psychiatry 2002;17:270–8
Not a disease modification trial
Pratt RD. Patient populations in clinical studies of donepezil in vascular dementia.
Int Psychogeriatr 2003;15(Suppl. 1):195–200
Not a disease modification trial
Prentice N, Van Beck M, Dougall NJ, Moffoot APR, O’Carroll RE, Goodwin GM, et al.
A double-blind, placebo-controlled study of tacrine in patients with Alzheimer’s disease
using SPET. J Psychopharmacol 1996;10:175–81
Not a disease modification trial
Pressman P, Gottfried JA. Journal Club: a randomised, double-blind, placebo-controlled
trial of simvastatin to treat Alzheimer disease. Neurology 2012;79:33–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
Rabey J, Dobronevsky E, Marton RG, Aichenbau S, Khaigrech M. Improved cognitive
function following treatment of Alzheimer’s patients with repetitive transcranial
magnetic stimulation (rTMS) interlaced with cognitive learning treatment. Alzheimers
Dement 2011;1:S694–5
Not published in a peer-reviewed
journal article or is an ongoing
trial
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Reference Reason for exclusion
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of
huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76:1389–94
Not a disease modification trial
Rankinen T. NCT00083811 A Phase 3, Multi-Centre, Randomised, Double-Blind
Placebo-Controlled Study to Evaluate the Safety and Tolerability of Dimebon
(PF-01913539) for up to 26-Weeks in Patients with Mild to Moderate Alzheimer’s
Disease. URL: http://clinicaltrials.gov/ct2/show/NCT0083811 (accessed 29 January 2016)
Not published in a peer-reviewed
journal article or is an ongoing
trial
Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN.
D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord
1994;8:198–205
Not a disease modification trial
Raskind M, Liang E, Sperling R, Boxer A, Ross J, Brody M, et al. Pharmacokinetics and
pharmacodynamics of bapineuzumab following multiple intravenous infusions in
patients with mild to moderate Alzheimer’s disease. Alzheimers Dement
2009;1:415–16
Not published in a peer-reviewed
journal article or is an ongoing
trial
Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits
of galantamine are sustained for at least 36 months: a long-term extension trial.
Arch Neurol 2004;61:252–6
Not a disease modification trial
Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month
randomised, placebo-controlled trial with a 6-month extension. Neurology
2000;54:2261–8
Not a disease modification trial
Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for
dementia in Parkinson’s disease: a randomised, double blind, placebo controlled,
crossover study. J Neurol Neurosurg Psychiatry 2005;76:934–9
Not a disease modification trial
Rebok GW, Ball K, Guey LT, Jones RN, Kim H-Y, King JW, et al. Ten-year effects of the
advanced cognitive training for independent and vital elderly cognitive training trial on
cognition and everyday functioning in older adults. J Am Geriatr Soc 2014;62:16–24
Not a disease modification trial
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label
extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol
2006;63:49–54
Not a disease modification trial
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in
moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333–41
Not a disease modification trial
Reisberg B, Kenowsky S, Boksay I, Golomb J, Heller S, Ghimire S, et al. Memantine and
comprehensive, individualised, person-centred management (CI-PCM) of Alzheimer’s
disease: a randomised controlled trial. Alzheimers Dement 2013;1:295–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
Riekkinen M, Laakso MP, Jakala P, Riekkinen P Jr. Clonidine impairs sustained attention
and memory in Alzheimer’s disease. Neuroscience 1999;92:975–82
Not a disease modification trial
Riekkinen P, Kuikka J, Soininen H, Helkala EL, Hallikainen M, Riekkinen P.
Tetrahydroaminoacridine modulates technetium-99 m labelled ethylene dicysteinate
retention in Alzheimer’s disease measured with single photon emission computed
tomography imaging. Neurosci Lett 1995;195:53–6
Not a disease modification trial
Riekkinen P, Riekkinen M. THA improves word priming and clonidine enhances
fluency and working memory in Alzheimer’s disease. Neuropsychopharmacology
1999;20:357–64
Not a disease modification trial
Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, et al. Effect of statins
on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheimers Dis
2006;10:399–406
No participants with mild or
moderate dementia
Rigaud AS, André G, Vellas B, Touchon J, Pere JJ, Loria-Kanza Y. [Oestro-progestagen
treatment combined with rivastigmine in menopausal women suffering from
Alzheimer’s disease. The results of a 28-weeks controlled study.] Presse Med
2003;32:1649–54
Full text unavailable in English
Rijpma A, Meulenbroek O, Van Hees AM, Sijben JW, Scheltens P, Olde Rikkert MG.
Effects of a medical food on plasma micronutrient and fatty acid levels in mild to
moderate Alzheimer’s disease. Clin Nutr 2014;33:S193
Not published in a peer-reviewed
journal article or is an ongoing
trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Rijpma A, Meulenbroek O, van Hees AM, Sijben JW, Vellas B, Shah RC, et al.
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and
mild to moderate Alzheimer’s disease. Alzheimers Res Ther 2015;7:51
Not a disease modification trial
Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al. Efficacy of
rosiglitazone in a genetically defined population with mild to moderate Alzheimer’s
disease. Pharmacogenomics J 2006;6:246–54
Not a disease modification trial
Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances
autonomy in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry
2004;19:458–64
Not a disease modification trial
Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in
patients with Alzheimer’s disease taking galantamine for up to 48 months. Int J Geriatr
Psychiatry 2008;23:207–14
Not a disease modification trial
Rockwood K, Fay S, Gorman M. The ADAS-Cog and clinically meaningful change in
the VISTA clinical trial of galantamine for Alzheimer’s disease. Int J Geriatr Psychiatry
2010;25:191–201
Not a disease modification trial
Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Video-imaging synthesis of
treating Alzheimer’s disease I attainment of treatment goals by people with
Alzheimer’s disease receiving galantamine: a randomised controlled trial. CMAJ
2006;174:1099–105
Not a disease modification trial
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible
galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol
Neurosurg Psychiatry 2001;71:589–95
Not a disease modification trial
Rodriguez-Sanchez E, Criado-Gutierrez JM, Mora-Simon S, Muriel-Diaz MP,
Gomez-Marcos MA, Recio-Rodriguez JI, et al. Physical activity program for patients
with dementia and their relative caregivers: randomised clinical trial in primary health
care (AFISDEMyF study). BMC Neurol 2014;14:63
Not a disease modification trial
Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical
trial of indomethacin in Alzheimer’s disease. Neurology 1993;43:1609
Not a disease modification trial
Rogers S, Perdomo C, Friedhoff L. Clinical Benefits are Maintained During Long-term
Treatment of Alzheimer’s Disease with the Acetylcholinesterase Inhibitor, E2020.
8th European College of Neuropsychopharmacology Congress Venice, Italy,
30 September–4 October 1995
Not published in a peer-reviewed
journal article or is an ongoing
trial
Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global
function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study.
Arch Intern Med 1998;158:1021–31
Not a disease modification trial
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind,
placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology
1998;50:136–45
Not a disease modification trial
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Ieni J, et al. Donepezil
improved cognitive and global function in mild to moderate Alzheimer disease.
Evid Based Med 1998;3:155
Not a disease modification trial
Rogers SL, Friedhoff LT. Donepezil Improves Cognition in Patients with Mild to
Moderate AD: Results of ADAS-Cog Analysis in a 30-Week Phase III Study.
10th European College of Neuropsychopharmacology Congress Vienna, Austria,
13–17 September 1997
Not published in a peer-reviewed
journal article or is an ongoing
trial
Rogers SL, Mohs RC, Friedhoff LT. Donepezil (E2020) Improves Cognition and Function
in Patients with Mild to Moderately Severe Alzheimer’s Disease Results from Phase.
150th Annual Meeting of the American Psychiatric Association San Diego, CA,
17–22 May 1997
Not published in a peer-reviewed
journal article or is an ongoing
trial
Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, et al. Randomised,
placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects
by hippocampal size. Stroke 2010;41:1213–21
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in
vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr
Cogn Disord 2005;20:338–44
Not a disease modification trial
Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, et al. A
single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with
mild-moderate Alzheimer’s disease. CNS Drugs 2014;28:1185–9
Not a disease modification trial
Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M. Acetylcholine
esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer
patients. J Neurol 2006;253:58–64
Not a disease modification trial
Roshchina IF, Kolykhalov IV, Selezneva ND, Zharikov GA, Gerasimov NP, Gavrilova SI.
[The influence of Cerebrolysin on the efficiency of subsequent therapy with amiridine++
in Alzheimer’s disease patients (neuropsychological investigation).] Zh Nevrol Psikhiatr
Im S S Korsakova 1999;99:43–6
Full text unavailable in English
Rosler M, Anand R, Cincin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and
safety of rivastigmine in patients with Alzheimer’s disease: international randomised
controlled trial. BMJ 1999;318:633–40
Not a disease modification trial
Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, et al. Evaluating
the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease:
analysis of effects of baseline features on treatment response. BMC Geriatr 2013;13:56
Not a disease modification trial
Sacktor N, Kieburtz K, Schifitto G, McDermott M, Bourgeois K, Palumbo D, et al.
A randomised, double-blind, placebo-controlled trial of deprenyl and thioctic acid in
human immunodeficiency virus-associated cognitive impairment. Neurology
1998;50:645–51
No participants with mild or
moderate dementia
Sadowsky CH, Grossberg GT, Somogyi M, Meng X. Predictors of sustained response to
rivastigmine in patients with Alzheimer’s disease: a retrospective analysis. Prim Care
Companion J Clin Psychiatry 2011;13:PCC.10m01101
Not a disease modification trial
Sahakian BJ, Coull JT. Tetrahydroaminoacridine (THA) in Alzheimer’s disease: an
assessment of attentional and mnemonic function using CANTAB. Acta Neurol Scand
Suppl 1993;149:29–35
Not a disease modification trial
Sahakian BJ, Coull JT. Nicotine and tetrahydroaminoacradine: evidence for improved
attention in patients with dementia of the Alzheimer type. Drug Develop Res
1994;31:80–8
Not a disease modification trial
Sainati SM ID, Talwalker S, Geis GS. Results of a Double-Blind, Randomised,
Placebo-Controlled Study of Celecoxib in the Treatment of Progression of Alzheimer’s
Disease. Proceedings of the 6th International Stockholm/Springfield Symposium on
Advances in Alzheimer Therapy, Stockholm, Sweden, 5–8 April 2000
Not published in a peer-reviewed
journal article or is an ongoing
trial
Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Böhmer F. EEG mapping and
psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiatry
1992;32:668–81
Not a disease modification trial
Saletu B, Hochmayer I, Grunberger J, Bohmer F, Paroubek J, Wicke L, et al. [Therapy
of multi-infarct-dementia with nicergoline: double-blind, clinical, psychometric and
EEG-imaging-investigation with two different drug administration schedules.] Wien
Med Wochenschr 1987;137:513–24
Full text unavailable in English
Salloway S, Sperline R, Gregg K, Black R, Grundman M. Cognitive and functional
outcomes from a phase II trial of bapineuzumab in mid to moderate Alzheimer’s
disease. Neurology 2009;72(Suppl. 3):A271
Not published in a peer-reviewed
journal article or is an ongoing
trial
Salloway S, Sperling R, Gregg K, Yu P, Joshi A, Lu M, et al. Incidence and clinical
progression of placebo-treated amyloidnegative subjects with mild to moderate
Alzheimer’s disease (AD): results from the phase III PET substudies of bapineuzumab
and solanezumab. Alzheimers Dement 2013;9(Suppl. 1):888–9
Not published in a peer-reviewed
journal article or is an ongoing
trial
Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, et al.
A randomised, double-blind, placebo-controlled clinical trial of intravenous
bapineuzumab in patients with Alzheimer’s disease who are apolipoprotein E 4
non-carriers. Eur J Neurol 2012;19:70
Not published in a peer-reviewed
journal article or is an ongoing
trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Salotti P, De Sanctis B, Clementi A, Fernandez Ferreira M, De Silvestris T. Evaluation of
the efficacy of a cognitive rehabilitation treatment on a group of Alzheimer’s patients
with moderate cognitive impairment: a pilot study. Aging Clin Exp Res 2013;25:403–9
Not a disease modification trial
Salva A, Andrieu S, Fernandez E, Schiffrin E, Moulin J, Decarli B, et al. Health and
nutrition promotion program for patients with dementia (NutriAlz): cluster randomised
trial. J Nutr Health Aging 2011;15:822–30
Not a disease modification trial
Salva A, Andrieu S, Fernandez E, Schiffrin EJ, Moulin J, Decarli B, et al. Health and
nutritional promotion program for patients with dementia (NutriAlz Study): design and
baseline data. J Nutr Health Aging 2009;13:529–37
Not a disease modification trial
Samorajski T, Vroulis GA, Smith RC. Piracetam plus lecithin trials in senile dementia of
the Alzheimer type. Ann NY Acad Sci 1985;444:478–81
Not a disease modification trial
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A
controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s
disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997;336:1216–22
Not a disease modification trial
Sanofi, ICD CSD. NCT00104013 A Randomised, Multicenter, Double-Blind,
Placebo-Controlled, 18-Month Study of the Efficacy of SR57746A in Patients with
Mild to Moderate Dementia of the Alzheimer. URL: https://clinicaltrials.gov/ct2/show/
NCT00104013 (accessed 29 January 2016)
Not published in a peer-reviewed
journal article or is an ongoing
trial
Sanofi, ICD CSD. NCT00103649 18-month Study of the Efficacy of Xaliproden
(SR57746A) in Patients with Mild to Moderate Dementia of the Alzheimer.
URL: https://clinicaltrials.gov/ct2/show/NCT00103649 (accessed 29 January 2016)
Not published in a peer-reviewed
journal article or is an ongoing
trial
Santens P, Ventura M. Donepezil in the treatment of mild to moderate Alzheimer’s
disease: report of a Belgian multicenter study. Acta Neurol Belg 2003;103:159–63
Not a disease modification trial
Saxton J, Hofbauer RK, Woodward M, Gilchrist NL, Potocnik F, Hsu HA, et al.
Memantine and functional communication in Alzheimer’s disease: results of a
12-week, international, randomised clinical trial. J Alzheimers Dis 2012;28:109–18
Not a disease modification trial
Schecker M, Pirnay-Dummer P, Schmidtke K, Hentrich-Hesse T, Borchardt D. Cognitive
interventions in mild Alzheimer’s disease: a therapy-evaluation study on the interaction
of medication and cognitive treatment. Dement Geriatr Cogn Disord Extra
2013;3:301–11
Not a disease modification trial
Scheltens NME, Van Berckel BNM, Boellaard R, Barkhof F, Van Der Flier WM, Kamphuis
PJGH, et al. A Dutch 24-week randomised controlled study exploring the effect of a
nutritional intervention on brain glucose metabolism in early Alzheimer’s disease
(NL-ENIGMA); rationale and design. Eur Geriatr Med 2014;5:91
Not published in a peer-reviewed
journal article or is an ongoing
trial
Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Wurtman RJ, Wilkinson D,
et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomised, controlled
trial. Alzheimers Dement 2010;6:1–10.e1
Not a disease modification trial
Scheltens P, Sperling R, Salloway S, Fox N. Bapineuzumab IV phase 3 results.
J Nutr Health Aging 2012;16:797
Not published in a peer-reviewed
journal article or is an ongoing
trial
Scheltens P, Stam C, Shah R, Bennett D, Wieggers R, Hartmann T, et al. Medical
nutrition in disease management of Alzheimer’s patients. Clin Nutr 2013;32:35
Not published in a peer-reviewed
journal article or is an ongoing
trial
Scheltens P, Verhey FRJ, Rikkert MGMO, Kamphuis PJGH, Wilkinson D, Kurz A. The
efficacy of a medical food (Souvenaid) in Alzheimer’s disease: results from the first trial
and design of future trials. Alzheimers Dement 2009;1:258–9
Not published in a peer-reviewed
journal article or is an ongoing
trial
Scherder E, Knol D, van Tol MJ, van Someren E, Deijen JB, Swaab D, et al. Effects of
high-frequency cranial electrostimulation on the rest-activity rhythm and salivary
cortisol in Alzheimer’s disease: a pilot study. Dement Geriatr Cogn Disord
2006;22:267–72
Not a disease modification trial
Scherder EJ, Tol MJ, Swaab DF. High-frequency cranial electrostimulation (CES) in
patients with probable Alzheimer’s disease. Am J Phys Med Rehabil 2006;85:614–18
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Schiffczyk C, Romero B, Jonas C, Muller F, Riepe MW. Efficacy of multimodal
intervention for people with Alzheimer’s disease. Alzheimers Dement 2013;1:654
Not published in a peer-reviewed
journal article or is an ongoing
trial
Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine
and HIV-associated cognitive impairment: a neuropsychological and proton magnetic
resonance spectroscopy study. AIDS 2007;21:1877–86
Not a disease modification trial
Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al. A multicenter trial
of selegiline transdermal system for HIV-associated cognitive impairment. Neurology
2007;69:1314–21
Not a disease modification trial
Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H, et al. Longitudinal
multimodal imaging in mild to moderate Alzheimer disease: a pilot study with
memantine. J Neurol Neurosurg Psychiatry 2008;79:1312–17
Not a disease modification trial
Schmitt F, Farlow M, Olin J. Effects of rivastigmine on executive function in Parkinson’s
disease dementia: results from a 24-week placebo-controlled clinical trial. Ann Neurol
2009;66:48
Not published in a peer-reviewed
journal article or is an ongoing
trial
Schmitt FA, Aarsland D, Bronnick KS, Meng X, Tekin S, Olin JT. Evaluating rivastigmine
in mild to moderate Parkinson’s disease dementia using ADAS-Cog items. Am J
Alzheimers Dis Other Demen 2010;25:407–13
Not a disease modification trial
Schmitt FA, Aarsland D, Bronnick KS, Olin JT, Meng X. Evaluating cognitive effects of
oral rivastigmine using subscales and items of the ADAS-Cog in patients with mild to
moderate Parkinson’s disease dementia. Am J Geriatr Psychiatry 2010;1:79
Not published in a peer-reviewed
journal article or is an ongoing
trial
Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive
function in patients with Parkinson’s disease dementia. CNS Neurosci Ther
2010;16:330–6
Not a disease modification trial
Schmitt FA, Saxton J, Ferris SH, Mackell J, Sun Y. Evaluation of an 8-item Severe
Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer’s disease
patients participating in a donepezil study. J Clin Pract 2013;67:1050–6
Not a disease modification trial
Schneider L, Porsteinsson A, Farlow M, Shimakura A, Nakagawa M, Iwakami N.
The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease:
randomised, double-blind, placebo controlled proof-of-concept trial outcomes.
Alzheimers Dement 2013;1:530–1
Not published in a peer-reviewed
journal article or is an ongoing
trial
Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomised,
double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in
dementia of the Alzheimer’s type. Curr Alzheimer Res 2005;2:541–51
Not a disease modification trial
Schneider LS, Farlow M. Combined tacrine and oestrogen replacement therapy in
patients with Alzheimer’s disease. Ann NY Acad Sci 1997;826:317–22
Not a disease modification trial
Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of oestrogen
replacement therapy on response to tacrine in patients with Alzheimer’s disease.
Neurology 1996;46:1580–4
Not a disease modification trial
Schneider LS, Farlow MR, Pogoda JM. Potential role for oestrogen replacement in the
treatment of Alzheimer’s dementia. Am J Med 1997;103:46–50
Not a disease modification trial
Schwam E, Evans R, Nicholas T, Chew R, Davidson W, Ambrose D, et al. PF-04447943:
A phase II controlled clinical trial of a selective pde9a inhibitor in Alzheimer’s disease.
Alzheimers Dement 2011;1:695
Not published in a peer-reviewed
journal article or is an ongoing
trial
Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of
donepezil in early-stage Alzheimer disease: a randomised placebo-controlled trial.
Arch Neurol 2004;61:1852–6
Not a disease modification trial
Seltzer B, Zolnouni P, Nunez M, Goldman R, Noble Y, Kumar D, et al. Donepezil
Treatment Improves Cognitive Performance in Patients with Very Mild Alzheimer’s
Disease. European Neuropsychopharmacology; 15th International Congress of the
European College of Neuropsychopharmacology, Barcelona, Spain, 5–9 October, 2002
Not published in a peer-reviewed
journal article or is an ongoing
trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
Reference Reason for exclusion
Ser T, Lovestone S, Boada-Rovira M, Dubois B, Hull M, Rinne J, et al. A phase II
randomised, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib
in Alzheimer’s disease (argo trial). Alzheimers Dement 2013;1:689–90
Not published in a peer-reviewed
journal article or is an ongoing
trial
Ser TD, Lovestone S, Rovira MB, Dubois B, Hull M, Rinne J, et al. Argo trial. Alzheimers
Dement 2012;1:455–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT,
et al. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitiser,
in patients with mild Alzheimer’s disease. Curr Alzheimer Res 2014;11:564–73
Not a disease modification trial
Shankle WR, Hara J. Longitudinal measure of IVIG treatment effect in patients with
Alzheimer’s and Lewy body disease. Alzheimers Dement 2009;1:430
Not published in a peer-reviewed
journal article or is an ongoing
trial
Shatenstein B, Kergoat M, Reid I, Chicoine ME. Dietary intervention in older adults
with early-stage Alzheimer dementia: early lessons learned. J Nutr Health Ageing
2008;12:461–9
Not a disease modification trial
Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, et al. DOMINO-AD
protocol: donepezil and memantine in moderate to severe Alzheimer’s disease –
a multicentre RCT. Trials 2009;10:57
Not a disease modification trial
Shifu X, Heqin Y, Peifen Y, Luning W, Jianjun J, Xin M, et al. Efficacy of FPF 1070
(Cerebrolysin) in patients with Alzheimer’s disease. A multicentre, randomised,
double-blind, placebo-controlled trial. Clin Drug Investig 2000;19:43–53
Not a disease modification trial
Shikiar R, Shakespeare A, Sagnier PP, Wilkinson D, McKeith I, Dartigues JF, et al.
The impact of metrifonate therapy on caregivers of patients with Alzheimer’s disease:
results from the MALT clinical trial. Metrifonate in Alzheimer’s Disease Trial. J Am
Geriatr Soc 2000;48:268–74
Not a disease modification trial
Shimizu S, Kanetaka H, Hirose D, Sakurai H, Hanyu H. Differential effects of
acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in
patients with Alzheimer’s disease: a 12-month, randomised, and open-label trial.
Dement Geriatr Cogn Disord Extra 2015;5:135–46
Not a disease modification trial
Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al.
A randomised placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid
in Alzheimer’s disease. J Alzheimers Dis 2014;38:111–20
Not a disease modification trial
Shrotriya RC, Cutler NR, Sramek JJ, Veroff AE, Hironaka DY. Efficacy and safety of BMY
21,502 in Alzheimer disease. Ann Pharmacother 1996;30:1376–80
Not a disease modification trial
Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, et al. Zidovudine
treatment of the AIDS dementia complex: results of a placebo-controlled trial.
Ann Neurol 1993;33:343–9
Not a disease modification trial
Siemers E, Henley D, Sundell K, Sethuraman G, Dean R, Wrobleski K, et al. Evaluating
semagacestat, a gammasecretase inhibitor, in a phase iii trial. Alzheimers Dement
2011;1:484–5
Not published in a peer-reviewed
journal article or is an ongoing
trial
Silva HA, Pathmeswaran A, Gunatilake SB. Efficacy of rivastigmine on activities of daily
living in Sri Lankan patients with Alzheimer disease and on improving caregiver
burden: a prospective study. Ceylon Med J 2005;50:106–9
Not a disease modification trial
Sinforiani E, Iannuccelli M, Mauri M, Costa A, Merlo P, Bono G, Nappi G.
Neuropsychological changes in demented patients treated with acetyl-L-carnitine.
Int J Clin Pharmacol Res 1989;10:69–74
Unable to find a copy of the full
text
Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive
decline in patients with vascular dementia or Alzheimer’s disease with cerebrovascular
disease. CNS Drugs 2003;17:905–14
Not a disease modification trial
Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, et al. Long-term
acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 1991;41:1726–32
Not a disease modification trial
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TABLE 15 Excluded studies and reasons for exclusion (n= 748) (continued )
Reference Reason for exclusion
Spector A, Orrell M, Woods B. Cognitive Stimulation Therapy (CST): effects on different
areas of cognitive function for people with dementia. Int J Geriatr Psychiatry
2010;25:1253–8
Not a disease modification trial
Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, et al. Efficacy
of an evidence-based cognitive stimulation therapy programme for people with
dementia. Br J Psychiatry 2003;183:248–54
Not a disease modification trial
Spector A, Woods B, Orrell M. Cognitive stimulation for the treatment of Alzheimer’s
disease. Expert Rev Neurother 2008;8:751–7
Not a disease modification trial
Spilich GJ, Wannenmacher W, Duarte A, Buendia R, Gomez JT, Ramirez S, et al.
Efficacy of pyritinol versus hydergine upon cognitive performance in patients with
senile dementia of the Alzheimer’s type: a double-blind multi-centre trial. Alzheimers
Res 1996;2:79–84
Not a disease modification trial
Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, et al. A ‘bridging’
(safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer’s
disease. Life Sci 1995;57:1241–8
Not a disease modification trial
Standridge JB. Donepezil did not reduce the rate of institutionalisation or disability
in people with mild to moderate Alzheimer’s disease. Evid Based Ment Health
2004;7:112
Not a disease modification trial
Steele LS, Glazier RH. Is donepezil effective for treating Alzheimer’s disease? Can Fam
Physician1999;45:917–19
Not a disease modification trial
Stein MS, Scherer SC, Ladd KS, Harrison LC. A randomised controlled trial high-dose
vitamin D2 followed by intranasal insulin in Alzheimer’s disease. J Alzheimers Dis
2011;26:477–84
Not a disease modification trial
Stein AM, Vital TM, Coelho FGM, Andrade LP, Pereira JR, Garuffi M, et al. Aerobic
exercise training effect on cognitive functions, neuropsychiatric disorders, functionality,
quality of life and lipid profile in elderly with Alzheimer’s disease. Eur Geriatr Med
2014;5:105–6
Not published in a peer-reviewed
journal article or is an ongoing
trial
Stern Y, Sano M, Mayeux R Long-term administration of oral physostigmine in
Alzheimer’s disease. Neurology 1988;38:1837–41
Not a disease modification trial
Storey P HL, Duke L, Callaway R, Marson D. Does chronic oral physostigmine alter the
course of Alzheimer’s disease? Neurobiol Ageing 1992;13(Suppl. 1):126
Not published in a peer-reviewed
journal article or is an ongoing
trial
Stott DJ, MacIntosh G, Lowe GDO, Rumley A, McMahon AD, Langhorne P, et al.
Randomised controlled trial of homocysteine-lowering vitamin treatment in elderly
patients with vascular disease. Am J Clin Nutr 2005;82:1320–6
Not a disease modification trial
Streater A, Spector A, Aguirre E, Hoe J, Hoare Z, Woods R, et al. Maintenance
cognitive stimulation therapy (CST) in practice: study protocol for a randomised
controlled trial. Trials 2012;13:91
Not a disease modification trial
Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect
of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with
dementia: a prospective study. BMJ Open 2014;4:e005158
Not a RCT/CCT
Suh GH, Jung HY, Lee CU, Choi S, Korean Galantamine Study G. Economic and clinical
benefits of galantamine in the treatment of mild to moderate Alzheimer’s disease in a
Korean population: a 52-week prospective study. J Korean Med Sci 2008;23:10–17
Not a disease modification trial
Suh GH, Jung HY, Lee CU, Lee SK, Lee NJ, Kim JH. [Effect of galantamine on caregiver
time and activities of daily living in mild to moderate Alzheimer’s disease: a 1-year
prospective study.] J Korean Geriatr Soc 2007;11:74–82
Full text unavailable in English
Suh GH, Jung HY, Lee CU, Oh BH, Lee SK, Lee N, et al. Effect of the apolipoprotein E
epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of
Alzheimer’s disease. Dement Geriatr Cogn Disord 2006;21:33–9
Not a disease modification trial
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Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, et al. A
prospective, double-blind, community-controlled comparison of three doses of
galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean
population. Clinical Therapeutics 2004;26:1608–18
Not a disease modification trial
Sun Y, Lu C-J, Chien K-L, Chen S-T, Chen R-C. Efficacy of multivitamin
supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment
with a cholinesterase inhibitor in Alzheimer’s disease: a 26-week, randomised, double-
blind, placebo-controlled study in Taiwanese patients. Clin Ther 2007;29:2204–14
Not a disease modification trial
Suzuki T, Futami S, Igari Y, Matsumura N, Watanabe K, Nakano H, et al. A Chinese
herbal medicine, choto-san, improves cognitive function and activities of daily living
of patients with dementia: a double-blind, randomised, placebo-controlled study.
J Am Geriatr Soc 2005;53:2238–40
Not a disease modification trial
Tadaka E, Kanagawa K. A randomised controlled trial of a group care program for
community-dwelling elderly people with dementia. Jpn J Nurs Sci 2004;1:19–25
Not a disease modification trial
Tadaka E, Kanagawa K. Effects of reminiscence group in elderly people with Alzheimer
disease and vascular dementia in a community setting. Geriatr Gerontol Int
2007;7:167–73
Not a disease modification trial
Tajadini H, Saifadini R, Choopani R, Mehrabani M, Kamalinejad M, Haghdoost AA.
Herbal medicine Davaie Loban in mild to moderate Alzheimer’s disease: a 12-week
randomised double-blind placebo-controlled clinical trial. Complement Ther Med
2015;23:767–72
Not a disease modification trial
Takahashi T, Matsushita H. Long-term effects of music therapy on elderly with
moderate/severe dementia. J Music Ther 2006;43:317–33
Not a disease modification trial
Tariot P, Sabbagh M, Flitman S, Reyes P, Taber I, Seely L. A safety, tolerability and
pharmacokinetic study of Dimebon in patients with Alzheimer’s disease already
receiving donepezil. Alzheimers Dement 2009;5:251
Not published in a peer-reviewed
journal article or is an ongoing
trial
Tariot P, Salloway S, Yardley J, Mackell J, Moline M. Long-term safety and tolerability
of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease. BMC Res
Notes 2012;5:283
Not a disease modification trial
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine
treatment in patients with moderate to severe Alzheimer disease already receiving
donepezil: a randomised controlled trial. JAMA 2004;291:317–24
Not a disease modification trial
Tariot PN, Goldstein B, Podgorski CA, Cox C, Frambes N. Short-term administration of
selegiline for mild to moderate dementia of the Alzheimer’s type. Am J Geriatr
Psychiatry 1998;6:145–54
Not a disease modification trial
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month,
randomised, placebo-controlled trial of galantamine in AD. The Galantamine USA-10
Study Group. Neurology 2000;54:2269–76
Not a disease modification trial
Tarraga L, Boada M, Modinos G, Espinosa A, Diego S, Morera A, et al. A randomised
pilot study to assess the efficacy of an interactive, multimedia tool of cognitive
stimulation in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006;77:1116–21
Not a disease modification trial
Teipel SJ, Drzezga A, Bartenstein P, Moller HJ, Schwaiger M, Hampel H. Effects of
donepezil on cortical metabolic response to activation during 18FDG-PET in
Alzheimer’s disease: a double-blind cross-over trial. Psychopharmacology
2006;187:86–94
Not a disease modification trial
Thai LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al. A 1-year
multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s
disease. Neurology 1996;47:705–11
Not a disease modification trial
Thal L, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al. Idebenone
treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology
2003;61:1498–502
Not a disease modification trial
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Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in
early-onset AD. Neurology 2000;55:805–10
Not a disease modification trial
Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomised trial of
controlled-release physostigmine in patients with Alzheimer’s disease. Neurology
1999;52:1146–52
Not a disease modification trial
Thal LJ, Forrest M, Loft H, Mengel H. Lu 25–109, a muscarinic agonist, fails to improve
cognition in Alzheimer’s disease. Lu25–109 Study Group. Neurology 2000;54:421–6
Not a disease modification trial
Thal LJ, Fuld PA, Masur DM, Sharpless NS. Oral physostigmine and lecithin improve
memory in Alzheimer disease. Ann Neurol 1983;13:491–6
Not a disease modification trial
Thal LJ, Masur DM, Sharpless NS. Acute and chronic effects of oral physostigmine
and lecithin in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry
1986;10:627–36
Not a disease modification trial
Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, et al. A multicenter
double-blind study of controlled-release physostigmine for the treatment of symptoms
secondary to Alzheimer’s disease. Physostigmine Study Group. Neurology
1996;47:1389–95
Not a disease modification trial
Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, et al. A comparison
of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with
Lewy bodies. Int J Geriatr Psychiatry 2005;20:938–44
Not a disease modification trial
Thompson ITL, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL. Lack of
efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med
1990;323:445–8
Not a disease modification trial
Tian J, Shi J, Miao Y, Wei M. Efficacy and safety of an herbal therapy in patients with
early stage of Alzheimer’s disease: a 24-week randomised phase III trial. Alzheimers
Dement 2011;1:790
Not a disease modification trial
Tian J, Shi J, Wei M, Qin R, Chen Y, Wang Y. Efficacy and safety of FFDS tablets
in people with mild to moderate vascular dementia: a 24-week randomised,
double-blind, placebo, parallel-controlled trial. Alzheimers Dement 2013;1:670–1
Not published in a peer-reviewed
journal article or is an ongoing
trial
Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, et al. Donepezil
treatment and Alzheimer disease: can the results of randomised clinical trials be
applied to Alzheimer disease patients in clinical practice? Am J Geriatr Psychiatry
2007;15:953–60
Not a disease modification trial
Tocco M, Hendrix S, Miller M, Pejovic V, Graham S. Effects of extended-release
memantine (28 MG/DAY) on activities of daily living in patients with moderate to
severe Alzheimer’s disease: post hoc factor analysis of a randomised trial. Alzheimers
Dement 2011;1:790–1
Not published in a peer-reviewed
journal article or is an ongoing
trial
Tocco M, Hendrix S, Miller M, Pejovic V, Graham S. Effects of extended-release
memantine (28 MG/day) on cognitive domains in patients with moderate to severe
Alzheimer’s disease: post hoc analysis of a randomised trial. Alzheimers Dement
2011;1:784–5
Not published in a peer-reviewed
journal article or is an ongoing
trial
Tocco M, Hendrix S, Miller M, Pejovic V, Graham S. Clinical benefits of extended-
release memantine (28 mg, once daily) as a function of disease severity in people with
moderate to severe Alzheimer’s disease: post hoc analysis from a randomised trial.
Alzheimers Dement 2013;1:655
Not published in a peer-reviewed
journal article or is an ongoing
trial
Tocco M, Hendrix S, Miller ML, Pejovic V, Graham SM. Effects of extended-release
memantine (28 mg, once daily) on language and communication abilities in patients
with moderate to severe Alzheimer’s disease. Ann Neurol 2012;72:S52–3
Not published in a peer-reviewed
journal article or is an ongoing
trial
Tollefson GD. Short-term effects of the calcium channel blocker nimodipine
(Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry
1990;27:1133–42
Not a disease modification trial
Trollor JN SP, Haindl W, Brodaty H, Wen W, Walker BM. Combined cerebral blood
flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early
Alzheimer’s disease. Psychiatry Clin Neurosci 2006;60:616–25
Not a disease modification trial
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Tsai GE, Falk WE, Gunther J. A preliminary study of D-cycloserine treatment in
Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1998;10:224–6
Not a disease modification trial
Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al.
A multi-centre randomised proof-of-concept clinical trial applying [18F]FDG-PET for
evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s
disease. J Alzheimers Dis 2010;22:1241–56
Not a disease modification trial
Van de Winckel A, Fey H, De Weerdt W, Dom R. Cognitive and behavioural effects of
music-based exercises in patients with dementia. Clin Rehabil 2004;18:253–60
Not a disease modification trial
van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly
people with dementia and age-associated memory impairment: a randomised clinical
trial. J Clin Epidemiol 2003;56:367–76
Not a disease modification trial
Van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Nelson JC, et al. The
acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in
Alzheimer’s disease. Psychopharmacology 1997;132:217–26
Not a disease modification trial
van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release physostigmine in
Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment.
Physostigmine Study Group. Arch Gen Psychiatry 2000;57:157–64
Not a disease modification trial
van Dyck CH, Tariot PN, Meyers B, Resnick E. A 24-week randomised, controlled trial
of memantine in patient with moderate-to-severe Alzheimer disease. Alzheimer Dis
Assoc Disord 2007;21:136–43
Not a disease modification trial
Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, et al. Cerebral
blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease.
Neuroreport 2002;13:83–7
Not a disease modification trial
Vereschagin NV NY, Lebedeva NV, Suslina ZA, Solovyev OI, Piradov MA, et al. [Mild
forms of multiinfarct dementia – effectiveness of Cerebrolysin.] Sov Meditsina
1991;11:6–8
Full text unavailable in English
Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in
Alzheimer disease: cognitive improvement measured using the Computerised
Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998;12:304–12
Not a disease modification trial
Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J. Clinical studies with oxiracetam in
patients with dementia of Alzheimer type and multi-infarct dementia of mild to
moderate degree. Neuropsychobiology 1992;25:24–8
Not a disease modification trial
Villardita C, Parini J, Grioli S, Quattropani M, Lomeo C, Scapagnini U. Clinical and
neuropsychological study with oxiracetam versus placebo in patients with mild to
moderate dementia. J Neural Transm Suppl 1987;24:293–8
Not a disease modification trial
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Pejoska S, et al.
A 52-week pilot study targeting abeta with PBT2: neuroimaging results. Neurodegen
Dis 2015;15:308
Not published in a peer-reviewed
journal article or is an ongoing
trial
Viola LF, Nunes PV, Yassuda MS, Aprahamian I, Santos FS, Santos GD, et al. Effects of
a multidisciplinary cognitive rehabilitation program for patients with mild Alzheimer’s
disease. Clinics 2011;66:1395–400
Not a disease modification trial
Vreugdenhil A, Cannell J, Davies A, Razay G. A community-based exercise programme
to improve functional ability in people with Alzheimer’s disease: a randomised
controlled trial. Scand J Caring Sci 2012;26:12–19
Not a disease modification trial
Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, et al. Add-on prolonged-
release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s
disease: a 6-month, randomised, placebo-controlled, multicenter trial. Clin Interv
Ageing 2014;9:947–61
Not a disease modification trial
Waldemar G, Hoffmann K, Sobol N, Frederiksen K, Beyer N, Vogel A, et al. Effect of
moderate-to-high intensity endurance exercise in elderly community-dwelling persons
with mild-moderate Alzheimer’s disease. Eur J Neurol 2015;22:95
Not published in a peer-reviewed
journal article or an ongoing trial
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Walzl M, Walzl B, Kleinert G, Schied G, Lechner H. [Heparin-induced extracorporeal
LDL precipitation (HELP). A new therapeutic possibility in cerebral multi-infarct
dementia.] Der Nervenarzt 1993;64:648–52
Full text unavailable in English
Wang P, Yang J, Liu G, Chen H, Yang F. [Effects of moxibustion at head-points on
levels of somatostatin and arginine vasopressin from cerebrospinal fluid in patients with
vascular dementia: a randomised controlled trial.] Chin J Integr Med 2010;8:636–40
Full text unavailable in English
Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, et al. Effects of oestrogen on
cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology
2000;54:2061–6
Not a disease modification trial
Warner J. Donepezil is more effective than galantamine for mild to moderate
Alzheimer’s disease. Evid Based Ment Health 2004;7:77
Not published in a peer-reviewed
journal article or is an ongoing
trial
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of
tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992–8
Not a disease modification trial
Wattmo C, Wallin AK, Londos E, Minthon L. Predictors of long-term cognitive outcome
in Alzheimer’s disease. Alzheimers Res Ther 2011;3:23
Not a disease modification trial
Wei MQ, Tian JZ, Shi J, Ma FY, Miao YC, Wang YY. Effects of Chinese medicine for
promoting blood circulation and removing blood stasis in treating patients with mild to
moderate vascular dementia: a randomised, double-blind and parallel-controlled trial.
Chin J Integr Med 2012;10:1240–6
Not a disease modification trial
Weiner MF, Bonte FJ, Tintner R, Ford N, Svetlik D, Riall T. ACE inhibitor lacks acute
effect on cognition or brain blood flow in Alzheimer’s disease. Drug Dev Res
1992;26:467–71
Not a disease modification trial
Weinstein HC, Teunisse S, van Gool WA. Tetrahydroaminoacridine and lecithin in the
treatment of Alzheimer’s disease. Effect on cognition, functioning in daily life,
behavioural disturbances and burden experienced by the carers. J Neurol
1991;238:34–8
Not a disease modification trial
Wesnes KA, Aarsland D, Ballard C, Londos E. Improvements to attention and verbal
episodic memory with memantine in Parkinson’s disease dementia and dementia with
Lewy bodies. J Nutr Health Aging 2013;17:781–2
Not published in a peer-reviewed
journal article or is an ongoing
trial
Wesnes K, Aarsland D, Ballard C, Londos E. Memantine improves attention and verbal
episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies: a
double-blind, placebo-controlled multicentre trial. Alzheimers Dement 2013;1:890
Not a disease modification trial
Wesnes KA, McKeith IG, Ferrara R, Emre M, Ser T, Spano PF, et al. Effects of
rivastigmine on cognitive function in dementia with Lewy bodies: a randomised
placebo-controlled international study using the cognitive drug research computerised
assessment system. Dement Geriatr Cogn Disord 2002;13:183–92
Not a disease modification trial
Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM. A controlled study of
2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology
1997;36:73–82
Not a disease modification trial
Weyer G, Erzigkeit H, Hadler D, Kubicki S. Efficacy and safety of idebenone in the
long-term treatment of Alzheimer’s disease: a double-blind, placebo controlled
multicentre study. Hum Psychopharmacol 1996;11:53–65
Not a disease modification trial
Weyer G, Eul A, Milde K, Wierich W, Herrmann WM. Cyclandelate in the treatment of
patients with mild to moderate primary degenerative dementia of the Alzheimer type
or vascular dementia: experience from a placebo controlled multi-centre study.
Pharmacopsychiatry 2000;33:89–97
Not a disease modification trial
White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive
performance in Alzheimer’s disease. Psychopharmacology 1999;143:158–65
Not a disease modification trial
Wieggers RL, Kamphuis P, Stam C, Shah R, Bennett D, Hartmann T, et al. An
overview of the medical food Souvenaid clinical trial program. Alzheimers Dement
2013;9(Suppl. 1):669
Not a disease modification trial
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Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term
comparison of galantamine and donepezil in the treatment of Alzheimer’s disease.
Drugs Aging 2003;20:777–89
Not a disease modification trial
Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre
study of memantine in mild to moderate vascular dementia (MMM500). Int Clin
Psychopharm 2002;17:297–305
Not a disease modification trial
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients
with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial.
BMJ 2000;321:1445–9
Not a disease modification trial
Wilcock GK, Surmon DJ, Scott M, Boyle M, Mulligan K, Neubauer KA, et al. An
evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin
in the treatment of Alzheimer’s disease. Age Ageing 1993;22:316–24
Not a disease modification trial
Wilkinson D, Colding-Jorgensen E, Windfeld K. A clinical phase II study of LU AE58054
added to stable donepezil treatment in patients with moderate Alzheimer’s disease.
Alzheimers Dement 2013;9(Suppl. 1):P529
Not published in a peer-reviewed
journal article or is an ongoing
trial
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil
in vascular dementia: a randomised, placebo-controlled study. Neurology
2003;61:479–86
Not a disease modification trial
Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P. Memantine and
brain atrophy in Alzheimer’s disease: a 1-year randomised controlled trial. J Alzheimers
Dis 2012;29:459–69
Not a disease modification trial
Wilkinson D, Murray J. Galantamine: a randomised, double-blind, dose comparison in
patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001;16:852–7
Not a disease modification trial
Wilkinson D, Róman G, Salloway S, Hecker J, Boundy K, Kumar D, et al. The long-term
efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr
Psychiatry 2010;25:305–13
Not a disease modification trial
Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A
multinational, randomised, 12-week, comparative study of donepezil and rivastigmine
in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 2002;56:441–6
Not a disease modification trial
Willan AR, Goeree R, Pullenayegum EM, McBurney C, Blackhouse G. Economic
evaluation of rivastigmine in patients with Parkinson’s disease dementia.
Pharmacoeconomics 2006;24:93–106
Not a disease modification trial
Wimo A, Gaudig M, Schauble B, Jedenius E. The economic impact of galantamine vs
placebo: an analysis based on functional capacity in a Swedish cohort study. J Med
Econ 2012;15:1019–24
Not a disease modification trial
Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T. Impact of donepezil
treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin
2004;20:1221–5
Not a disease modification trial
Wimo A, Winblad B, Soininen H, Verhey F, Waldemar G, Wetterholm AL, et al. An
economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a
1-year, double-blind, randomised trial. Dement Geriatr Cogn Disord 2003;15:44–54
Not a disease modification trial
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year,
randomised, placebo-controlled study of donepezil in patients with mild to moderate
AD. Neurology 2001;57:489–95
Not a disease modification trial
Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, et al. Phenserine
efficacy in Alzheimer’s disease. J Alzheimers Dis 2010;22:1201–8
Not a disease modification trial
Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, et al. A 6-month,
double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Neurology 2007;69(Suppl. 1):14–22
Not a disease modification trial
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Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-year study
of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy.
Dement Geriatr Cogn Disord 2006; 21:353–63
Not a disease modification trial
Wirth Y, Rive B. Memantine enhances autonomy in moderate to severe Alzheimer’s
disease patients already receiving donepezil. Eur J Neurol 2012;19:474
Not a disease modification trial
Wolters E, Riekkinen P, Lowenthal A, Van der Plaats J, Zwart J, Sennef C. DGAVP
(Org 5667) in early Alzheimer’s disease patients: an international double-blind,
placebo-controlled, multicenter trial. Neurology 1990;40:1099–101
Not a disease modification trial
Wong WJ, Liu HC, Fuh JL, Wang SJ, Hsu LC, Wang PN, et al. A double-blind,
placebo-controlled study of tacrine in Chinese patients with Alzheimer’s disease.
Dement Geriatr Cogn Disord 1999;10:289–94
Not a disease modification trial
Woods B, Thorgrimsen L, Spector A, Royan L, Orrell M. Improved quality of life and
cognitive stimulation therapy in dementia. Ageing Ment Health 2006;10:219–26
Not a disease modification trial
Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL. [Oral galantamine versus
rivastigmine transdermal patch: a descriptive study at a memory clinic in The
Netherlands.] Tijdschr Gerontol Geriatr 2010;41:146–50
Full text unavailable in English
Xiao S, Wang T, Huang Q, Chen K, Reiman E. Changes of biological markers and brain
PET imaging and clinical effects of memantine for patients with moderate to severe
Alzheimer’s disease: a 24 week double-blind, randomised, placebo-controlled study.
J Nutr Health Aging 2012;16:855
Not published in a peer-reviewed
journal article or is an ongoing
trial
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TABLE 15 Excluded studies and reasons for exclusion (n = 748) (continued )
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Appendix 7 List of consensus conference
attendees
Twenty-seven attendees:
1. Sube Banerjee
2. Frances Bunn
3. David Challis
4. Georgina Charlesworth
5. Alison Evans
6. Katie Featherstone
7. Chris Fox
8. Claire Goodman
9. Anna Grinbergs-Saull
10. Derek Groskreutz
11. Rob Howard
12. Roy Jones
13. Louise Lafortune
14. Sallie Lamb
15. Gill Livingston
16. Esme Moniz-Cook
17. Gail Mountain
18. John O’Brien
19. Robert Perneckzy
20. James Pickett
21. Charlotte Roberts
22. Justine Schneider
23. Sasha Shepperd
24. Clare Surr
25. Jo Thompson-Coon
26. Lucy Webster
27. Bob Woods.
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